Board Decisions

<p>The Board:</p> <ol> <li>Approves the Global Fund Evaluation Strategy 2012-2016 (as set out in Annex 1 to the Report of the Policy and Strategy Committee (GF/B25/12));<br /><br /></li> <li>Acknowledges that the Global Fund Evaluation Strategy 2012-2016 may require additional revisions in order to ensure consistency with the final Global Fund Strategy 2012-2016, as approved under GF/B25/DP5, and requests that the Secretariat, working together with the TERG, update the Global Fund Evaluation Strategy 2012-2016 as may be required;<br /><br /></li> <li>Requests the TERG to develop an annual implementation plan for the Global Fund Evaluation Strategy 2012-2016; and<br /><br /></li> <li>Requests the TERG, through the new Strategy, Investment and Impact Committee, to submit a revised Global Fund Evaluation Strategy 2012-2016 and the first annual implementation plan to the Twenty-Sixth Board Meeting for approval, and to submit subsequent annual implementation plans thereafter.</li> </ol>

<p>The Board approves the Report of the 39th Board Meeting, as set forth in GF/B39/26 – Revision 2.</p>

The Board acknowledges that the special condition upon which the Board approved the Togo Round 4 Malaria grant to the United Nations Development Programme (UNDP) of the delivery at the end of year 3 of a detailed assessment of program progress and performance was fulfilled later than anticipated in the grant agreement. Although the revised timeline for the program assessment has delayed confirmation that the condition has been fulfilled, in recognition of the subsequent improved program performance of the grant the Board decides to retrospectively approve continued funding for years 4 and 5 of the Togo Round 4 Malaria grant (TGO-405-G05-M).

<p>The Board refers to its earlier decisions regarding the Affordable Medicine Facility - malaria ("AMFM") (GF/B16/DP14 and GF/B17/DP16).</p> <p>The Board approves the Policy Framework and Implementation Plan set out in the AMFm Ad Hoc Committee Report to the Board (GF/B18/7 - the "AMFm Report") and reaffirms its decision to host and manage the AMFm for an initial phase ("Phase 1") in a limited number of countries. The Board requests the Secretariat to begin operation of Phase 1 of the AMFm.</p> <p>The Board requests the AMFm Ad Hoc Committee to continue to oversee the pre-launch preparations</p> <p>of AMFm Phase 1 in keeping with its current committee mandate up to the 19th Board meeting (and authorizes it to make minor modifications to the Policy Framework and Implementation Plan). At the 19th Board meeting, the Board will decide on the governance structure for the oversight and performance monitoring of the implementation of Phase 1.</p> <p>The Board requests the Secretariat to commission an independent technical evaluation of the roll-out of the AMFm in the AMFm Phase 1 countries. The Board requests the committee with oversight of AMFm Phase 1 to review the findings of such evaluation and to make a recommendation to the Board on its completion (estimated for the second half of 2010), at which time the Board will determine whether to expand, accelerate, terminate or suspend the AMFm business line.</p> <p>The Board acknowledges the work and support of the RBM Task Force, UNITAID and other partners and requests its partners to continue to support the development and implementation of the AMFm.</p>

<p>Dasho Kunzang Wangdi from the South East Asia Constituency is designated as Rapporteur for the Extraordinary Board Meeting.</p>

The Board recognizes the significant improvements in collaboration between UNDP and the Global Fund on audits and investigations relating to grant funds. However, the Board notes that there are still areas where the collaboration could be improved and therefore requests the Chair of the Board, in support of the OIG and Secretariat, to secure greater assurance from the UNDP Board regarding audits and investigations of Global Fund grants where UNDP acts as Principal Recipient, including access to the full text of audit and investigation reports.

<p>1. Given the new and encouraging financial forecasts presented to the Global Fund’s Board at its Twenty-Sixth Meeting in Geneva in May 2012, the Board decides to accelerate the implementation of the new Global Fund Strategy ‘Investing for Impact’ by opening new funding opportunities starting in late September 2012 to allow for Board funding decisions to be made no later than the end of April 2013.</p> <p>2. The Secretariat, under the guidance of the Strategy, Investment and Impact Committee (‘SIIC’), will design in consultation with countries, partners and other stakeholders, the elements of the new funding models, including the structure and parameters of the new ‘iterative process’, options for distribution of funds available, and other elements, and the SIIC will bring its recommendation to a special Board meeting in September 2012.</p> <p>3. The Finance and Operational Performance Committee will work with the Secretariat to test the resource forecasting model on a monthly basis and confirm the resource forecast in September 2012.</p> <p>4. As soon as possible, and under the oversight of the SIIC, the Secretariat will work with countries and partners to develop estimates of demand for programs for the three diseases and related health systems and civil society strengthening investments that are consistent with the new strategic approach and take into account existing resources available in country, by September to inform the Board and other stakeholders and to aid replenishment.</p> <p>5. The new funding models will be developed in line with the new Strategy and the principles articulated in the Framework Document that the ‘Fund will base its work on programs that reflect national ownership and respect country-led formulation and implementation processes’.</p> <p>6. It is envisaged that this will :</p> <blockquote> <p>a. create a specific opportunity for countries to assess the gap between national coverage levels for the 3 diseases and actual need;</p> </blockquote> <blockquote> <p>b. permit the establishment of multiple funding opportunities per year and have a mechanism that allows for high quality, grant ready proposals to be financed as funding becomes available ;<br />Accelerating Implementation of the Global Fund Strategy</p> </blockquote> <blockquote> <p>c. ensure a comprehensive and specific analysis of complementarity among funders; and</p> </blockquote> <blockquote> <p>d. increase the sustainability of Global Fund supported programs.</p> </blockquote>

<ol><li>The Board directs the MEFA Committee in its December 2003 meeting to finalize its review and recommendations of the 2004 budget, including comments made by the Board and to bring its final recommendation to the Board at its next meeting in 2004.</li><li>The Board authorizes the Secretariat to continue to operate with the ceiling of the 2003 budget until the 2004 budget can be adopted by the Board. During this interim period, in the event the Secretariat must incur specific expenses not included in the 2003 budget (e.g. Partnership forum venue costs), it shall do so with the understanding that the expense will be covered within the finally adopted 2004 budget. The Secretariat will present a report of its first quarter expenses to the Board in March.</li><li>The Board directs the MEFA Committee to finalize the review of the budget for 2005 and report to the Board for their decision in 2004.</li></ol>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex to GF/B32/ER14 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>See Details: Annex including table of recommendation on Additional Funding from the 2014 Allocation- Afghanistan (HSS and Tuberculosis - AFG-T-UNDP, AFG-T-MOPH), Ghana (Malaria - GHN-M-MOH, GHN-M-AGAMal), Multi-country Africa - SADC (HIV/AIDS - QML-H-SADC), Pakistan (Malaria - PAK-M-SC, PAK-M-DOMC), Paraguay (HIV/AIDS - PRY-H-CIRD), South Sudan (Malaria - SSD-M-PSI), Sudan (Malaria - SUD-M-UNDP).</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B47/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:<br/><br/>1. Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B33/ER18.</p><p><b>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</b> <br/></p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2020 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in Annex 2 to GF/B44/ER15.</p>

The Board requests the Office of the Inspector-General to implement an independent, confidential and technically robust reporting hotline to support the Whistle-blowing Policy for Secretariat and Governance Bodies of the Global Fund and In-Country Whistle-blowing Policy, as a matter of urgency.

<p>The Board amends the first sentence of Article 6.3 of the By-laws as follows:</p><p>"The Partnership Forum will meet biennially, at any time during even calendar years".</p>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>The Board approves additional funding for the Phase 2 period of the Round 5 Nigeria TB grant (NGA-506-G06-T) as a Conditional Go in the amount of up to US$ 39,617,817, subject to TRP clarifications and conditions within a limited timeframe, and also subject to possible additional conditions to be cleared by the Secretariat.The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><p>Brazil, TB – Round 5 <br/>Grant Number: BRA-506-G01-T <br/>CCM Requested Amount (Total Phase 2 in US$): 2,183,419 <br/>Approved Funding Amount (Incremental in US$): 1,754,028 <br/>Recommendation Category: Go <br/><br/>Brazil, TB – Round 5 <br/>Grant Number: BRA-506-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 11,960,082 <br/>Approved Funding Amount (Incremental in US$): 9,664,550 <br/>Recommendation Category: Conditional Go <br/><br/>China, Malaria – Round 6 <br/>Grant Number: CHN-607-G09-M <br/>CCM Requested Amount (Total Phase 2 in US$): 10,121,428 <br/>Approved Funding Amount (Incremental in US$): 8,471,314 <br/>Recommendation Category: Go <br/><br/>Djibouti, Malaria – Round 6 <br/>Grant Number: DJB-607-G02-M <br/>CCM Requested Amount (Total Phase 2 in US$): 1,190,000 <br/>Approved Funding Amount (Incremental in US$): 958,138 <br/>Recommendation Category: Conditional Go <br/><br/>India, HIV – Round 6 <br/>Grant Number: IDA-607-G10-H <br/>CCM Requested Amount (Total Phase 2 in US$): 22,729,077 <br/>Approved Funding Amount (Incremental in US$): 20,390,449 <br/>Recommendation Category: Go <br/><br/>India, HIV – Round 6 <br/>Grant Number: IDA-607-G11-H <br/>CCM Requested Amount (Total Phase 2 in US$): 145,546,072 <br/>Approved Funding Amount (Incremental in US$): 97,852,982 <br/>Recommendation Category: Conditional Go <br/><br/>Namibia, Malaria – Round 6 <br/>Grant Number: NMB-607-G06-M <br/>CCM Requested Amount (Total Phase 2 in US$): 7,152,683 <br/>Approved Funding Amount (Incremental in US$): 5,015,506 <br/>Recommendation Category: Conditional Go <br/><br/>Paraguay, HIV – Round 6 <br/>Grant Number: PRY-607-G02-H <br/>CCM Requested Amount (Total Phase 2 in US$): 5,749,894 <br/>Approved Funding Amount (Incremental in US$): 5,395,205 <br/>Recommendation Category: o <br/><br/>Tajikistan, TB – Round 6 <br/>Grant Number: TAJ-607-GO6-T <br/>CCM Requested Amount (Total Phase 2 in US$): 7,251,791 <br/>Approved Funding Amount (Incremental in US$): 6,865,442 <br/>Recommendation Category: Go <br/><br/>Ukraine, HIV – Round 6 <br/>Grant Number: UKR-607-G05-H <br/>CCM Requested Amount (Total Phase 2 in US$): 66,026,690 <br/>Approved Funding Amount (Incremental in US$): 63,557,000 <br/>Recommendation Category: Conditional Go <br/><br/>Ukraine, HIV – Round 6 <br/>Grant Number: UKR-607-G06-H <br/>CCM Requested Amount (Total Phase 2 in US$): 42,717,774 <br/>Approved Funding Amount (Incremental in US$): 38,366,000 <br/>Recommendation Category: Conditional Go <br/><br/>Total US$258,290,614</p><p>The Secretariat received comments from Board members on some of the grants. The comments will be taken into account during grant negotiations.</p><p>Next Steps:The Secretariat will begin negotiations immediately for the extension of the grants listed in Schedule A and the Nigeria Round 5 TB grant (NGA-506-G06-T)</p>

<ol start="1" type="1"><li>Requests the Board to endorse the approaches to Communications outlined in the Communications Report GF/B4/10.</li></ol><ol start="2" type="1"><li>Requests the Board to work with the Secretariat and to assist them in their need for additional spokespeople and partners in Communications.</li></ol><ol start="3" type="1"><li><b>(Deferred)</b> Requests the Board to endorse the logo and the Logo Policy and to instruct the Secretariat to continue the process of legal registrations of the logo.</li></ol><ol start="4" type="1"><li>Recommends that the Resource Mobilization Committee Terms of Reference be revised to include communications, as recorded in the document below.</li></ol>

<p>During the 6^thBoard meeting, the Board took the following decision:</p> <p>"The Board approves proposals in TRP category 2B, subject to the completion of TRP clarifications. This decision would become effective upon Board confirmation by email in January 2004. Meanwhile the Secretariat can proceed with resolving TRP clarifications for these proposals." </p> <p>The Board reviewed and confirmed its approval of the decision on category 2B proposals for a total amount of US$138,463,324.</p> <p>The Board noted that as of january 2004, US$604 million is forecastto be available for the Fourth Call for Proposals.</p> <p>The Board noted that this amount will be reducedby the aggregate amount of successful appeals of Third round decisions.</p> <p>The Board noted that the total amount of funds requested in proposals submitted to the AppealsPanel following round 3 and deemed eligible for review is US$101.5million.</p>

<p>The Board:</p> <ol> <li>Approves waiver of the Board condition imposed in the Congo HIV grant (COG-911-G06-H) restricting the “use of funds to finance activities other than (i) the procurement of Health Products and Pharmaceuticals and (ii) other activities deemed essential in the framework of the program,” and</li> <li>Approves disbursement of grant funds to the principal recipient the Secretariat Executif Permanent/Comité National de Lutte contre le SIDA (SEP /CNLS) to conduct activities essential to the implementation of the HIV program.</li> </ol>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period^[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 157,073, 590 for the following grants: BAN-M-NMCP ; BAN-M-BRAC ; TCD-810-G04-H ; TCD-810-G05-H ; TCD-810-G06-H ; ZAR-809-G10-H ; ZAR-810-G11-H ; ZAR-810-G12-H</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2016 Annual Financial Report, which includes the 2016 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in GF/B37/02 Annex 1.</p>

<ol> <li>The Board approves the appointment of Magda Robalo Correia e Silva as Chair of the Ethics and Governance Committee.</li> <li>The Board notes that the Chair of the Ethics and Governance Committee appointed under this decision point shall begin her term on 16 May 2020 and serve for two years or until the appointment of her successor.</li> </ol>

<ul type="disc"><li>Dr. Ren Minghui from the Western Pacific Region (China) Constituency is designated as Rapporteur for the Tenth Board Meeting.</li></ul>

<p>The Board:</p> <p>1. Notes the paper presented by the Secretariat on potential options and implications for enhancing Global Fund contributions to maternal and newborn and child health (GF/B22/DP4, Annex 3), consistent with its previous decision entitled "Exploring Options for Optimizing Synergies with Maternal and Child Health." (GF/B21/DP20);</p> <p>2. Encourages countries, where applicable, to strengthen the MNCH content of their Global Fund-supported investments, maximizing existing flexibilities for integrated programming as noted in the previous Decision Point;</p> <p>3. Requests the Secretariat to develop, under the oversight of PIC and in collaboration with partners, clear guidance (including indicators) for countries on strengthening the MNCH content of their HIV/AIDS, tuberculosis, malaria, and health systems strengthening portfolios. As part of this work, the Secretariat will detail the operational and budgetary implications of rolling out the guidance; and</p> <p>4. Acknowledges the need to define longer-term possibilities for increased engagement by the Global Fund in MNCH, as part of the Strategy Development Process. </p>

The Board approves the 2007 Corporate Key Performance Indicators and associated 2007 targets contained which will also serve as the Key Performance Indicators/Targets for the Executive Director.

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER07; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board refers to its Decision GF/B20/DP11 regarding approval of Round 9 proposals and approves for funding for an initial two years those Round 9 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals and as listed in the following table. Such approval is subject to the Comprehensive Funding Policy, satisfactory completion by the applicants of the Technical Review Panel (TRP) clarifications as set out in paragraph 5 of Decision GF/B20/DP11 and the measures associated with funding of Round 9 proposals and national strategy applications set out in Decision GF/B20/DP9.</p> <p>See attached tabledetailing total TRP recommended Phase 1 Upper Ceiling (2 years) funding amount of US$ 719,921,434 for the Category 2B grants.</p>

The report of the Eighteenth Board Meeting (GF/B19/2, Revision 2) is approved.

The Board approves the Guidelines for the Fifth Call for Proposals.

We, the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria, wish to express our heartfelt thanks and appreciation to Professor Sir Richard Feachem for his tremendous service as our founding Executive Director. He has helped lead a Secretariat of the Global Fund from vision to reality. There is no greater measure of success than the estimated 1.25 million lives saved because of Global Fund-supported grants. We thank him for his tremendous service and wish him continued success as a global leader committed to improving the health and wellbeing of the world's poorest citizens.

<p>The Board:</p> <ol> <li>Approves the extension budget and revised implementation period recommended for each grant listed in Table 3 of GF/B46/ER11 (“Table 3”); and</li> <li>Affirms that any additional funding provided to fund the extension budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 3, and (b) is subject to the availability of funding.</li> </ol>

Carsten Staur from the Point Seven constituency is designated as Rapporteur for the 36th Board Meeting.

<p>The Board notes the concepts set out in the Letter of Intent (GF/FAC13/20, Annex 2) to be signed with a property developer, and requests the Secretariat to engage in further negotiations for the construction of a building to be leased by the Secretariat. </p><p>The Board notes the importance for the Secretariat to identify a suitable entity that, at the time the Secretariat signs a lease agreement, provides a binding commitment to share the rent for space in this office building, in the case where the building contains more space than what would be necessary to house the Fund at that time. The Board also encourages the Secretariat to minimize the Fund's financial exposure for the costs of the building prior to occupancy, and to provide additional information about interim arrangements between the date of the expiration of the current lease and the expected date of occupancy of the new space. </p><p>The Board requests the Finance and Audit Committee to oversee the arrangements for the Secretariat's future office space.</p>

Mr. Alexander Konuzin from the Eastern Europe constituency is appointed as Rapporteur for the Fifteenth Board Meeting.

<ol><li><p>The Board:</p><p>a. Expresses its strong commitment to the Global Fund Fifth Replenishment (2017-2019) aimed at raising the appropriate levels of funding for implementation of the "Investing to End Epidemics" Strategy; </p><p>b. Recognizes the importance of the preparatory meeting that will take place in Tokyo in December 2015; and</p> c. Acknowledges the challenging environment for mobilizing resources, the need to continue maximizing the Global Fund's results and impact, and the initiative to maximize absorption capacity. <br/><br/></li><li>Accordingly the Board will: <br/><br/> a. Explore options to enhance its active engagement in contributing towards a successful outcome of the Replenishment, including the broadening of the donor base; and <br/><br/> b. Seek the support of high-level individual(s) who, in collaboration with the Board leadership and Secretariat, will advocate on its behalf for a successful Global Fund Replenishment.</li></ol>

<p>1. The Board approves the following amendments to the fourth paragraph of Article 7.6 of the Bylaws: </p><p>Notwithstanding the foregoing, the Board may decide to take action on a no-objection basis. On such basis, and subject to procedures set by the Board, a motion shall be deemed approved unless four Board members of one of the voting groups described above objects to the motion<b>.</b>, except that a motion not to renew funding for a proposal beyond the initial funding commitment shall be deemed approved unless four Board members of each of the voting groups described above object to the motion. </p><p>2. The Board approves the following amendments to Article 12 of the Board Operating Procedures:</p><p>"<b>Article 12. No-Objection Process for Approving Funding </b></p><p>Notwithstanding Sections 10 and 11, decisions by the Board to provide funding for approved proposals beyond the initial funding commitment or proposals requesting continued funding for grants that are reaching the end of their funding terms may be made on a no-objection basis under the following process.</p><p>As directed by the Board, the Secretariat shall issue a request for decision on each funding commitment for which a Board decision is required, and shall notify the Board accordingly. Unless four Board members of one of one of the voting groups described in Section 10 object to the requested decision within a time period specified by the Board following the date of notification the requested decision shall be deemed approved by the Board, except that a requested decision not to renew funding of a proposal beyond the initial funding commitment shall be deemed approved by the Board unless four Board members of each of the voting groups described in Section 10 object to the recommendation within a time period specified by the Board following the date of notification."</p>

<p>The Board:</p> <ol> <li>Recalls GF/B43/EDP07 where it decided to extend the scope of the wambo.org pilot to allow for eligible buyers, as defined in GF/B42/DP05, to purchase all COVID-19products available in wambo.org for procurement by Global Fund Principal Recipients and specified that such non-Global Fund financed transactions forCOVID-19 products will be issued as purchase orders by wambo.org within the period ending 31 December 2020, unless extended by the Board following recommendation by the Strategy Committee;</li> <li>Recalls GF/B43/EDP17 where the Board approved the change in the end date of such period to 31 May 2021; and</li> <li>Based on the recommendation of the Strategy Committee, approves the change in the end date of such period through which non-Global Fund financed transactions for COVID-19 products may be issued as purchase orders by wambo.org until November 2022 or until the Board approves a future strategy for wambo.org if earlier and confirms that all other conditions and flexibilities set forth in GF/B43/EDP07 shall continue to apply.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER05 – Revision 1 ( “Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Bhutan (BTN-H-MOH), Bulgaria (BGR-T-MOH), Burkina Faso (BFA-T-PADS, BFA-H-SPCNLS, BFA-C-IPC), Cambodia (KHM-M-UNOPS), Cape Verde (CPV-M-CCSSIDA), Côte d'Ivoire (CIV-M-PNLP), Eritrea (ERI-T-MOH, ERI-H-MOH), Ethiopia (ETH-H-HAPCO, ETH-T-FMOH), Fiji (FJI-T-MHMS), Ghana (GHA-H-ADRA, GHA-H-PPAG, GHA-H-MOH, GHA-H-GAC, GHA-T-MOH), Mauritius (MUS-H-NAS, MUS-H-PILS), Multicountry Western Pacific (QMJ-C-UNDP, QMJ-M-UNDP), Nicaragua (NIC-H-INSS), Niger (NER-H-CISLS), Pakistan (PAK-T-NTP, PAK-T-MC), Russian Federation (RUS-H-OHI), Rwanda (RWA-T-MOH, RWA-H-MOH), Solomon Islands (SLB-M-MHMS, SLB-T-MHMS), Sudan (SDN-H-UNDP), Swaziland (SWZ-T-NERCHA) and Tanzania (TZA-C-STC).</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2018 Annual Financial Report, which includes the 2018 Consolidated Financial Statements that have been audited by KPMG SA, as set forth in Annex 1 to GF/B41/04.</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period1 for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat in consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 187,471,224 for the following grants: VTN-S10-G09-H ; HTI-811-G07-M ; MLW-911-G08-M ; TGO-910-G10-M ; TGO-910-G11-M ; KEN-S11-G11-T ; KEN-S11-G12-T ; MON-S-MOH</p>

<p>The Board notes with concern increasing reports of threats to HIV/AIDS, tuberculosis (TB), and malaria treatment continuity. For example, recent estimates by the World Bank indicate that antiretroviral treatment to 1.7 million people is under threat, with 15 countries "highly exposed" to the risk of treatment interruption. </p><p>Therefore, the Board requests the Chair and Vice Chair to delegate to the appropriate committee(s) the task of reporting back to the Board at its Twentieth Meeting with an update on this issue, including an analysis - undertaken by the Secretariat in cooperation with partners as a matter of urgency - that indicates which countries receiving Global Fund support for HIV/AIDS, TB and malaria treatment are at risk of treatment disruption in 2009-10. The Board requests that the Secretariat, while continuing its ongoing work to minimize the risk of stock-outs and treatment disruption, report to the appropriate committee(s) on whether or not existing procedures are adequate and propose solutions to minimize the risk of stock-outs and treatment disruption on an ongoing basis. </p><p>The Board also requests the Secretariat to designate a focal point to liaise with specified focal points among relevant partners and affected communities to facilitate communication and respond effectively and collectively to threats to treatment continuity. </p>

<ol><li>The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposals recommended for funding by the Technical Review Panel (TRP) as ‘Category 2’ which are listed in Annex 1 to the Report of the TRP and the Secretariat on Funding Recommendation for Wave 8 Rolling Continuation Channel Proposals (the “Wave 8 RCC Report”). The Board approves funding for up to three years for each proposal (indicated as “Total 3 Years” in Annex 1 to the Wave 8 RCC Report). The Board’s approval is made with the clear understanding that the grant amounts requested are upper ceilings subject to TRP clarifications and grant negotiations rather than final approved grant amounts. For <br/>further clarity, this decision is subject to the revised Comprehensive Funding Policy approved at the Twentieth Board meeting.</li><li>The applicants whose proposals are recommended for funding as ‘Category 2’ shall: <ol><li type="i">provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board’s decision; and</li><li type="i">conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than two months from the Secretariat’s receipt of the applicant’s initial detailed response to the issues raised for clarification and/or adjustment.</li></ol></li><li>The Board declines to approve for funding those proposals categorized by the TRP as ‘Category 3A’ as indicated in Annex 1 to the Wave 8 RCC Report, however such applicants are strongly encouraged to resubmit a revised proposal, taking into account the issues raised by the TRP, for consideration in the final resubmission wave of Rolling Continuation <span style="font-size: 12px; line-height: 1.5;">Channel review.</span></li><li>The Board declines to approve for funding proposals categorized by the TRP as ‘Category 3B’ as indicated in Annex 1 to the Wave 8 RCC Report, however such applicants are encouraged to resubmit the proposal through the Rounds-Based Channel following major revision.</li></ol>

Based on the recommendation of the Audit and Ethics Committee, the Board approves the appointment of Ernst &amp; Young as the Global Fund’s external auditor for the 2013 fiscal year.

The agenda for the Eighth Board Meeting is approved.

<p>The Board approves the appointment of Ms. Sandra Roelofs as a voting member of the Strategy, Investment and Impact Committee (the “SIIC)”) for a term that will expire on 9 March 2016, or until the appointment of her successor.</p>

<ol> <li>Based on the recommendation of the Strategy Committee as presented in GF/B42/04- Revision 1, the Board:<br /><br /> <ol type="i"> <li>reaffirms the importance of wambo.org and supports evolving the wambo.org pilot approved by the Board pursuant to GF/B37/DP09, as the number of transactions was increased pursuant to GF/SC09/DP01, to further its development and advancement;</li> <li>decides that, in connection with the evolution of the wambo.org pilot, wambo.org may be made available for non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible and transitioned countries, for all products, services and functionalities as they become available on wambo.org, subject, if applicable, to agreement by the product catalogue owners, as described in GF/B42/04- Revision 1, up to a cap of USD 50 million of transactions within the above scope from the date of this Decision Point; and</li> <li>instructs the Secretariat to undertake consultations early in 2020, an evaluation of the wambo.org pilot in 2022 and bi-annual reporting on progress of the wambo.org pilot to the Strategy Committee.<br /><br /></li> </ol> </li> <li>The Board delegates to the Strategy Committee the authority to: <ol type="i"> <li>approve a higher cap for transactions within the scope of Section 1(ii) above on a pilot basis prior to the consultations in 2020; and</li> <li>establish the future parameters of the wambo.org pilot within the scope of Section 1(ii) above, based on the outcome of the 2020 consultations.</li> </ol> </li> <li>The Board requests the Secretariat to include the results of the evaluation referred to in Section 1(iii) in the development of a strategy for future advancement of wambo.org to be presented for Board approval at the conclusion of the wambo.org pilot for non-Global Fund-financed orders no later than November 2022.</li> </ol>

Dr. Reinhard Tittel-Gronefeld from the Germany (Canada, Switzerland) constituency is designated as rapporteur for the Twenty-Sixth Board Meeting.

One additional item is added to the Board’s agenda, proposed at 1800 today. The Board approves the revised Agenda.

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B32/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol><li>The Board endorses the Global Fund's Monitoring and Evaluation strategy as described by the MEFA Committee [the Monitoring and Evaluation Strategy document GF/B6/1 and annex 1 GF/B6/11.1 which describes the management arrangements for the Fund's M&amp;E].</li><li>The Board approves the correction of the Round 1 grant amounts previously recorded as approved by the Board, in these cases, to reflect the Board's overall decision to approve the first two years of each proposal, thus endorsing the amounts agreed to in the grant agreements.</li></ol>

<p>Referring to its earlier decision on 23 November 2010 (GF/B21/EDP27), the Board:</p> <ol> <li>Notes a transcription error was made in the reporting of the amounts requested and the Secretariat‘s recommendation for incremental funding for the Phase 2 period for the Zambia grants numbered ZAM-708-G18-T and ZAM-708-G17-M listed in Schedule A of that earlier decision point.</li> <li>Decides to amend its funding decision for the two Zambia grants numbered ZAM-708-G18-T and ZAM-708-G17-M, by replacing the earlier approved amounts with the corrected funding amounts as set out in Schedule A to this decision point, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).¹</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each of affected proposals shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 102,377,215 for the following grants: NEP-708-G06-M ; IRN-708-G02-M ; IRN-708-G03-T ; SLE-708-G03-T ; SUD-708-G09-M ; MDG-708-G09-M ; AFG-708-G04-H ; AFG-708-G05-H ; ZAM-708-G16-T ; ZAM-708-G18-T ; ZAM-708-G17-M ; ZAM-708-G19-M ; GIN-607-G05-M</p>

Mr Luis Riera Figueras from the European Commission (Belgium, Finland, Portugal) constituency is designated as Rapporteur for the Sixteenth Board Meeting.

<p>The Board recognizes that, as described in the Portfolio and Implementation Committee's Report to the Board (GF/B20/5), there are challenges with identifying sources for certain essential and long-established multi-source treatments that meet the requirements of the Global Fund's revised Quality Assurance Policy for Pharmaceutical Products ("QA Policy"). In order to avoid disruption to treatment of patients, but without compromising the fundamental quality assurance principles of the QA Policy, the Board therefore decides to revise the QA Policy to expand the eligibility criteria for a risk/benefit review of products by the Expert Review Panel (ERP) by adding the following interim provision at the end of paragraph 13 of the QA Policy: </p><p>"Provided that the criterion in paragraph (ii) above is met, certain multi-source [8] FPPs for malaria and first-line tuberculosis treatment that do not meet the criteria in paragraph (i) above are also eligible for review by the ERP for associated potential risks/benefits in accordance with paragraph 10 of this Policy. The list of ERP-recommended FPPs that is made publicly available will indicate which of the ERP-recommended FPPs were eligible for review as a result of this paragraph. </p><p>Footnote 8: For these purposes, "multi-source" means a pharmaceutical product for which the monograph of the finished dosage form was published in the International, U.S. or U.K. Pharmacopeia before 10 October 2002"</p><p>The Board requests the Market Dynamics and Commodities Committee to review this amendment to the QA Policy, with special attention to the working, transparency and reporting requirements of the ERP review process, and to report to the Board at its last meeting in 2010.</p><p>The Board notes that it will take some time for dossiers for these multi-source FPPs to be prepared and submitted to the next set of ERP reviews and that an interim exception is necessary to avoid disruption in essential treatment. The Board decides that, on an exceptional basis and for the period up to 31 December 2010 only, grant funds may be used to procure certain multi-source FPPs for malaria and first-line tuberculosis treatment, provided that:</p><p>a. there are no other FPPs for that product formulation available (as defined in the QA Policy) that are WHO-prequalified or SRA-authorized or ERP-recommended;</p><p>b. the site at which such FPP is being manufactured must, at the time of the procurement, be in compliance with the relevant GMP standards as verified by the WHO Prequalification Program, or an SRA or a regulatory authority participating in PIC/S; </p><p>c. the FPP has been selected for procurement by relevant UN procurement agencies; and</p><p>d. the notification/confirmation and testing processes described in paragraphs 9 and 31 of the QA Policy will apply to such procurement.</p><p>The Board requests the MDC to consider, as a matter of urgency, contingency plans regarding the recently notified disruption of funding for certain life-saving medicines (e.g. artemisinin intra-rectal and injectable medicines) in situations where no FPPs for such medicines meet the criteria in paragraph 7 of the QA Policy and to make recommendations to the Board at the earliest opportunity.</p>

<p>The Board approves the 2011 Operating Expenses Budget in the amount of US$ 324.7 million as set out in Annex 1 to the Report of the Finance and Audit Committee (FAC) to the Twenty-Second Board (GF/B22/6), based on the exchange rate applicable on the date of release of the Report of the FAC.</p><p>Following approval of the budget, the Secretariat shall enter into a forward contract with a reputable bank. In the event that the exchange rate determined on the date of signature of the forward contract results in a change in the budget, the Secretariat shall notify the Board of such change. The new amount shall thus be deemed to be the approved Operating Expenses Budget for 2011. </p><p>The use of any amount in the US$ 3.0 million contingency within the OIG budget for 2011 is conditional upon the advance approval of the FAC.</p>

<p>1. The Board notes that up to USD 800 million is available for catalytic investments, subject<br />to the amount of sources of funds for allocation, in accordance with the allocation<br />methodology approved in April 2016 under decision point GF/B35/DP10 and set forth in<br />Annex 1 to GF/B35/05 - Revision 1.<br /><br />2. Based on the recommendation of the Strategy Committee (the "SC") and the amount of<br />sources of funds for allocation recommended by the Audit and Finance Committee (the<br />"AFC") in GF/B36/03, the Board decides USD 800 million will be available for catalytic<br />investments over the 2017 - 2019 allocation period for the priorities and associated costs<br />presented in Table 1 of GF/B36/04 - Revision 2, of which no portion will be moved to<br />further balance scale up, impact and paced reductions through country allocations.<br /><br />3. The Board notes the Secretariat will have flexibility to operationalize catalytic investments,<br />update the SC and Board on such operationalization, and present any reallocations of the<br />associated costs among the approved priorities for the SC's approval.<br /><br />4. The Board asks the Secretariat to provide the SC with a scope of effort and expected<br />outcomes at the start of all strategic initiatives and to seek SC approval during<br />implementation if there is a substantial change to the relevant strategic initiative's scope.</p>

<p>The Board:</p> <p>i. acknowledges its previous decisions (GF/B15/DP17 and GF/B18/DP20) concerning the need for and value of a National Strategy Applications ("NSAs") procedure; and</p> <p>ii. recognizes the ongoing learning process with partners from the launch of the First Learning Wave of NSAs ("FLW").</p> <p>Therefore, the Board requests the Secretariat to prepare appropriate in-depth analyses and recommendations, taking into account:</p> <p>i. the feedback from the Technical Review Panel and other relevant partners on the FLW; and</p> <p>ii. the new architecture approved at this Board meeting;</p> <p>for further investment on the basis of NSAs; and present it to the Policy and Strategy Committee for further consideration at its next meeting.</p>

<p>The Board:</p><ol><li>Approves additional 3-month extensions to Phase 1 ending dates for Ecuador Round 9 HIV and TB grants (ECU-910-G06-H, ECU-910-G08-T) following the “Resubmission Request” recommendation2. Additional funding is not provided for these grant extensions while the CCM submits a revised Request for Renewal.</li><li>Approves 3-month extensions to Phase 1 ending dates with funding for the grants listed in Table 2 in the amounts indicated for each grant, following the “Resubmission Request” recommendation. Additional Funding will be provided to the grants implemented by Civil Society Principal Recipients in order to prevent disruption of programmatic activities while the CCM submits a revised Request for Renewal.</li></ol><p>See attached tabledetailing total recommended funding amount of USD 482,472 for the following grants: ECU-910-G07-H ; ECU-910-G09-T</p>

<p>The Board acknowledges that, even though the condition is not fully fulfilled, there is some progress made on the condition upon which the Board approved the Uganda Round 6TB grant to the Ministry of Finance, Planning and Economic Development of the Government of Uganda (UGD-607-G06-T). The Board decides to waive this condition to allow signing of the Phase 2 extension.</p><p>This decision does not have material budgetary implications.</p>

The Board approves additional funding for the Phase 1 period of the Round 9 Nigeria HIV/AIDS proposal to accelerate the scale-up of prevention of mother-to-child transmission interventions in the amount of up to US$ 29,325,424 subject to TRP clarifications and conditions within a limited timeframe. Approval is given for this amount on the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and is based on the understanding that the overall life-time budget for the proposal of US$ 341,019,908 does not change by this Decision.

<p>The Board recognizes that, in exceptional circumstances, there may be a need to provide funding for the continuation of treatment in grants where funding ends. </p> <p>The Board wishes to revise its policy on continuity of services for treatment (as amended at the Twelfth and Thirteenth Board Meetings) to reflect the differing circumstances of grants that end because of suspension, force majeure situations, a decision not to provide Phase 2 funding, or other unforeseen causes ("unanticipated terminations") and grants which reach the end of their term ("anticipated expirations"). </p> <p>The Board accordingly revokes the Continuity of Services decision, as amended at the Thirteenth Board Meeting (GF/B14/2) and replaces it with this decision:</p> <p>The Board adopts the following system for addressing continuity of services following both unanticipated termination and anticipated expiration of grants: </p> <p>i. A recipient (typically a CCM) whose funding has ended may submit an Extraordinary Request for Continued Funding for Treatment.</p> <p>ii. The Extraordinary Request will be limited to expenses directly related to the continuation of courses of treatment (including medicines [which, in the case of discontinuation of anti-retroviral therapy, includes drugs for HIV-related opportunistic infections], diagnostics, and, as appropriate, costs for medical staff and other personnel directly involved in care of the patients on treatment) for those people already placed on courses of treatment under the existing proposal at the time of the Extraordinary Request. "Courses of treatment" includes treatment that is for a limited duration (such as for tuberculosis), or is life-long (such as for antiretroviral therapy).</p> <p>iii. The Extraordinary Request will be limited to the amount required to provide services directly related to the continuation of courses of treatment for up to two years (taking into account any amount which remains available under the existing grant).</p> <p>iv. The Extraordinary Request shall contain a description of the steps taken to find sustainable sources of financing for the people on courses of treatment, and to ensure the recipients are delivering courses of treatment effectively. To be eligible for funding under this provision, the CCM (or, in the case of non-CCM proposals, the grant applicant) must demonstrate that it has used its best efforts to identify other sources of funding to provide continuity of services, but has been unsuccessful.</p> <p>v. The Secretariat will review the Extraordinary Request, and provide a funding recommendation to the Board for its approval. The Secretariat will take into account performance issues, as appropriate, and shall make any adjustments to existing implementation arrangements necessary to ensure the effective use of Global Fund financing.</p> <p>vi. Throughout the process, the Secretariat will encourage CCMs and PRs to actively engage with technical partners to identify mechanisms to ensure continuity of services. </p> <p>vii. In a resource-constrained environment, the Global Fund shall prioritize Extraordinary Requests for Continued Funding for Treatment for anticipated expiration and Extraordinary Requests for Continued Funding for Treatment for unanticipated termination at the same level as Phase 2 renewals.</p> <p>The following additional conditions shall apply in cases of anticipated expiration:</p> <p>viii. CCMs that submit an Extraordinary Request must provide evidence of compliance with Global Fund counterpart financing requirements during the period for which they make the request.</p> <p>ix. In addition to the merit of the request, the primary factor affecting the Secretariat's recommendation to the Board with respect to the amount and duration of funding for the continuity of treatment shall be the income level of the country of the applicant (as defined by the World Bank income classification of the applicant in the year of application of an Extraordinary Request); the Secretariat may also take into account other relevant considerations such as the size of the treatment program (in terms of cost or number of patients).</p>

The Board recommends that the option of top-up grants should not be pursued as mechanisms to protect against exchange rate fluctuations.

<p>The Board takes note of the Secretariat's work to date in exploring alternative options to WHO for contracting certain administrative services, undertaken against the objective of "delivering a plan by November 2005 for transition to a fully independent entity" (Executive Director's performance objectives, Arusha, November 2004).</p><p>Having regard to the Finance and Audit Committee's request for clarification of the Board's intent with respect to a possible transition from current administrative arrangements with WHO, the Board requests the Secretariat to continue its analysis of advantages and disadvantages of alternative arrangements, including their costs, and report back, providing a proposed implementation plan if appropriate, at the Thirteenth Board meeting.</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the <span style="font-size: 12px; line-height: 1.5;">amounts indicated for each proposal, with the clear understanding that the amounts </span><span style="font-size: 12px; line-height: 1.5;">approved are upper ceilings rather than final funding amounts, and based on an </span><span style="font-size: 12px; line-height: 1.5;">understanding that the Secretariat shall pursue on-going implementation arrangements for </span><span style="font-size: 12px; line-height: 1.5;">each proposal consistent with the recommendations set forth in its Grant Score </span><span style="font-size: 12px; line-height: 1.5;">Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification </span><span style="font-size: 12px; line-height: 1.5;">of Grant Renewals and Transition to New Funding (GF/B25/DP16).</span><sup style="font-family: inherit; font-style: inherit; font-weight: inherit;">[1]</sup></li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 1,654,675 for the following grant: KGZ-811-G09-M</p>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁷</p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached table detailing total recommended funding amount of US$ 102,377,215 for the following grants: NEP-708-G06-M ; IRN-708-G02-M ; IRN-708-G03-T ; SLE-708-G03-T ; SUD-708-G09-M ; MDG-708-G09-M ; AFG-708-G04-H ; AFG-708-G05-H ; ZAM-708-G16-T ; ZAM-708-G18-T ; ZAM-708-G17-M ; ZAM-708-G19-M ; GIN-607-G05-M</p>

<p>Consistent with the Board’s November 2011 decision titled ‘Modification of Grant Renewals and Transition to New Funding’ (GF/B25/DP16) as it applies to grant renewals:</p> <ol> <li>While the Secretariat works on scenarios to model the impact of the 55% rule, and the most effective measures for implementation, grant renewal invitation letters issued to Country Coordinating Mechanisms will have ceilings of 90% for Low Income Countries and Low-Lower Middle Income Countries, and 75% for all other country income level categories;</li> <li>New ceilings will apply to all grant renewal invitation letters issued on or after 1 January 2012; and</li> <li>The letters will explain the reasons for these (in some cases) new ceilings, and will also mention that the ceilings may be adjusted later.</li> </ol>

<p>The Board appoints Marijke Wijnroks to serve as Interim Executive Director of the Global Fund, effective as of 01 June 2017 until the commencement of the term of the new Executive Director of the Global Fund.</p>

<p>The Board appoints the following individuals to serve as members of the Inspector General Nomination Committee (Nomination Committee) in accordance with the terms of reference of the Nomination Committee approved under decision point GF/B43/DP03 and set out in Annex 1 to GF/B43/12 – Revision 1:</p> <ul> <li>Grace Rwakarema, Chair</li> <li>Thomas Alexander, Vice-Chair</li> <li>Allan Maleche, Member;</li> <li>Thomas Morrow, Member;</li> <li>David Webb, Member;</li> <li>Diana Isiye; Independent Member and,</li> <li>Norbert Hauser, Independent Member.</li> </ul>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER21; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18. </li> </ol>

1.<b> </b> Chair and Vice Chair of the Board will discuss with the Executive Director on issues related to committee leadership and composition and revert to the Board as soon as possible.

<ol> <li>The Board: <ol type="a"> <li>Notes additional analysis was required to finalize the performance targets for the updated 2014 - 2016 Global Fund Corporate Key Performance Indicator Framework (the "KPI Framework") that was approved in November 2014 (GF/B32/DP10); and</li> <li>Acknowledges the Secretariat's presentation of 2014 performance assessments and updates, as well as updated performance targets, for the KPI Framework, as set forth in GF/B33/04B.</li> </ol> </li> <li>Accordingly, the Board approves the updated performance targets for Key Performance Indicators 6, 12 and 16, as presented in GF/B33/04B.</li> </ol>

<ol> <li>The Board approves for funding the Round 3 categories 1 and 2A today, (15 October) subject to the completion of TRP clarifications.</li> <li>The Board approves proposals in TRP category 2B, subject to the completion of TRP clarifications. This decision would become effective upon Board confirmation by email in January 2004. Meanwhile the Secretariat can proceed with resolving TRP clarifications for these proposals.</li> <li>The completion of TRP clarifications in Category 1 should be completed within 4 weeks of the applicant's receipt of the initial decision of the Board, and given final approval by the TRP Chair and/or Vice Chair.</li> <li>The initial reply to TRP clarifications for proposals in Category 2 should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further clarifications should be completed within 4 months from the receipt of the initial reply from the applicant. The TRP Chair and/or Vice Chair shall give final approval based on consultations with the primary and secondary reviewers.</li> <li>Proposals in Category 3 are not recommended in their current form but are encouraged to resubmit.</li> <li>Proposals in Category 4 are not recommended for funding.</li> <li>The Board requests the PMPC and GPC to examine the issue of non-CCM proposals that have been approved by the Board and that may be against the criteria for non-CCM proposals, and report to the Seventh Board Meeting.</li> <li>The Board requests the PMPC and GPC to review the applicability of the eligibility criteria to future non-CCM applications.</li> <li>The Board requests the GPC todevelop with reference to the Framework Document guidelinesrecommendations for alternative funding mechanisms where particular constraints exist about funding the proposed Principal Recipients and sub recipients. These recommendations should reflect the humanitarian spirit of the Global Fund and the desire to direct funds quickly and accountably to affected populations. These modalities, subject to approval by the Board, should also apply to all approved proposals in Round 3.</li> <li>The Board requests the GPC to examine the possible conflicts of interest between the Chairs of CCMs and the Principal Recipients, particularly in the process of selecting Principal Recipients.</li> <li>The Board requests the GPC to examine the eligibility of CCM applications when the composition of CCMs lacks representation of communities affected by the three diseases and civil society.</li> </ol>

<p>The Board:</p><ol><li>Refers to condition number 5 in its decision approving as a „Conditional Go‟ the Phase 2 of the Kenya Round 6 TB grant (KEN-607-G08-T) (“Condition 5”) which states that: “Not later than 30 September 2010, the Principal Recipient must finalize and submit to the Global Fund the reports for the audits of the Financial Management Agent and the Procurement Consortium,” and</li><li>Decides to extend the deadline in Condition 5 from 30 September 2010 to 31 March 2011.</li></ol>

<p>Erika Satterwhite from the Private Sector Constituency is designated as Rapporteur for the 48th Board Meeting.</p>

In accordance with Section 26 of the Board Operating Procedures and based on the satisfactory performance appraisal of Professor Michel Kazatchkine in the role of the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Board decides to extend his appointment for a further term of three years from the end of his current term till the end of the month of the first Board meeting in 2014.

<p>The Board:</p> <ol> <li>Notes its decision in GF/B46/EDP06, which requires the Secretariat to recommend tothe Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awardsexceeding US$45 million, as measured in aggregate by country (not including anyfunding awarded for COVID-19 commodities through fast-track investments orC19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 ofGF/B46/ER18; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling offunding available for each country among its constituent grants in accordance with thepreviously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria expresses its shock and deep sorrow at the untimely death of Ambassador Richard C. Holbrooke.</p><p>In his position as the United States Ambassador to the United Nations and later as the founding President of the Global Business Coalition against AIDS, Ambassador Holbrooke played a ground-breaking role in ensuring that the world accepted HIV and AIDS as a threat to international security and global business as well as being a humanitarian catastrophe. He was one of the drivers behind the allocation of large, additional resources to fight HIV and AIDS and was a tireless advocate for the engagement of the private sector in the fight against the pandemic and for testing and prevention as a crucial part of this struggle. </p><p>The fight against HIV and AIDS has lost one of its most influential and passionate ambassadors. Richard Holbrooke will be missed by all who knew him and the millions who benefitted from his work.</p><p>The members of the Board and the staff of the Global Fund send our thoughts to Ambassador Holbrooke's wife, their children and grandchildren.</p>

<p>The Board approves those AMFm Phase 1 applications recommended for approval by the Technical Review Panel (TRP) as 'Category 1' and 'Category 2', as listed in Annex 1 to the Report of the Technical Review Panel and Secretariat on AMFm Applications (GF/B20/10), subject to paragraphs 2-3 below. The Board's approval is for re-programmed and new grant funding (as the case may be) for a full two<b>-</b>year period for each AMFm Phase 1 application and is not subject to prioritization.</p><p>The applicants whose applications are recommended for approval as 'Category 2' shall:</p><p>a. provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than four weeks after receipt of notification in writing by the Secretariat of the Board's funding decision; and</p><p>b. conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than 31 January 2010.</p><p>For those applications recommended for approval as 'Category 2', if the TRP clarification process is not concluded to the satisfaction of the TRP by the deadline stipulated in paragraph b above, the AMFm application in its entirety will be deemed not approved.</p><p>The Board declines to approve for funding those applications recommended by the TRP as 'Category 3' as indicated in Annex 1 in GF/B20/10. </p>

Peter van Rooijen from the Developed Country NGO Constituency is designated as Rapporteur for the Twelfth Board Meeting.

<ol> <li>Based on the joint recommendation of the Strategy, Investment and Impact Committee (the “SIIC”) and the Finance and Operational Performance Committee (the “FOPC”), as outlined in GF/B32/23, the Board:</li> <ol type="a"> <li>Affirms its commitment to optimizing the performance and impact of investments in health products and devices, through the review and updating of the Market Shaping Strategy (Annex 1 to GF/B23/09 - Revision 1) as well as oversight of its implementation and operationalization;</li> <li>Decides the Market Dynamics Advisory Group (the “MDAG”) will cease as of the date of this decision, and that no advisory body shall be created or utilized to support the Board and its Committees in their responsibilities over market-dynamics matters;</li> <li>Acknowledges the Secretariat’s responsibility to develop, update and implement strategic policies and initiatives on market-dynamics matters in collaboration with partners with relevant expertise;</li> <li>Decides that the overall responsibilities for oversight and monitoring of market-dynamics matters, which include strategic and operational components, shall rest with the FOPC and SIIC as follows: <ol type="i"> <li>The SIIC shall be responsible for guiding and overseeing the development and updating of strategic policies related to market-dynamics matters, such as the Market Shaping Strategy for recommendation to the Board by its November 2015 meeting; and</li> <li>The FOPC shall be responsible for oversight of the implementation of strategic policies, including the financial and operational aspects of related sourcing and procurement initiatives.</li> </ol> </li> </ol> <li>Accordingly, the Board approves the amendments and restatements of the following governance documents, which shall become effective as of the date of this decision: <ol type="a"> <li>Bylaws, as set forth in Annex 1 to GF/B32/23;</li> <li>Charter of the Finance and Operational Performance Committee, as set forth in Annex 2 to GF/B32/23; and</li> <li>Charter of the Strategy, Investment and Impact Committee, as set forth in Annex 3 to GF/B32/23.</li> </ol> </li> <li>The Board directs the FOPC and SIIC, in collaboration with the Secretariat, to develop procedures and mechanisms on reporting and engagement to facilitate the FOPC and SIIC in the discharge of their responsibilities, including establishment of methods for how the committees will communicate, as a whole and through focal points, and ways to enlist experts that can provide technical support when appropriate. Such procedures and mechanisms will be in place and communicated among the members of the FOPC and SIIC by the end of the 2014 calendar year.</li> </ol>

<p>The Board recognizes that, as a result of the termination of the Administrative Services Agreement with the World Health Organization, all operating expenses are now required to be paid through the Global Fund's Credit Suisse bank account. The Board decides to rescind its previous decision on the policy for the Credit Suisse bank account (GF/SB1/DP6). The Credit Suisse bank account shall be maintained and used by the Global Fund in accordance with the Global Fund's Financial Rules and Regulations for the following:</p> <p>1. to hold the foundation's capital, of CHF 50,000, as required by Swiss law;</p> <p>2. to pay for all Secretariat operating expenses in accordance with the Board-approved annual budget; and </p> <p>3. to receive private-sector contributions that the Trustee is not able to receive directly and other miscellaneous receipts.</p> <p>The Board requests the Finance and Audit Committee to continue its oversight of the Credit Suisse bank account.</p>

<p><b>Decision Point 1</b> </p><p>The Board approves the list of persons contained in Annex 3 of the Report of the Portfolio Management and Procurement Committee (GF/B9/9) who have been recommended by the Portfolio Management and Procurement Committee and the Executive Director to fill the vacancies on the Technical Review Panel.</p><p>There are no material budgetary implications for this decision point. </p><p><b>Decision Point 2</b> </p><p>The Board approves the list of persons contained in Annex 4 that have been recommended by the PMPC and the Executive Director to comprise the TRP Support Group.</p><p>There are no material budgetary implications for this decision point. </p><p><b>Decision Point 3</b> </p><p>Board decides that the language used in its decisions for the approval of Category 2 proposals shall be modified to read as follows:</p><p>"Recommended proposals provided adjustments and clarifications are met within a limited timeframe (the initial reply to TRP adjustments and clarifications should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further adjustments and clarifications should be completed within 4 months from the receipt of the initial reply from the applicant). The TRP Chair and/or Vice-Chair shall give final approval based on consultations with the primary and secondary reviewers."</p><p>There are no material budgetary implications for this decision point. </p>

<p>The Board approves the Report of the 42nd Board Meeting, as set forth in GF/B42/ER22.</p>

<p>1. The Board:</p> <p>a. Acknowledges the Secretariat's presentation of the mid-2015 performance assessments for the 2014-2016 Corporate Key Performance Indicator Framework, as set forth in GF/B34/08; and</p> <p>b. Notes the Secretariat's response to requests by the Board at its November 2015 meeting for additional analysis on certain indicators, including proposed management actions to improve performance, as set forth in GF/B34/ER03 - Annex 1.</p> <p>2. Accordingly, the Board:</p> <p>a. Approves the 2016 performance targets presented in GF/B34/ER03 - Annex 1; noting the revisions to the 2016 performance targets for KPI 7 (Access to Funding) and KPI 10 (Value for Money); and</p> <p>b. Directs the Secretariat to implement its proposed management actions, continue to identify lessons that can inform the next Corporate Key Performance Indicator Framework, and update the committees and the Board at their first meetings in 2016.</p>

<p>1. The Board recalls its decision of 17 July 2007 regarding the establishment of continuity of services arrangements for 2,300 patients in Togo following the expiration of the Togo Round 2 HIV grant (TOG-202-G01-H-00). These arrangements will expire in September 2008.</p><p>2. The Board understands that no alternative sources of funding have yet been secured to sustain treatment for these patients and that, unless funding can be secured rapidly, treatment availability for such patients is likely to be interrupted.</p><p>3. The Board decides to the extend the current continuity of services arrangements for the Togo Round 2 HIV grant and approves the use of existing grant funds to procure buffer stocks to cover continued treatment for 2,300 patients for a period of up to six months following the end of the current continuity of services arrangements (i.e. 31 March 2009).</p><p>4. The Board notes with appreciation the efforts of technical and bilateral partners, civil society and the government in preparing Togo's Round 8 application and urges the government to redouble its efforts and the Global Fund's partners to help contribute to meeting the country's urgent needs. </p>

<p>The Board approves additional funding for the Continuity of Services for the proposals listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</p><p>See attached tabledetailing total recommended funding amount⁶ of US$ 1,579,508 for the following grants: BOL-307-G07-H ; COM-304-G02-H ; SUR-305-G01-H</p>

<p>The Board requests the Portfolio Committee to recommend to the Board at the Sixteenth Board meeting changes to the requirements with respect to the eligibility of applicants from upper-middle income economies for HIV/AIDS grants based on the following principles:</p><ol type="a"><li> An applicant would be eligible if:<ol type="i"><li> the epidemic in the country targeted in the proposal is of such magnitude that it has measurable impact on population demographics such as life expectancy and significant additional external resources are required to adequately address the epidemic; or</li><li>. the epidemic in a vulnerable population in the country targeted in the proposal is of such a nature and/or magnitude that there is risk of accelerated spread within that vulnerable population and significant additional external resources are required to adequately address the epidemic.</li></ol></li><li> Applicants with higher income levels should contribute through appropriate levels of counterpart financing and domestic investments.</li><li> Applicants must be included in the list of Official Development Assistance recipients published by the Organization for Economic Cooperation and Development (OECD) Development Assistance Committee.</li></ol>

<p>The Board:</p><ol><li>Amends the composition of the Ad Hoc Market Dynamic and Commodities Committee (as set out in GF/B19/4, Attachment 4) as follows:… <br/><br/>Composition: <br/><br/>The proposed membership to include (8) <u>10 </u>representatives of voting Board constituencies + WHO + World Bank <u>UNAIDS </u>+ 2-4 external experts … <br/><br/></li><li>Approves the appointment of the following members to the Ad Hoc Market Dynamic and Commodities Committee.</li></ol> <table class="table"><tbody><tr><td style="cursor: default;"> </td><td style="cursor: default;"><b>Constituency</b> </td><td style="cursor: default;"><b>Name </b> </td><td style="cursor: default;"><b>Role </b> </td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Leadership </b> </td></tr><tr><td style="cursor: default;"> 1</td><td style="cursor: default;">Private Foundations</td><td style="cursor: default;">Dai Ellis Executive Vice President, Access Programs, Clinton HIV/AIDS Initiative </td><td style="cursor: default;">Chair</td></tr><tr><td style="cursor: default;"> 2</td><td style="cursor: default;">UNAIDS</td><td style="cursor: default;">Shanelle Hall Director, Supply Division, UNICEF  </td><td style="cursor: default;">Vice-Chair </td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"> <b>Donor </b></td></tr><tr><td style="cursor: default;"> 3</td><td style="cursor: default;">Private Sector</td><td style="cursor: default;">Ian Boulton Managing Director, TropMed Pharma Consulting </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 4</td><td style="cursor: default;">Point 7</td><td style="cursor: default;">Turid Kongsvik Counselor, Norwegian Permanent Mission to the Council of Europe </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 5</td><td style="cursor: default;">United Kingdom</td><td style="cursor: default;">Saul Walker Senior Policy Adviser (Access to Medicines), DFID, (AIDS expert) </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 6</td><td style="cursor: default;">United States</td><td style="cursor: default;">Mike Hope Senior Pharmacist, Office of HIV/AIDS, USAID</td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Implementer </b> </td></tr><tr><td style="cursor: default;"> 7</td><td style="cursor: default;">Western and Central Africa</td><td style="cursor: default;">Lazare Bansse General Manager, Central Purchasing of Essential and Generic Drugs, Burkina Faso and Permanent Secretary, Association of Central Purchasing of Essential Drugs, Africa</td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 8</td><td style="cursor: default;">Latin America and the Caribbean</td><td style="cursor: default;">Carl Browne Director, Pan Caribbean Partnership Against HIV/AIDS </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 9</td><td style="cursor: default;">Developed Country NGOs</td><td style="cursor: default;">Mohga Kamal-Yanni Senior Health and HIV Policy Advisor, Oxfam </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 10</td><td style="cursor: default;">Eastern Europe</td><td style="cursor: default;">Tonka Varleva, Secretary, National Committee for Prevention of AIDS and STIs, Bulgaria </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;"> 11</td><td style="cursor: default;">Western Pacific </td><td style="cursor: default;">Lin-hua Tang Director, National Institute of Parasitic Disease, China, (malaria expert) </td><td style="cursor: default;">Member</td></tr><tr><td style="cursor: default;" rowspan="1" colspan="4"><b> Non-voting member </b> </td></tr><tr><td style="cursor: default;"> 12</td><td style="cursor: default;">WHO </td><td style="cursor: default;">Rob Matiru Chief of Operations, Global Drug Facility, (TB expert) </td><td style="cursor: default;">Member</td></tr></tbody></table>

<p>The Board:</p> <ol> <li>Notes the recommendation of the Ethics and Governance Committee of a Code of Conduct for Country Coordinating Mechanisms (the “CCM Code”), developed in furtherance of the Ethics and Integrity Framework adopted by the Board at its 32nd Meeting (GF/B32/DP09);</li> <li>Approves the CCM Code, as presented in Annex 4 in GF/B39/04- Revision 1;</li> <li>Based on the recommendation of the Strategy Committee (“SC”), decides that no less than the amount of USD 1,219,700 should be made available over a three year period to fund the implementation and enforcement of the CCM Code, as described in GF/B39/04- Revision 1;</li> <li>Recognizes that the Audit and Finance Committee approved USD 50 million as available sources of funds (“Available Funds”) to finance prioritized and costed areas of need on the register of unfunded quality demand, as per GF/AFC04/DP01, and based on the recommendation of the SC, (i) decides that the amount of USD 1,219,700 of such Available Funds be used instead to fund the implementation and enforcement<br />of the CCM Code, and (ii) decides to add CCMs as a “Strategic Initiative” to the list of catalytic investment priorities presented in Table 1 of GF/B36/04 – Revision 2;</li> <li>Based on the recommendation of the SC, decides to replace the Guidelines and Requirements for Country Coordinating Mechanisms, as approved by the Board under GF/B23/DP17, with the CCM Policy as set out in Annex 3 of GF/B39/04- Revision 1 (the “CCM Policy”); and</li> <li>Delegates authority to the SC to approve amendments to the CCM Policy, and requests the Secretariat to operationalize the CCM Policy and regularly report on its implementation to the SC.</li> </ol>

The status quo will be retained, namely that five members (the Board member and four others) of each constituency should be allowed in the Board meeting room. There will be video transmission of Board proceedings to a controlled-access room occupied by the additional delegation and Secretariat members who do not have access to the main Board meeting room.

<ol start="1" type="1"><li>The Board takes note of the options for sourcing candidates for the position of the Inspector General as described in the draft Action Plan for Recruitment of a New Inspector General (the "Draft Action Plan") that is appended to the Report of the Finance and Audit Committee (GF/B15/8), Addendum 1, as Attachment 2, and decides to adopt a combination of option 1 and 2 as set out therein.</li></ol><ol start="2" type="1"><li>The Board approves, in principle, the process and responsibilities for selection of the new Inspector General set out in the draft Revised Action Plan, as modified and set forth in Attachment 3 to GF/B15/8 (Addendum 1), and the desired role and personal competencies of the Inspector General that are listed in the draft Action Plan.</li></ol><ol start="3" type="1"><li>The Board decides to establish a Selection Panel to lead the recruitment process. The composition of the Selection Panel shall include two representatives of Board delegations, the Inspector General<i>ad interim </i> and an external advisor,supported by a member of the human resources staff of the Secretariat. The Chair and the Vice Chair of the Board shall appoint the two Board representatives and the external adviser to the Selection Panel. The Inspector General ad interim shall be the chair of the Selection Panel.</li></ol><ol start="4" type="1"><li>The Selection Panel shall be constituted not later than 11 May 2007. The Board requests that the Selection Panel take all necessary steps to agree a final action plan and an expeditious and appropriate timescale for the selection process and transmit them to the Board for information as soon as possible.</li></ol><ol start="5" type="1"><li>The Board decides to establish a special Sub-committee of the Board to interview not more than three candidates recommended as suitable by the Selection Panel and to select the new Inspector General from among these candidates. The Sub-committee shall consist of the Vice Chair of the Board and two other Board Members who have not participated in the Selection Panel. Notwithstanding Article 23 of the Board Operating Procedures, the Chair and the Vice Chair of the Board shall appoint the two Board Members of the Sub-committee. The Sub-committee shall notify the Board of its selection of the new Inspector General promptly after the selection has been made.</li></ol>

<p>1. Approve the Global Fund work plan and budget for 2003 with the proposed changes as presented in Part 2 of this report, with the understanding that some degree of flexibility is required in the specific allocation of resources during the year.</p><p>2. Request the MEFA Committee to continuously work with the Secretariat to monitor budget implementation in relation to priority and end product accomplishment and report to the Board on budget performance semi-annually.</p><p>3. Request the Secretariat, with MEFA Committee approval, to adjust this approved 2003 budget to reflect decisions made at the January 2003 Board meeting if those decisions impact the 2003 budget.</p>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER12 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

1. The Board acknowledges the process led by the Board Chair and Vice-Chair to identify candidates to serve as independent committee members on the Audit and Finance Committee (the "AFC"), as set forth in GF/B35/ER04". 2. Accordingly, the Board approves the appointment of the following individuals to serve as non-voting independent members of the AFC listed below, in the areas of expertise listed by their name: i. Peter Maertens, audit ii. Jean-Michel Ferat, forensic investigation<br/>3. In accordance with the AFC Charter, which provides that independent committee members may receive honoraria, the Board also decides to make available to each of the individuals serving as independent committee members an annual amount of USD 13,500.<br/>4. The Board notes each independent committee member appointed under this decision point shall begin their term on 9 June 2016 and serve for two years or until the appointment of their respective successor.

<p><i><b>Additional Safeguard Policy</b> </i></p><p><b>Decision Point 1</b> </p><p>The Board adopts the paper on the Additional Safeguard Policy as outlined in Annex 4.</p><p>The Board requests the Secretariat to include additional operating principals/procedures to address non-performance of PRs in appropriately rapid disbursement of Global Fund grant funds to sub-recipients.</p><p><i><b>Grant Agreements</b> </i></p><p><b>Decision Point 2</b> </p><p>The Board requests the Governance and Partnership Committee, in consultation with its other appropriate bodies, to develop a standard template grant agreement containing clear and detailed definition of role, obligations and competence of main actors in grant disbursement process (i.e. CCM, LFA, PR, Global Fund Secretariat) and to elaborate procedures for ensuring timely, sound and unhindered implementation of grant agreements for consideration by the Board at its Eighth Meeting.</p><p><b><i>Study of Board Governance and the Role and Composition of Board Committees</i></b> </p><p><b>Decision Point 3</b><br/> </p><p>The Board mandates a study of, and recommendations regarding, the structures, role and composition of any Board committees. The findings and recommendations of the study should be presented, via the Governance and Partnership Committee with options, to the Board at the Ninth Board Meeting.</p><p><i><b>Conflict of Interest</b> </i></p><p><b>Decision Point 4</b> </p><p>The Board adopts the revised version of the Policy on Ethics and Conflict of Interest for Global Fund Institutions as outlined in Annex 5 with the exception of the changes on Post-Board employment should be referred back to the committee (Section 7 GF/B7/7 page 6).</p><p><b>Decision Point 5</b> </p><p>The Board requests the GPC to address the conditions under which the Communities delegation can become a voting member of the Board and report back with decision points to the Eighth Board Meeting.</p><p><i><b>Board Member Terms</b> </i></p><p><b>Decision Point 6:</b> </p><p>The Board adopts the proposed amendment to Article A. Paragraph 1 of the Board Operating Procedures as underlined below:</p><p>Board Members terms shall begin at the opening of the first Board meeting in a given year, and end at the opening of the first Board meeting in the second calendar year following the commencement of their term.</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER03.</li> </ol> <p>Annex: Malawi (MLW-H-NAC), Multi Country Americas REDCA+ HIV Grant (MAR-H-SICSA).</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER14 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The agenda for the 37th Board Meeting (GF/B37/01- Revision 4) is approved.</p>

<p>The Board:</p> <ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Guideline for Annual Performance Assessment of Board Direct Reports as set forth in Annex 1 to GF/B38/ER04. This Guideline shall apply to the assessment of the performance of the Executive Director and the Inspector General during 2018 and onward.</li> <li>The Board directs the Ethics and Governance Committee (EGC) to review the guideline every three years, starting in 2020, to ensure its continued relevance.</li> <li>The Board delegates to the EGC the authority to approve revisions to the Guideline for Annual Performance Assessment to Board Direct Reports and to report such changes to the Board.</li> <li>The Board delegates to the EGC the authority to appoint a member of the EGC in replacement of the Board Chair or Vice Chair for the purposes of the performance assessment of the Executive Director or Inspector General in the event of a recusal of any of the said officials.</li> </ol>

<p>The Board hereby notes the Executive Director’s appointment of the following senior management official of the Global Fund:</p> <ol type="i"> <li>Adda Faye, as Chief Financial Officer.</li> </ol>

<p>The Board:</p> <ol type="i"> <li>Acknowledges the decision of the Strategy Committee concurring with the Risk Appetite Statements for the risks under such committee’s purview, as set forth in the table in Annex 3 to GF/SC06/03 – Revision 2;</li> <li>Acknowledges that the Strategy Committee will further discuss the Human Rights and Gender Inequality, Transition, and Drug and Insecticide Resistance risks at its meeting in July 2018, which will include discussion of the risk management strategy for these risks, including mitigation measures in place and/or planned, and a determination of the appropriateness of setting risk appetite statements for these risks;</li> <li>Further acknowledges the decision of the Audit and Finance Committee concurring with the Risk Appetite Statements for the risks under such committee’s purview, as set forth in the table in Annex 3 to GF/AFC06/16 – Revision 1; and</li> <li>Based upon the recommendation of the Audit and Finance Committee, approves the Risk Appetite Framework, including Risk Appetite, Target Risk levels and the indicative timeframes for achieving Target Risk, as described in the table in Annex 3 to GF/B39/07.</li> </ol>

<ol> <li>The Board acknowledges the progress update on wambo.org presented by the Secretariat and notes the proposal contained in the paper “Wambo.org: Progress Update and Steps for Advancement”, as set forth in GF/B37/07 – Revision 2, to pilot a limited number of transactions by current Principal Recipients (“PRs”) using domestic funding via wambo.org.</li> <li>Based on the recommendation of the Strategy Committee, the Board approves the piloting of a limited number of transactions (at a maximum ten in total) by current PRs using domestic funding via wambo.org.</li> <li>Accordingly, the Board: <ol type="i"> <li>requests that the Secretariat: (i) provide to the Strategy Committee, by its next meeting, clearly defined draft indicators of success for the pilot; and (ii) report regularly to the Strategy Committee on the operationalization of this pilot, including any lessons learned from such transactions in light of the long-term perspective for wambo.org; and</li> <li>delegates to the Strategy Committee the authority to approve further transactions with domestic funding through wambo.org on a pilot basis, with the objective to provide input into further strategic and operational planning for wambo.org.</li> </ol> </li> </ol>

<p><b>Decision Point 1:</b> </p><p>Dr. Carol Jacobs of the Latin America and Caribbean constituency is unanimously elected as Chair of the Board of The Global Fund to Fight AIDS, Tuberculosis &amp; Malaria for the period of 2005-2007.</p><p><b>Decision Point 2:</b> </p><p>Prof. Michel Katzatchkine of the France (Luxemburg, Spain) constituency is unanimously elected as the Vice Chair of the Board of The Global Fund to Fight AIDS, Tuberculosis &amp; Malaria for the period of 2005-2007.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/EDP07 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board recalls its decision GF/B14/DP/28 in which it authorized the Secretariat, on an exceptional basis, to consider the Request for Continued Funding submitted by the CCM of South Africa for the Round 3 South Africa Grant number SAF-304-G04-H, which anticipated a 4-year Phase 2 term.</p> <p>This decision was based on the commitment of the Government of South Africa at the time to achieve sustainability of the HIV/AIDS program in the Western Cape province and not requiring further Global Fund support for those activities beyond September 2010. The Board decides that due to the change in circumstances surrounding the implementation of the Western Cape HIV/AIDS program, it is willing to consider a further request from the CCM of South Africa for continued support of the program by the Global Fund, and authorizes the Secretariat to consider the grant for qualification under the Rolling Continuation Channel.</p>

<p>The Board:</p> <ol> <li>Establishes a seven member ad hoc nominations committee to assist the Board with its appointment of the next Inspector General (“IG AHNC”) according to the Terms of Reference set out at Annex 1 to this Decision Point with the following membership:<br /><br />• Gabor AMON<br />• Wendy HARRISON<br />• Aida KURTOVIC<br />• Galina MIKHLIN-OLIVER<br />• Jan PAEHLER<br />• Navin RUGHOONUNUN<br />• Timothy ZIEMER<br /><br /></li> <li>Requests the Audit and Ethics Committee, working in collaboration with Legal Counsel of the Global Fund, and the Interim Inspector General, to present for Board approval by not later than 5 March 2013:<br /><br />a. revised Terms of Reference for the role of Inspector General; and<br /><br />b. a revised Charter for the Office of the Inspector General.<br /><br /></li> <li>Requests the Audit and Ethics Committee to develop, and apply to candidates shortlisted by the AHNC, an appropriate conflict of interest assessment process to ensure that the Board will receive from the AHNC only the names of candidates who are without any conflict of interest for the role.<br /><br /></li> <li>Requests the AHNC to incorporate the AEC’s final recommendations into the AHNC’s decision making and present to the Board the AHNC’s recommendation on the strongest candidate(s) for the role of Inspector General, and the reasons for its recommendation, by 10 June 2013.</li> </ol>

<ol><li>The Board decides to create one additional non-voting seat on the Board to represent the constituency of key partners (Partners Constituency) whose mission is directly related to the Global Fund and who are not currently represented on the Board. <br/><br/></li><li>The Board decides to invite the Stop TB Partnership, Roll Back Malaria and UNITAID to be the founding members of the Partners Constituency. Any key partner that wishes to be represented on the Global Fund Board through the Partners Constituency should make a formal request to the Board who will determine the appropriateness of their inclusion in the Partners constituency. <br/><br/></li><li>Accordingly, the Board approves the following amendments to the By-laws: <br/><br/>Article 7. Foundation Board <br/><br/>7.1. Composition <br/><br/>The Foundation Board shall consist of twenty voting members and five six nonvoting members. Each voting member shall have one vote. <br/><br/>[…] <br/><br/>The <strike>five</strike><u>six</u> ex-officio nonvoting members of the Foundation Board shall consist of: <br/><br/><ul><li>One representative from the WHO;</li><li>One representative from the Joint United Nations Programme on HIV/AIDS ("UNAIDS"); </li><li><u> One representative from the Partners constituency; </u></li><li> One representative from the trustee; <strike>and</strike></li><li> One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Foundation to the extent required by Swiss law.; <u>and</u></li><li>The Executive Director of the Foundation. <br/><br/></li></ul></li></ol><li type="1" value="4">The Board requests the PSC to review the purpose, allocation and composition of all non-voting Board seats and report to the Board at its Twenty-Third Meeting. </li>

The Board decides to make an exception to Article 17 of the Terms of Reference of the Technical Review Panel (Annex 1 of GF/B21/5, Revision 1) only for Round 10 to permit existing Permanent TRP Members to serve more than four Rounds to ensure that a sufficient pool of experienced TRP Members are available on which to draw on for Round 10. 

<p>The Board adopts the Procurement Policy for the Secretariat as presented.</p><p> The Board appoints Ernst &amp; Young, Ltd. as external auditor of the Global Fund</p>

<p>The Board approves the 2007 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young as set out in Attachment 1 to the Report of the Finance and Audit Committee (GF/B17/6).</p><p><b>Annex 1 to Decision Point GF/B17/DP8:</b> </p><p><b>Principles for AMFm Policy Framework, Implementation and Business Plan</b> </p><p>• The timing of the AMFm-launch and implementation in endemic countries should be developed on the basis of the phase-in paper set out as Attachment 3 to the PSC Report (GF/B17/4), to include the following factors:</p><p>- A phased launch starting with a first group of countries to be selected according to criteria developed by the Secretariat and agreed at the 18^th Board Meeting;</p><p>- Roll-out of the AMFm in these selected countries for an initial phase until a Board decision on full roll-out is reached;</p><p>- Operational research and extensive M&amp;E efforts carried out in these first countries accessing the AMFm to assess the extent to which the AMFm can meet its objectives and provide lessons learned about the design and implementation of the AMFm that would inform a subsequent Board decision on full roll-out;</p><p>- An independent technical evaluation of the roll-out of the AMFm in the selected countries will be commissioned by the Global Fund Secretariat , under the guidance of the appropriate committee, using a set of pre-defined key indicators to be further elaborated and agreed at the Eighteenth Board Meeting to assess potential failures and short-comings("red flags") in the AMFm;</p><p>- At its first meeting in 2010, the Board will consider findings from this evaluation for a decision on whether to expand, accelerate, terminate or suspend the AMFm business line;</p><p>- Expansion from the initial phase to a full roll-out in all eligible countries will occur within a year of launch unless clear failures ("red flags") in the AMFm design are observed.</p><p>• The AMFm should be designed to increase access to ACTs by requiring national roll out plans/strategies that:</p><p>- Emphasize reaching women, children and the poor, </p><p>- Are fully financed, including sources of funding for supporting interventions to enable safe and broad access (notably among those who are currently unable to purchase ACTs because of their low income);</p><p>- Include plans for training, supervision and monitoring of providers, especially to ensure patient safety;</p><p>- Explain how the plan and its interventions link with national malaria control strategies and programs and how AMFm will be coordinated with supporting interventions.</p><p>- Are reviewed and approved by an independent standing technical body that determines that the AMFm roll-out plan is technically sound, with a particular focus on assuring sufficient investment in necessary supporting interventions, prior to provision of co-payment funding</p><p>• The AMFm should pursue responsible negotiations and contracting with manufacturers:</p><p>- Manufacturer sales prices for private sector buyers must not exceed the price available to public sector buyers (currently US$1/dose);</p><p>- Quality standards applied to drugs that qualify for the co-payment must, as a minimum, meet the quality standards outlined in the Global Fund's Quality Assurance policies; and</p><p>- The duration of copayment contracts should not extend beyond the duration of the first phase of roll-out so as to ensure continuation of market competition to reduce prices and encourage market entry of new participants.</p><p>• The AMFm should pursue a responsible funding policy and resource mobilization strategy:</p><p>- The AMFm will not become operational until sufficient funds have been contributed to cover co-payment costs for the full first phase of roll-out;</p><p>- Resources mobilized by the Global Fund Secretariat for the AMFm copayment should be additional to and separate from resources raised for ongoing Global Fund grant making and, must be held in a separate account with the Trustee;</p><p>- Resource mobilization for supporting interventions will be part of ongoing resource mobilization for Global Fund grant making and should be integrated into the Global Fund resource mobilization strategy;</p><p>- No funds can be transferred from the Global Fund's "general" account with the Trustee to support AMFm co-payments;</p><p>- The Global Fund will not make contractual commitments with manufacturers unless the necessary funds are available in the copayment account with the Trustee.</p><p>• The AMFm should work with partners to ensure that:</p><p>- The process for country access, including the development and assessment of roll-out plans, is simple and well-supported;</p><p>- Provider training and supervision emphasizes appropriate use of ACTs; and</p><p>AMFm implementation builds on consultation with the Private Sector in participating countries to ensure the co-payment is passed on through the supply chain.</p>

<p>The Board decides to re-advertise the position of Executive Director, and constitute a Nomination Committee. </p><p>The Nomination Committee shall refine the process for selecting the shortlist of candidates for the new Executive Director and present them to the Board no later than its Fifteenth Board Meeting (April 2007).</p><p>The Board requests the Nomination Committee to recommend to the Board possible changes in the Selection Process and Voting Procedures for deciding amongst the short-listed candidates for Executive Director, based on the experience of the Fourteenth Board Meeting (November 2006) and advise the Board (in consultation with the Chair of the Finance and Audit Committee) of the budgetary implications of this decision.</p>

The Board acknowledges the lessons learned by the TRP and Secretariat during the Round 7 proposals process as presented in the Report of Technical Review Panel and the Secretariat on Round 7 Proposals (GF/B16/5), and requests the Portfolio Committee to include appropriate revisions to the Proposal Form and Guidelines for Round 8 by 1 March 2008.

The Board approves the 2009 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young.

The Board recognised and thanked Mr Claudio Spinedi for the very valuable contribution he has made to the establishment of the Global Fund and wished him well in his new responsibilities.

The Board approves the appointment of Sanne Fournier-Wendes to serve as a non-voting member of the Audit and Finance Committee, representing the Partners Constituency, for a two-year term or until the appointment of her successor.

1. Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B35/ER10.

The Board requests that the Secretariat shall focus on the current move to rented offices (BIBC) with a view to expanding within, while continuing to pursue the Swiss (FIPOI) loan option and to explore low cost commercial financing alternatives for a Secretariat office premises, with no commitment to rent elsewhere or to purchase without prior authorization from the Board.

<p>The agenda for the Thirty-First Board Meeting (GF/B31/01) is approved.</p>

<p>The Global Fund does not tolerate corruption, fraud, misappropriation or abuse of any kind in relation to its grants. As part of the comprehensive risk management framework, the Board requests the Executive Director to take strong, immediate action in all circumstances where the Inspector General has determined that there is credible and substantive evidence of fraud, abuse, misappropriation or corruption involving Global Fund grants. </p><p>Such action will include the Executive Director restricting the signature of new grants with the nominated principal recipient(s), if the evidence concerns the nominated principal recipient(s), or of all new grants in the country, if the evidence points to country risks.</p><p>Restrictions may also include the suspension of disbursements under existing grants in the affected country or countries, the temporary or permanent debarment of any entity under investigation from receiving grant funding or any other measure deemed appropriate and justified under the circumstances by the Executive Director. </p><p>In such situations, the Executive Director shall ensure that measures imposed balance the impact on the country's health systems, other reliant projects and the continuation of the provision of essential services, against the risks to the Global Fund and adherence to the Global Fund's core ethical values and principles. This balance to be struck should not allow any acceptance of fraud.</p><p>The Secretariat and the OIG will - each based on their respective role and responsibilities - report on restrictions imposed in relation to any grant(s) in such situations, the specific actions required to lift such restrictions, and the status of the situation. This will be done as soon as possible to the Board via an appropriate mechanism as well as on a regular basis through the FAC and at the Board meeting.</p><p>If signature of a new grant with a nominated principal recipient has been restricted, the deadline for signature of a grant agreement shall automatically be extended by a period equal to the period of the restriction in the following limited situations: (i) an OIG investigation or audit by the OIG finds no wrongdoing, or (ii) in the opinion of the Secretariat and OIG, the wrongdoing is not material or the risks to Global Fund grant funds under the new grant are manageable, or (iii) a new principal recipient is identified for the grant under implementation arrangements that address the risks. </p>

<ol> <li>The Board recognizes that the Global Fund is well-positioned to drive value for money and should leverage its role as the primary financier of essential health products so as to improve quality, price, design, and sustainable supply. In this context the Board asks the Market Dynamics Committee to propose to the Twenty-Fourth Board meeting expanded uses for the MDC's "toolkit" of interventions- including opt-out mechanisms.<br /><br /></li> <li>When value for money efforts generate savings, the normal consequence is that such savings should stay in countries to scale up efforts against one or more of the three diseases.<br /><br /></li> <li>In order to drive value for money, the Board requests the Secretariat to:<br /><br />i. Take all necessary and appropriate measures to (1) fully implement voluntary pooled procurement (VPP) and (2) aggressively execute the Market Dynamics Committee recommendations.<br /><br />ii. Work with the MDC to determine reference prices to establish maximum levels of Global Fund payments for appropriate products. Reference prices should be set at the lowest accessible competitive price consistent with well-functioning and sustainable markets, recognizing differences according to country income and disease burden.<br /><br />iii. Set limits on how much support the Global Fund will provide in categories of expenditure where there is a risk of overuse or inefficiency ("yellow light" items, e.g., vehicles).<br /><br />iv. Work proactively with Principal Recipients (PRs) and Country Coordinating Mechanisms (CCMs) to use reprogramming within countries to ensure increased use of cost-effective interventions to maximize health impact. The Secretariat should incorporate guidance from technical partners to help guide this reprogramming.<br /><br /></li> <li>In the context of reporting to the Board on the Global Fund's portfolio and its impact on the three diseases, the Secretariat is asked to provide an annual report on its value for money work, including quantified results in terms of savings and additional coverage or impact.</li> </ol>

<p>Robin Montgomery from the Developed Country NGOs constituency is designated as Rapporteur for the 44th Board Meeting.</p>

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of GF/B38/ER02 (“Table 2”);</li> </ol>

The Board approves the 2008 Operating Expense budget in the amount of US$ 176,610,000 as set out in Annex 1 to the Report of the Finance and Audit Committee GF/B16/8 and proposed by the Secretariat. 

<p>Mr. Rico Gustav from the Communities constituency is designated as Rapporteur for the 38th Board Meeting.</p>

<p>The Board appoints Tracy Staines to serve as the next Inspector General of the Global Fund for a six-year term to begin not later than 1 January 2021.</p>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grants listed in Table 1 of GF/B47/ER13 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceilingamount that may be available for the relevant implementation period of each country diseasecomponent’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, aslisted in Table 1 of GF/B46/ER21 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposedPrincipal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by theSecretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shallbe committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for eachcountry disease component among its constituent grants, provided that the Technical Review Panel (the“TRP”) validates any redistribution that constitutes a material change from the program and fundingrequest initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li>The Board approves the appointment of Mr Mauro Ghirotti, representing the European Commission, Belgium, Italy, Portugal, Spain Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of his successor.</li> <li>The Board approves the appointment of Mr Josephat Kakoma from the Eastern and Southern Africa Constituency, to serve in his personal capacity as a voting member of the Ethics and Governance Committee for a term that will expire in May 2022, or until the appointment of his successor. </li> </ol>

<ol> <li>The Board approves the revised Governance Performance Assessment Framework as set forth in Annex 1 to GF/B41/ER01 (“Framework”), which shall enter into force upon Board approval of this decision point.</li> <li>The revised Framework shall supersede all prior versions of the Governance Performance Assessment Framework.</li> <li>The Board mandates the Ethics and Governance Committee (“EGC”) to regularly review the Framework and delegates decision-making powers to the EGC for any future changes to the Framework and any supporting materials related to it.</li> </ol>

<p>The Board approves the Report of the Global Fund 47th Board Meeting, as set forth in GF/B47/22.</p>

<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the new proposal for exceptional funding in 2021 presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B44/ER16 and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B44/ER16 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B44/ER16 and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 6,000,000, for the year 2021, to support the procurement of critical HIV &amp; TB health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>

<p>1.Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the revised Eligibility Policy, as set forth in Annex 2 to GF/B35/06 - Revision 1 (the "Revised Eligibility Policy").</p> <p>2.Accordingly, the Board: </p> <p>a.Acknowledges this decision point and the Revised Eligibility Policy supersede Board decision point GF/B30/DP05 and the previous Eligibility Policy as set forth in Attachment 1 to GF/B30/6 - Revision 1 (the "Previous Eligibility Policy"); and</p> <p>b.Notes that notwithstanding paragraph 2.a. of this decision point, the Previous Eligibility Policy remains applicable to grant programs originating from the 2014 - 2016 allocation period. </p>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Annex: Afghanistan (AFG-M-UNDP), Botswana (BWA-M-BMOH), Comoros (COM-T-ASCOBEF), Congo (Democratic Republic) (COD-H-CORDAID, COD-H-SANRU, COD-H-MOH, COD-T-CARITAS, COD-H-MCOD-T-MOH), Somalia (SOM-T-WV) and Swaziland (SWZ-H-CANGO, SWZ-H-NERCHA).</p>

<p>The Board approves the Report of the Thirty-Second Board Meeting (GF/B32/29 - Revision 1).</p>

<p>1.2 Set forth below is the Secretariat’s recommendation to approve grant extensions.</p> <p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B37/ER04.</li> </ol>

<p>The Board: </p> <p>1. Refers to its decision entitled "Multi-Year Contributions and Promissory Notes from Private Donors" taken by electronic vote on 13 September 2010 (EDP/B21/20) to permit the use of promissory notes by private donors when providing contributions to the Global Fund. </p> <p>2. Acknowledges the potential for the Global Fund to mobilize additional resources from private foundations through the use of innovative long-term promissory notes, while being mindful of the associated opportunity costs.</p> <p>3. Notes that the forms of contribution instruments provided by donors should not conflict with the principles and requirements set forth in the Comprehensive Funding Policy (CFP), including the conditions under which instruments may be characterized as assets for the purpose of determining commitment authority. </p> <p>4. Notes the practice of the Global Fund of accepting promissory notes with encashment schedules for annual payments over the next succeeding three years, which is in line with grant disbursement profile and thereby ensures that the Global Fund will continue to meet grant disbursement needs. </p> <p>5. Decides that, for an initial period of three years, and upon the approval of the Finance and Audit Committee, the Global Fund may accept promissory notes issued by private foundations available for encashment only at the end of terms exceeding three years ("Long-Term Promissory Notes"). However, the acceptance of Long-Term Promissory Notes is contingent upon the compliance of such instruments with the requirements of the CFP and the right of the Global Fund to automatic early encashment where the Global Fund requires cash to meet grant disbursement needs. </p> <p>6. Decides that contributions to the Global Fund through Long-Term Promissory Notes shall be limited to those from private foundations. </p> <p>7. Requests the Secretariat to establish a minimum cash policy in order to ensure a requirement of a minimum cash threshold equal to six months of projected disbursements at any given time, as may be amended from time to time by the Finance and Audit Committee. The minimum cash threshold requirement established by the Secretariat would underpin the early encashment provisions of the long-term promissory notes to allow for payment at any point at which the cash available to the Global Fund to fund disbursements falls below the required minimum cash threshold.</p>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p> The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><ol><li>Egypt, TB – Round 6 <br/>Grant Number: EGY-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 3,541,080 <br/>Approved Funding Amount (Incremental in US$): 4,124,080 <br/>Recommendation Category: Conditional Go<br/><br/></li><li>Guatemala, TB – Round 6 <br/>Grant Number: GUA-607-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$): 4,098,790 <br/>Approved Funding Amount (Incremental in US$): 3,699,920 <br/>Recommendation Category: Go<br/><br/></li><li>Kazakhstan, TB – Round 6 <br/>Grant Number: KAZ-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 4,400,023<br/> Approved Funding Amount (Incremental in US$): 3,672,383 <br/>Recommendation Category: Go<br/><br/></li><li>Lao PDR, Malaria – Round 6 <br/>Grant Number: LAO-607-G07-M <br/>CCM Requested Amount (Total Phase 2 in US$): 2,109,804 <br/>Approved Funding Amount (Incremental in US$): 1,941,538 <br/>Recommendation Category: Conditional Go<br/><br/></li><li>Liberia, HIV – Round 6 <br/>Grant Number: LBR-607-G04-H CCM <br/>Requested Amount (Total Phase 2 in US$): 20,515,516 <br/>Approved Funding Amount (Incremental in US$): 19,142,000 <br/>Recommendation Category: Go<br/><br/></li><li>Maldives, HIV – Round 6 <br/>Grant Number: MDV-607-G01-H <br/>CCM Requested Amount (Total Phase 2 in US$): 1,905,124 <br/>Approved Funding Amount (Incremental in US$): 1,486,772 <br/>Recommendation Category: Conditional Go<br/><br/></li><li> Mali, Malaria – Round 6 <br/>Grant Number: MAL-607-G05-M <br/>CCM Requested Amount (Total Phase 2 in US$): 11,010,553 <br/>Approved Funding Amount (Incremental in US$): 8,965,242 <br/>Recommendation Category: Go</li></ol><p>Total US$43,031,935</p><p>Next Steps:The Secretariat will begin negotiations immediately for the extension of the grants listed in Schedule A.</p>

<p>The agenda for the 43rd Board Meeting (GF/B43/01) is approved.</p>

Hélène Rossert-Blavier of the Developed Country NGOs is unanimously elected as Vice Chair of the Board of The Global Fund to Fight AIDS, Tuberculosis &amp; Malaria for the unexpired term of the outgoing Vice Chair. 

<ol> <li>Based on the recommendation of the Ethics and Governance Committee, the Board approves the Global Fund Policy to Combat Fraud and Corruption as set forth in Annex 4 to GF/B38/06 – Revision 2;</li> <li>The Board directs the Executive Director to develop an implementation plan, and to periodically report to the Board through the Ethics and Governance Committee on its implementation of the Policy to Combat Fraud and Corruption, as part of regular updates pursuant to the Ethics and Integrity Framework; </li> <li>Consistent with his/her authority to implement the Policy to Combat Fraud and Corruption, the Executive Director shall have delegated authority to approve exceptions to the Policy. This provision does not apply to access rights of the Office of the Inspector General for which the Inspector General shall have such delegated authority; and</li> <li>The Board further directs that appropriate and regular reporting be made by the Executive Director and Inspector General to the Ethics and Governance Committee or the Audit and Finance Committee on the exercise of the authority delegated under paragraph 3 of this Decision Point; and</li> <li>The authority delegated to the Executive Director and the Inspector General, as the case may be, under paragraph 3 of this Decision Point expires at the moment when the Board has adopted the framework the Board has requested the Secretariat to develop in GF/B37/DP07.</li> </ol>

<p>1.1 Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 2,051,987,870 and € 105,315,127.</p> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Section IV to GF/B37/ER04 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches;</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP; and</li> <li>For country disease components specifically noted in Table 1, notes that the final upper-ceiling for such country disease components may be adjusted to reflect a redistribution of funding across country disease components for the applicant, provided that (a) any redistribution of funding is invested in activities validated by the TRP, and (b) the final upper-ceilings for such country disease components will be subject to Board approval.</li> </ol>

<p>Approves the Global Fund Honorarium Framework, as set forth in Annex 1 to GF/B38/ER09.</p>

<ul><li><b>(Not Approved)</b> Acknowledge the approach to partnerships outlined in the paper and authorizes the Secretariat to pursue such partnerships as appropriate.</li></ul><ul><li>Asks the Governance Committee to examine and comment on partnership arrangements negotiated by the Secretariat in light of the framework and present them to the following Board for acknowledgement, or as appropriate, for approval.</li></ul><ul><li>Requests the Executive Director to provide ongoing updates of Global Fund partnership activity in his communications with the Board.</li></ul><ul><li>Board takes note with satisfaction of the MOU with UNAIDS.</li></ul>

The agenda for the Fifteenth Board Meeting (GF/B15/1, Revision 3), as amended at the Fifteenth Board Meeting, is approved.

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituentgrants, as listed in Table 1 of GF/B47/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by theproposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemedappropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and(b)shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding availablefor each country disease component among its constituent grants, provided that the TechnicalReview Panel (the “TRP”) validates any redistribution that constitutes a material change fromthe program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Based on the recommendation of the Strategy, Investment and Impact Committee, the Board approves the Global Fund Strategy 2017 - 2022: Investing to End Epidemics, as presented in Annex 1 to GF/B35/02- Revision 1. </p>

<p>The Board decides that the compensation of the Executive Director shall correspond to that offered at the appropriate rate of the WHO UG02 grade.</p>

<p>Based on the recommendation of the Strategy Committee described in [GF/B47/ER08], the Board:</p> <ol> <li>Acknowledges that the Eligibility Policy (GF/B47/03) allows certain non-eligible countries to be recommended to be exceptionally eligible for malaria in line with paragraph 11 of the Policy;</li> <li>Acknowledges that the Eligibility Policy’s treatment of Venezuela’s exceptional tuberculosis (“TB”) eligibility must consider the fact that Venezuela is the only country in the World Bank’s classification system that is temporarily unclassified;</li> <li>Based on the Secretariat and technical partners’ recommendation described in [GF/B47/ER08], approves that Venezuela’s malaria and TB components be made exceptionally eligible for the 2023-2025 Allocation period; and</li> <li>Notes that any components made exceptionally eligible will be governed by the Allocation Methodology 2023-2025 and existing Global Fund policies and processes.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the appointment of Madame Perrine Bonvalet-Doring, representing the French Constituency, as a voting member of the Audit and Finance Committee (“AFC”);</li> <li>Ambassador Anders Nordström, representing the Point Seven Constituency, as a voting member of the Strategy Committee (“SC”); and</li> <li>Doctor Manabu Sumi, representing the Japan Constituency, as a voting member of the SC,</li> </ol> <p>Each for a term that will expire in May 2018, or until the appointment of their successors</p>

<ol> <li>The Board notes its decision to establish a dedicated group of donor and implementer representatives to identify strategies and advocate for the acquisition of privileges and immunities for the Global Fund (GF/B32/DP06).</li> <li>Accordingly, the Board approves the terms of reference of the Privileges and Immunities Advisory Group as set forth in Annex 1 to GF/B32/ER12.</li> </ol>

<ol> <li>The Board hereby delegates to each of the Chair and Vice-Chair of the Board and the Executive Director, individual signature authority on behalf of the Global Fund.</li> <li>The Board hereby authorizes the Executive Director to: <ol type="i"> <li>further delegate his signature authority to Secretariat staff, who may exercise such authority in sole or joint capacities as may be necessary and appropriate for the day-to-day management of the operations of the Global Fund under the direction of the Executive Director and in accordance with the applicable regulations of the Global Fund; and</li> <li>memorialize such delegations of signature authority and any limitations or conditions applicable thereto in proxies and/or signature authority regulations.</li> </ol> </li> <li>The Board hereby affirms the further delegation of individual signature authority, in accordance with the Executive Director’s issuance of proxies and/or signature authority regulations, to each of the Chief of Staff and the Chief Financial Officer of the Global Fund.</li> <li>This decision supersedes the Board’s delegation of signature authority contained in Decision Point GF/B19/DP23 (May 2009).</li> </ol>

<p>The Board decides to extend the application of the Phase 2 Decision-Making Policies and Procedures set out in Annex 1 to the Report of the Portfolio Committee to the Twelfth Board Meeting (GF/B12/6) and as amended at the Twelfth Board Meeting, until the Fifteenth Board Meeting.</p> <p>The Board requests the Portfolio Committee to review the Phase 2 Decision-Making Policies and Procedures and develop recommendations for the Board to consider at its Fourteenth meeting.</p>

<p><span><b>Decision Point 1:</b> </span></p><p><span>1.1 The Board decides that special policies and procedures are required in the event o insufficient resources during a certain calendar year to fund all Phase 2 grant renewals. Such a situation of resource constraints would become evident at the final </span><span>Board meeting of the previous year.</span></p><p><span>1.2 The Board decides that provided funding is available for at least one year of renewals, available resources will be allocated among all grants that satisfy the Global Fund's renewal criteria according to a time-limited partial allocation system.</span></p><ol type="a"><li><span>A time-limit for renewed grants should be established by the Board at the final Board meeting of the year prior to the year of renewals. This time limit will be based on conservative estimates of resource needs for renewals as compared to resources available for the calendar year of resource constraints.</span></li><li><span>Initial amounts committed during the year may be adjusted at the end of the year based on actual resource needs for renewals as compared to resources available.</span></li></ol><p><span>There are no material budgetary implications for this decision point.</span></p><p><b><span>Decision Point 2:</span></b> </p><p><span>The Board decides that for subsequent year(s), the following priority system will apply in the event of resource constraints:</span></p><p><span><u>First funding priority</u>: Unfunded portions of prior year(s) renewals.</span></p><p><span><u>Second funding priority</u>: Renewals due in the current year. A time limited partial allocation system will be established as necessary (seeDecision Point 1.)</span></p><p><span><u>Third funding priority</u>: New proposal rounds (as already established in the Comprehensive Funding Policy).</span></p><p><span>There are no material budgetary implications for this decision point.</span></p><p><b><span>Decision Point 3:</span></b> </p><p><span>The Board recommends that if funding is not available for at least one year of Phase 2 grant renewals during a certain calendar year, special procedures will be decided by the Board at the final Board meeting of the previous year.</span></p><p><span>There are no material budgetary implications for this decision point.</span></p><p><b><span>Decision Point 4:</span></b> </p><p><span>The Board recognizes the importance of sustaining ongoing treatment, as well as prevention, care and support services.</span></p><p><span>The Board requests the Secretariat urgently to explore internal mechanisms and to work with partners to develop options for the continuity of services through broader country partnerships associated with common national strategic framework for the three diseases. The Board requests the Secretariat to report back to MEFA, PMPC and the Ethics Committee on these issues in time for the development of recommendations by the Ninth Board Meeting.</span></p><p><span>Budgetary implications of this decision point:</span></p><p><span>The additional cost of implementing this decision is approximately US $135,000.</span></p>

The Board decides to extend of the term of the two Sri Lanka Round 1 Malaria Programs (Grant No. SRL-102-G01-M-00 and SRL-102-G02-M-00) by an additional six months beyond the original five year proposal term at no additional cost and provided that targets are maintained at the levels originally set in the proposal.

<p>The Board amends Section 18 the Board Operating Procedures as follows:</p><p><b>18. Timing of Elections; Commencement of Terms</b> </p><p>Elections of the Chair and Vice Chair shall take place at the first Board meeting of the year. In the case of a vacancy, elections to fill the vacant slot shall take place at the first Board meeting at which a vacancy exists. The terms of office for Chair and Vice Chair shall commence <u>upon the adjournment of the Board meeting at which the election is held</u> except in the case of elections to fill a vacancy, where terms shall commence immediately upon election.</p>

<ol><li>The Board approves a budget ceiling for the 2012 Operating Expenses Budget in the amount of US$ 369.9 million, as set out in Attachment 1 to the Report of the Finance and Audit Committee ("FAC") to the Twenty-Fifth Board Meeting (GF/B25/14), based on the exchange rate outlined in Attachment 1 of the Report of the FAC (GF/B25/14) and subject to the Secretariat providing a budget paper to be presented to the Finance and Operational Performance Committee and shared with the Board before the end of the calendar year 2011.<br/><br/></li><li>The Secretariat shall enter into a forward contract with a reputable bank and shall notify the Board of the budget amount at the exchange rate determined on the date of the signature of the forward contract in a paper submitted to the Board. The new amount shall thus be deemed to be the approved Operating Expenses Budget for 2012.<br/><br/></li><li>The use of any amount in the US$ 3.0 million contingency within the OIG budget for 2012 is conditional upon the advance approval of the Finance and Operational Performance Committee on the recommendation of the Audit and Ethics Committee.</li></ol>

<p>The Board amends paragraphs (a) and (c) of decision point 3 under the Comprehensive Funding Policy approved at the Sixth Board Meeting as follows:</p> <p>3. Proposals are approved for the entire term of the proposal (up to five years) with a financial commitment for the initial two years with the possibility of renewal for up to an additional three years, with the following conditions:</p> <p>a. The Board may approve proposals and commit funds for two years up to the cumulative uncommitted amount of assets <span style="text-decoration: line-through;">pledged through the calendar year of the Board decision</span> <u>that the Board determines will be available at the time of signing the related grant agreements in accordance with 3(b)</u>;</p> <p>b. A sufficient amount of assets to meet the full cost of two years of implementation of approved grants must be deposited with the Trustee or readily available on demand prior to the Secretariat signing a grant agreement;</p> <p>c. Based on successful implementation of a grant, funding beyond its first 2 years receives priority over the funding of new proposals. <u>A sufficient amount of assets to meet the cost of such additional funding for the grant must be deposited with the Trustee or readily available on demand prior to the Secretariat signing an amendment to the grant agreement committing such additional funding</u>;</p> <p>d. No funds for appeals should be reserved. Successful appeals should be funded immediately if resources are available or as soon as new resources become available.</p>

<p>The Board approves a six-month extension to the Phase 1 period of the Round 7 Central African Republic HIV grant (CAF-708-G05-H), which shall therefore end on 31 December 2011, in order to allow for an enhanced program audit of the grant to take place.</p><p>This decision does not have material budgetary implications.</p>

<p>a) Based on the recommendation of the Strategy Committee, the Board approves the revisions for Key Performance Indicators 2, 5c, 6e, 9c and 11 as presented in GF/B45/ER01.</p> <p>b) Based on the recommendation of the Audit and Finance Committee, the Board approves the revision for Key Performance Indicator 7a as presented in GF/B45/ER01.</p>

<p>The Board approves the appointment of:</p> <ol> <li>Harriet Ludwig, representing the Germany Constituency, as a voting member of the Strategy Committee for a term that will expire on May 2025, or until the appointment of her successor;</li> <li>Rouksana Simjee, to serve in her personal capacity as a voting member of the Ethics and Governance Committee for a term that will expire on May 2025, or until the appointment of her successor.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B39/ER12 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a and Table 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

The Board extends the deadline for the signing of a grant agreement for the Andean Regional Project - Malaria control in cross border areas of the Andean countries for three months to 19 June 2005.

<p>The Board amends the Key Performance Indicator ("KPI") assessment process approved in GF/B15/DP34 as follows:</p> <p>(a) KPIs for the following year shall be developed and approved by the Policy and Strategy Committee ("PSC"). The PSC shall present the approved KPIs at the last Board meeting of each calendar year.</p> <p>(b) KPIs for 2008 shall exceptionally be reviewed at the PSC's meeting in the first quarter of 2008.</p> <p>All other requirements and timelines set forth in decision GF/B15/DP34 remain unchanged. The PSC shall accordingly assess results achieved against KPIs during the previous year and report on them at the first Board meeting of each calendar year.</p>

The Board acknowledges that, due to serious governance issues at the Ministry of Public Health, frequent changes of the Minister and a volatile political situation in Niger the condition upon which the Board approved the Round 5 malaria and tuberculosis grants to the United Nations Development Program (NGR-506-G04-M and NGR-506-G05-T) has not been fulfilled. However, the Board decides to waive this condition in light of the context in Niger.

<p>The Board:</p> <ol> <li>Expresses continuing concern about the protracted public health crisis in Venezuela, which has been further exacerbated by the COVID-19 pandemic, and continues to adversely impact the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Notes that while the Board exceptionally approved the eligibility of Venezuela’s malaria component under GF/B41/EDP06, resulting in an allocation of US$ 19,800,000 for the 2020-2022 allocation period, Venezuela’s HIV and tuberculosis components were not eligible to receive allocations in the 2020-2022 allocation period;</li> <li>Acknowledges the new proposal for exceptional funding in 2022 and 2023 presented by the Secretariat and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B46/ERXX and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B46/ERXX and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B46/ERXX and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional US$ 12,000,000, for the years 2022 and 2023, to support the procurement of critical HIV &amp; TB health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>

The Board adopted the meeting agenda with the provision that the topic on communication be included under the Global Partnerships Agenda item and CCM issues be discussed during the item on the Report of the Proposals Working Group. The issue of introducing agenda topics will be addressed under the item on the Report of the Governance Working Group. 

<span>The Board extends the deadline for the signingof a grant agreement for the Timor Leste Round 5 HIV proposal for three monthsto 16 March 2007.</span>

<p>The Board declines approval of additional funding for the next implementation period for them Round 8 Guyana HSS (GYA-809-G05-S) grant.</p><p>See attached table.</p>

<p><span>The Board:</span><span></span></p> <ol> <li><span>Approves the revised budget recommended for each grant listed in Table 1 of GF/B41/ER03 (“Table 1”);</span><span></span></li> <li><span>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</span><span></span></li> <li><span>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</span></li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER03 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol><li>The Board decides to extend the membership and leadership terms of all the existing standing and ad hoc Board Committees until the appointment of the incoming Board Committee membership and leadership, which shall be no later than the end of the last Board meeting of 2011. <br/><br/></li><li>The Board extends its gratitude to all Committee leaders and members for their continued commitment to the Global Fund.</li></ol>

<span>The Board extends the deadline for the signing of a grant agreement for the countries listed in Annex A for three months to 31 December, 2006. </span>

<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 2 (the “Recommended Incremental Funding under the New Funding Model” column), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grants shall be committed in annual tranches</p> <p>See attached tabledetailing total recommended funding amount of US$ 2,248,918 for the following grants: EGY-607-G02-T ; SUR-708-G04-M</p>

<p>Based on the Audit and Ethics Committee recommendation, set forth in GF/B34/ER13, the Board authorizes the appointment of KPMG SA as the Global Fund's external auditor for an initial three year term beginning with the 2016 fiscal year.</p>

<ol> <li>The Board refers to its decisions at the Twenty-Second Board Meeting entitled "Review of the Eligibility and Cost Sharing Policy" (GF/B22/DP8), "Measures associated with funding future proposals" (GF/B22/DP25), and "Launch of Round 11, the Second Wave of National Strategy Applications and a Health Systems Funding Platform Pilot" (GF/B22/DP26).<br /><br /></li> <li>The Board approves the document entitled "Policy on Eligibility Criteria, Counterpart Financing Requirements, and Prioritization of Proposals for Funding from the Global Fund" as set out in Attachment 1 (GF/B23/14) as the new policy governing these matters with the intention that this new policy shall apply to Round 11, the Second Wave of National Strategy Applications, the Health Systems Funding Platform Pilot and future funding opportunities.<br /><br /></li> <li>To give effect to the new Policy on Eligibility Criteria, Counterpart Financing Requirements, and Prioritization of Proposals for Funding from the Global Fund from Round 11 onwards, the Board decides as follows:<br /><br />a. To revoke the current policy on Income Level and Cost-Sharing Eligibility Criteria for Proposals for Funding from the Global Fund approved during the Sixteenth Board Meeting (GF/B16/DP18, Document GF/B16/7 Revision 1, Attachment 1) as amended at the Nineteenth Board Meeting (GF/B19/D13, GF/B19/DP14, GF/B19/DP15, Document GF/B19/05, Attachment 1); and<br /><br />b. To amend the Comprehensive Funding Policy and Related Board Decisions as approved at the Sixth Board Meeting (as amended at the Thirteenth Board Meeting and by GF/B15/27, GF/B20/DP9, EDP/B21/20 and GF/B22/DP22) by deleting paragraph 8 and replacing paragraph 7 b. of the Comprehensive Funding Policy with the following new sub-paragraph as follows:<br /><br />"7 b. If sufficient resources are not immediately available to approve all TRP-recommended proposals, proposals shall be prioritized in accordance with the Prioritization requirements set out in the "Policy on Eligibility Criteria, Counterpart Financing Requirements and Prioritization of Proposals for Funding from the Global Fund" (GF/BM23/DP6)."</li> </ol>

The Board approves additional funding up to US$ 13,055,416 for the Phase 2 period of the Round 6 South Africa HIV grant (SAF-607-G06-H) to improve the quality and scale of PMTCT activities, subject to Technical Review Panel (TRP) clarifications and conditions within a limited timeframe. The Board approves the revised Phase 2 incremental amount up to US$ 37,951,822 which includes an additional sum of US$ 13,055,416 allocated for PMTCT activities. This funding may also be subject to additional conditions to be cleared by the Secretariat as part of its risk management function.

<p><b>Decision Point 1</b> </p><p>The Board approves the 2005 Secretariat Budget and associated Secretariat staffing as attached in Annex 6 to the report of the October 12 - 13 MEFA meeting and as informed by that report. </p><p><b>Decision Point 2</b> </p><p>The Board takes note that the additional budgetary costs associated with any new rounds of proposals are excluded from the base 2005 budget and are highlighted separately.</p><p><b>Decision Point 3</b> </p><p>The Board approves that the agreed costs associated with Rounds 5 and 6 will be treated by the Board as an integral part of the decision to launch the relevant Round.</p>

<p>The report of the Twenty-Eighth Board Meeting (GF/B29/2) is approved.</p>

<p>The Board recalls its decision regarding the Affordable Medicine Facility - malaria ("AMFM") (GF/B18/DP7).</p> <p>The Board notes that it will vote on the AMFm proposals at its Twentieth meeting. The Board understands that the independent evaluation of AMFm Phase 1 is now estimated to be completed in the second half of 2011. </p> <p>The Board decides to maintain the AMFm Ad Hoc Committee as a separate committee of the Board for the duration of the AMFm of the AMFm Phase 1 period with the terms of reference set out in Annex 1 to the Report of the AMFm Committee (GF/B19/7).</p> <p>The Board confirms that the Technical Evaluation Reference Group (TERG) will provide guidance with regard to the technical parameters of the design of the independent evaluation of the AMFm, under the oversight of the AMFm Ad Hoc Committee. Consistent with its previous decisions, the Board confirms that the Secretariat will continue to have responsibility for commissioning of the independent evaluation, under the oversight of the AMFm Ad Hoc Committee.</p> <p>The Board notes pending WHO guidance that fixed-dosed co-formulations (FDCs) are strongly preferable to co-blistered ACTs and may help to delay resistance to artemisinin. The Board also notes that multiple technical issues need to be taken into account to ensure a smooth transition to an exclusive use of FDC ACTs. The Board urges that WHO expedite finalization of this guidance on FDCs and co-blistered ACTs.</p> <p>The Board requests its Chair to delegate to the relevant committee(s) the task of identifying and considering options for the Global Fund, within its mandate as a financing institution, to support countries in expediting the transition to FDCs, taking into consideration the implications for quality, supply, pricing and appropriate use of ACTs, and to report back to the Board at its Twentieth meeting.</p>

<p>The Board approves a modification to the mandate and functions of the Office of the Inspector General through a change to the Charter of the Office of the Inspector General (the “OIG Charter”), as revised and set forth in Annex 1 to GF/B47/EDP04.</p>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding USD 35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER04; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

<ol><li>The Board approves, subject to paragraph 2 below, the Rolling Continuation Channel proposal recommended for funding by the Technical Review Panel (TRP) as "Category 2" which is listed in Annex 1 to the Report of the TRP and the Secretariat on Funding Recommendation for the Final Resubmission Wave of Rolling Continuation Channel Proposals (the "Final Resubmission Wave RCC Report"). The Board approves funding for up to three years for the proposal (indicated as "Total 3 Years" in Annex 1 to the Final Resubmission Wave RCC Report). The Board‘s approval is made with the clear understanding that the grant amount requested is an upper ceiling subject to TRP clarifications and grant negotiations rather than a final approved grant amount. For further clarity, this decision is subject to the revised Comprehensive Funding Policy approved at the Twentieth Board meeting.</li><li>The applicant whose proposal is recommended for funding as "Category 2" shall: <ol><li type="i">provide an initial detailed written response to the requested TRP clarifications and adjustments by no later than four weeks after notification in writing by the Secretariat to the applicant of the Board‘s decision; and</li><li type="i">conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than two months from the Secretariat‘s receipt of the applicant‘s initial detailed response to the issues raised for clarification and/or adjustment.</li></ol></li><li>The Board declines to approve for funding proposals categorized by the TRP as "Category 3B" as indicated in Annex 1 to the Final Resubmission Wave RCC Report. Such applicants are encouraged to submit a revised proposal through the Rounds-Based Channel, taking into account the TRP‘s recommendations. The Board approves, on an exceptional basis, a two week extension of the Round 10 submission deadline (i.e. to 3 September 2010) for such applicants.</li></ol>

<p>The Board expresses its deep appreciation to Simon Bland for his leadership as Chair of the Board. He has served the Global Fund with a high degree of personal commitment and passion. During his tenure, Simon has successfully guided the Board through significant challenges and important decisions that will continue to shape the future of the Global Fund.</p> <p>The Board also expresses sincere gratitude to Mphu Ramatlapeng for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and distinction. During her tenure, Mphu has been instrumental in driving governance reform, coordinating important deliberations, and facilitating decisions of the Board that will have a lasting impact on the Global Fund.</p> <p>Their stewardship of the Board through the Consolidated Transformation Plan, the development of a new funding model, and the appointments of the Executive Director and the Inspector General have pointed the Global Fund towards continued success and efficiency in achieving its mission.</p> <p>The Board wishes Simon and Mphu all the success in their future endeavors and bestows upon them the honorary titles of Chair Emeritus and Vice-Chair Emeritus of the Board, respectively.</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1)</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 401,799,230 for the following grants: AGO-911-G05-T ; CIV-910-G12-H ; CIV-910-G13-H ; ZAR-M-MOH ; ZAR-M-SANRU ; ZAR-M-PSI ; GHN-809-G11-H ; GUA-311-G05-H ; GUA-311-G06-H ; MLW-H-NAC ; MSA-910-G01-H ; NMB-T-MoHSS ; THA-M-DDC</p>

#

<p>The Board resolves to expand the membership of the Ethics Committee from four members to six voting members. Desiring to achieve appropriate balances between geographic representation, gender, and government and civil society participation, 3 members shall come from the voting group encompassing the donor and private sector constituencies and 3 from the recipient, NGO and Communities constituencies.</p><p>The Board resolves that the Ethics Committee shall also appoint one independent, nonvoting expert to advise the Committee.</p>

<p>The Board expresses its deep appreciation to Mr. Norbert Hauser for his leadership as Chair of the Board. Over his time working with the Global Fund, he has shown a high degree of personal commitment, willingness to devote his time and energy, and passion for the work of the Global Fund. During his tenure, Norbert has presided over significant and complex deliberations and decisions that will continue to shape the future of the Global Fund.</p> <p>The Board also expresses sincere gratitude to Aida Kurtović for her leadership as Vice-Chair of the Board. She has served the Global Fund with dedication and continues to show her personal conviction for the mission of the Global Fund by focusing her efforts as the incoming Chair of the Board. During her tenure as Vice-Chair, Aida has been an active driver of relationship building and collaborations that will have a lasting impact on the Global Fund.</p> <p>Their stewardship of the Board delivered the enhanced governance structure, strengthened ties across Global Fund stakeholders, and helped to guide and direct external relations.</p> <p>The Board wishes Norbert every success in the future and bestows upon him the honorary title of Chair Emeritus. The Board welcomes Aida into her new role, and looks forward to her tenure, as Chair of the Board.</p>

<ol> <li>Based on the recommendations of the Finance and Operational Performance Committee, the Board approves the Amended and Restated Global Fund Policy for Restricted Financial Contributions, as set forth in Annex 1 to GF/B32/20 (the “Amended and Restated Policy”).</li> <li>The Amended and Restated Policy shall supersede the prior version of the Policy for Restricted Financial Contributions (GF/B15/DP29) and be effective as of 22 November 2014, and shall not alter the characterization of any sources of funds that have been factored into the 2014 allocation of resources.</li> </ol>

<p>The Board acknowledges UNITAID's offer to finance the purchase by the Green Light Committee of the Stop TB Partnership ("GLC") as procurement agent of MDR-TB medicines (the "MDR-TB Contributions"), to eligible programs financed by the Global Fund (the "GF Programs") for scale-up of their existing MDR-TB targets. The Board acknowledges, further, UNITAID's initial approval of USD 7.9 million (the "Initial MDR-TB Funding") to finance MDR-TB Contributions and acknowledges UNITAID's intention to approve additional funding for MDR-TB Contributions (the "Additional Funding") once the Global Fund Secretariat has determined the estimated maximum amount needed for the scale-up of potentially eligible GF Programs through their Phase 2 (the "Maximum MDR-TB Amount"). The Additional Funding shall be equal to the difference between the Maximum MDR-TB Amount and the Initial MDR-TB Funding.</p><p>The Board accepts, in principle, UNITAID's request that the Global Fund assume sole responsibility for (a) the determination of which GF Programs shall receive MDR-TB Contributions; (b) the adjustment of the relevant grant agreements to reflect MDR-TB scale-up; (c) the monitoring of GF Program results linked to MDR-TB scale-up; (d) the authorization of the delivery of shipments of MDR-TB Contributions to GF Programs procured by the GLC based on performance; and (e) the determination at the end of Phase 1 of funding (where applicable) of whether GF Programs receiving MDR-TB Contributions shall continue to receive MDR-TB Contributions during their Phase 2. </p><p>The Board acknowledges that UNITAID's funding is limited to medicines and diagnostics only, and does not include operational costs that enable scale-up in MDR-TB treatment. The Board acknowledges UNITAID's intention, where a GF Program is covered by MDR-TB Contributions and a material increase in expenditure on operational costs is caused by the scale-up in MDR-TB targets, to finance up to the entire purchase price of MDR-TB medicines that the Global Fund is already committed to purchasing, so as to allow the Global Fund to shift expenditure to required operational costs that UNITAID could not finance.</p><p>The Board requests the Secretariat to contact Country Coordinating Mechanisms and Principal Recipients which, based on past performance, appear to have demonstrated the capacity to scale up existing MDR-TB targets, and invite them to apply for MDR-TB contributions, stating in their applications the value of such requested MDR-TB contributions. Based on these applications, the Secretariat shall calculate the Maximum MDR-TB Amount so that the UNITAID Board can approve the Additional Funding.</p><p>Once UNITAID has approved the Additional Funding, the Global Fund Board shall, if appropriate, delegate to the Secretariat the authority to do the following:</p><ol><li>enter into contracts with UNITAID and the GLC to document how MDR-TB Contributions by UNITAID will be financed and made available;</li><li>determine which GF Programs shall receive MDR-TB Contributions ("Approvals"), subject to the following: <ol type="a"><li>the Local Fund Agent shall make recommendations with respect to the capacity of Principal Recipients to implement the proposed scale-up, and the Secretariat shall consider such recommendations prior to any Approvals; </li><li>the Technical Review Panel ("TRP") shall make funding recommendations with respect to applications where the scale-up in MDR-TB targets causes material variations in other objectives of the relevant GF Program; and</li><li>the total value of the MDR-TB Contributions authorized by the Secretariat shall not exceed the Maximum MDR-TB Amount;</li></ol></li><li>negotiate and execute amendments of grant agreements to reflect the approved scale-up and MDR-TB Contributions; and</li><li>monitor the GF Program results linked to MDR-TB scale-up, and authorize the delivery of MDR-TB Contributions procured by the GLC to GF Programs based on performance.</li></ol><p>The Board requests the Secretariat to report back to it on implementation of this decision at the Fifteenth Board meeting.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2015 Statutory Financial Statements, which have been audited by Ernst &amp; Young SA, as set forth in GF/B35/09 Annex 2.</p>

<p>The Board refers to the strategic issue of "Global Fund size" which the Policy and Strategy Committee (PSC) is currently considering. The Board recognizes that significantly increased resources are needed in the fight against the three diseases, including additional contributions to the Global Fund.</p><p>The Board requests the proposed Resource Mobilization Task Team to develop a resource mobilization strategy for how to achieve the following annual target funding levels, and to highlight in each case the associated implications:</p><p>• US$ 4-6 billion per year by 2010; and</p><p>• US$ 8-10 billion per year by 2010.</p><p>The Board further requests the proposed Resource Mobilization Task Team to deliver its findings by 15 February 2007 to inform the PSC's further deliberations on the strategic issue of "Global Fund size".</p>

<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grants in Table 3 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grants’ total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for each grant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 56,526,508 for the following grants: BAN-T-NTP ; BAN-T-BRAC ; IDA-708-G14-H ; IDA-708-G15-H ; IND-M-MOH ; JAM-708-G02-H ; RUS-506-G05-H ; SUD-708-G10-M ; ZIM-809-G12-T</p>

The Board agrees to have a retreat of Board Members and Alternates to discuss the core business model of the Global Fund, to be held in Arusha, Tanzania on Saturday 20 November 2004.

<ol> <li>The Board acknowledges the nominations for membership of the Board’s Strategy, Investment and Impact Committee (the “SIIC”), as set forth in GF/B31/10”.</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the SIIC, representing the Board constituencies listed by their name, for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"> <li>Aida Kurtovic, Eastern Europe and Central Asia;</li> <li>Vinand Nantulya, Eastern and Southern Africa;</li> <li>Abdalla Osman, Eastern Mediterranean Region;</li> <li>Mirta Roses, Latin America and the Caribbean;</li> <li>Asia Russell, Developed Country NGO;</li> <li>Helga Fogstad, Point 7;</li> <li>Jason Lane, UK-Australia;</li> <li>Julia Martin, USA;</li> <li>Philippe Meunier, France; and</li> <li>Jan Paehler, European Commission.</li> </ol> </li> <li>Noting that the Chair of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the SIIC, the Board appoints the following individuals to serve as additional non-voting members of the SIIC, representing the Board constituencies listed by their name, for a term that will expire on 9 March 2016, or until the appointment of their respective successors: <ol type="a"> <li>Lucica Ditiu, Partners; and</li> <li>Mbulawa Mugabe, UNAIDS.</li> </ol> </li> <li>The Board decides to launch a new call for nominations for the Finance and Operational Performance Committee (the “FOPC”) with a due date for nominations by 26 March 2014. The Chair and Vice-Chair of the Board will present its recommendation of candidates to the Board for approval by 15 April 2014.</li> <li>The Board notes that qualified candidates that have already been nominated, but not appointed, for a Committee role will remain in consideration for FOPC membership.</li> <li>The Board urges constituencies to nominate additional candidates that clearly demonstrate the competencies and skills that are required to perform the responsibilities of FOPC members. </li> </ol>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B44/ER17; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1, based on the understanding that the amount approved is upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for the grant listed shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of the additional funding requested and to the provision that such additional funding if available shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of the proposed grant shall be the sum of the amount set out in Table 1 below for the listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation</p> <p>See attached table detailing total recommended funding amount of EUR 971,313 for CAF-911-G09-T (Central African Republic).</p>

<p>The Board took the following decisions:</p><p>1. <i>Decide on a location for the Forum</i></p><p>The location for the Partnership Forum will be ______________ [and the indicative number of participants therefore ____________.]</p><p>2. <i>Mandate the Chair of the Board to establish a Steering Committee for the Forum.</i></p><p>The Chair is mandated to form a Steering Committee.</p><p>3. <i>Mandate the Secretariat to proceed with a process for contracting a conference organiser for the Forum</i>.</p><p> The Secretariat is mandated to proceed with the contracting of a conference organiser firm.</p>

<ol><li>The Board decides to commit additional funds equal to U.S.$3,500,000 to the Round 1 Indonesia malaria grant (IND-102-G02-M-00) pending the Phase 2 renewal decision with respect to this grant.<br/><br/></li><li>The Board decides to extend of the term of the Cote D’Ivoire Round 3 HIV Program (Grant No. CIV-304-G02-H) for an additional three months beyond the original eighteen month proposal term.</li></ol>

The Board requests the Secretariat to prepare for the Seventeenth Board Meeting, in consultation with its partners, an analysis of those grants that have been discontinued to identify any systemic weaknesses that led to that decision and recommend steps to address those weaknesses.

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that on-going implementation arrangements for each grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related documentation submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that funding for renewals of existing grants shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 below for each listed grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 842,017,272 for the following grants: CIV-809-G09-M ; GEO-H-GPIC ; GEO-T-GPIC ; GYA-304-G01-H ; LBR-M-PII ; LBR-M-MOH ; MKD-011-G04-T ; MEA-011-G01-H ; MEI-011-G01-H ; NGA-H-NACA ; NGA-H-ARFH ; NGA-H-SFHNG ; SAF-H-RTC ; SAF-910-G09-H ; SAF-304-G04-H ; SAF-H-NDOH ; SAF-H-NACOSA ; South Africa Grant TBD ; TNZ-M-MOFEA ; TNZ-809-G11-M ; TNZ-102-G01-M ; ZAM-811-G28-H ; ZAM-011-G29-H</p>

#

<ol> <li>Notes its commitment to continue to strengthen Global Fund governance processes and requests that the Ethics and Governance Committee (“EGC”) undertakes a review of the existing processes for selection of committee leadership and members, and makes recommendations to the Board on revisions to these selection processes, aiming for a decision at the 40th Board Meeting;</li> <li>Requests that as part of this recommendation, the EGC (i) puts forward principles and concrete actions to underpin and guide the selection processes, including transparency, rotation of constituency representation, relevant experience, institutional memory, and gender equality; (ii) develops standards and processes for due diligence undertaken as part of the selection processes; and (iii) reviews the size and composition of the EGC; and</li> <li>Requests that the EGC seeks feedback broadly from across Board constituencies in formulating its recommendations, including through inviting a representative of civil society to be a participant in EGC deliberations on this review.</li> </ol>

Regarding the election of Board Chair and Vice Chair, it is approved that this decision will be deferred until Friday, 31 January 2003. Nominations will be accepted by 1200 noon and announced at 1400 on Thursday, 30 January 2003.

<p>The Board requests the Finance and Audit Committee (FAC) to develop a framework to guide future reviews by the FAC of the Secretariat's annual budget proposals. </p><p>As part of the framework development process, (i) the Board requests the Executive Director, in consultation with the FAC and other Board committees to initiate an external evaluation of the Global Fund's staffing, including its structure and size; and (ii) the FAC will identify appropriate budgetary parameters to assist future budget reviews. </p><p>The Board requests the FAC to take into account the operational implications of the Resource Mobilization Task Team and the Four-Year Strategic Plan.</p><p>The Board requests that the FAC report to the Board on its progress at the April 2007 Board meeting.</p>

The Board: <br/>Approves extension of the relevant implementation period for each grant listed in Table 3 of Section IV to GF/B34/ER09.

The Report of the Thirteenth Board Meeting (GF/B14/2) is approved, as amended at the Fourteenth Board Meeting.

<ol> <li>Based on the recommendation of the Audit and Ethics Committee, the Board approves the Policy for Disclosure of Reports Issued by the Inspector General, as revised and set forth in Annex 1 to GF/B31/12, which supersedes and replaces the disclosure policy adopted by the Board under GF/B20/DP23.</li> <li>Accordingly, the Board approves the following revision to Section 15 of the Charter of the Office of the Inspector General <a>[1]</a>(the “OIG Charter”) to align the OIG Charter with the revised Policy for Disclosure of Reports Issued by the Inspector General:</li> </ol> <blockquote> <p>“15. Reporting: Final reports of Office of the Inspector General regarding its <span style="text-decoration: line-through;">external</span> assurance and investigations work will be posted on the Global Fund’s public internet site in accordance with the Board-approved ‘Policy for Disclosure of Reports Issued by the Inspector General’<span style="text-decoration: line-through;">. Internal assurance findings will be promptly reported to the Executive Director and the AEC for internal action.</span>”</p> </blockquote>

<p>The Board approves:</p><p>a) Dr. Blaise Genton as a new Technical Review Panel (TRP) member to fill the vacancy of a Malaria expert commencing from Round 6;</p><p>b) In respect of Round 6, seventeen (17) Alternate Member positions in total, and specifically in respect of the 2006 TRP replenishment process, those persons recommended by the Portfolio Committee and the Executive Director from the Support Group to fill the fourteen (14) Round 6 TRP Alternate Member position vacancies (as presented in Table 1 of Annex 7 of GF/B13/8); and</p><p>c) A Technical Review Panel Support Group (as presented in Table 1 of Annex 7 of GF/B13/8), comprising the group of experts from which TRP membership will be replenished in the event of TRP member vacancies as they may arise.</p>

<p>The Board, cognizant of the overarching desire of fostering the further participation of constituencies across the Board Standing Committees, and mindful that the composition of the Board Standing Committees should reflect the broad partnership that brings together representatives from donor and implementer governments, communities, civil society, the private sector, the private foundations and the technical partners:</p> <ol> <li>Expresses its sincere appreciation for the comprehensive work done by the Ethics and Governance Committee (“EGC”) over the course of the last year in relation to the strengthening the process for the selection of committee members.</li> <li>Decides that the Board Leadership shall consider the principles set out below when submitting the list of proposed members for committee membership pursuant to article 43.3 of the Board and Committees Operating Procedures as of the next selection process of the members of the Board Standing Committees:<br /><br /> <ol type="i"> <li>Each voting constituency should be represented in the Strategy Committee (“SC”) and the Audit and Finance Committee (“AFC”) for at least one term within a three two-year terms cycle;</li> <li>Each voting constituency should be represented, in any given term, in at least, the SC or the AFC;</li> <li>For the above committees, the implementer group representation should include government and civil society/communities;</li> <li>Each voting constituency should have the opportunity to have an individual nominated by it serving in their personal capacity in the EGC within a three two-year terms cycle;</li> <li>In setting out the list of proposed members, the Board Leadership shall consider experience, competency, continuity and gender balance.<br /><br /></li> </ol> </li> <li>Decides to amend article 4 of the Charter of the EGC by deleting the words “according to a pre-established rotation of membership of constituencies”; the revised article 4 of the EGC Charter, as amended, shall therefore read as follows: “Nomination and appointment of Committee Members shall be according to the Operating Procedures of the Board and Committees”.</li> <li>Decides to amend article 3.a. the Charter of the SC and article 3.a. of the Charter of the AFC by, in each case, increasing the number of voting representatives of constituencies from the implementer group by one; the revised article 3.a. of the Charter of the SC and article 3.a. of the Charter of the AFC, as amended, shall therefore read as follows: “Six voting representatives of constituencies from the implementer group”.</li> <li>Decides to amend article 3.b. of the Charter of the SC and article 3.b. of the Charter of the AFC by increasing the number of voting representatives of constituencies from the donor group by one in each case; the revised article 3.b. of the Charter of the SC and article 3.b. of the Charter of the AFC, as amended, shall therefore read as follows: “Six voting representatives of constituencies from the donor group”.</li> <li>The amendments to the EGC Charter, the AFC Charter and the SC Charter set out in paragraphs 3 to 5 of this decision point shall enter into force upon the expiry of the term of the current EGC, the AFC and SC in May 2020.</li> </ol>

The Board approves the 2010 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young.

<p>The Board approves the appointment of Eiji Hinoshita as a voting member of the Finance and Operational Performance Committee for a term that will expire on 1 May 2016, or until the appointment of his successor. </p>

The Board renews its delegation of authority to the Finance and Audit Committee to approve the Global Fund's cash balance pension fund, and requests the Executive Director to take all necessary action, including the execution of legal agreements, to establish the pension fund following such approval.

<ul><li>Acknowledge the evaluation of the Global Fund fiduciary arrangements undertaken by the Committee and direct the MEFA Committee to continue to improve the Fund's fiduciary arrangements that should include reviewing LFA performance and fees, developing a LFA conflicting of interest policy, together with the Governance and Partnership Committee, and report on the results of the Round 2 LFA selection. These actions should be reported to the Board in June 2003.</li></ul>

<p>As a temporary measure, the Board decides that the two-year limit on funding for Country Coordinating Mechanisms contained in GF/B11/2, p. 12, Decision Point 2 (the "CCM Funding Decision") shall not apply to CCMs whose funding expires prior to 31 December 2007. In such circumstances, the Board authorizes the continued payment of grant funds to the CCM, provided that the funding:</p><p>- complies with the requirements of the CCM Funding Decision, other than the otherwise applicable two-year limit;</p><p>- is disbursed at a similar rate as that at which funding was disbursed during the preceding two-year funding period; and</p><p>- expires not later than (i) the ending date of the proposal term of a grant that the CCM is overseeing; and (ii) 31 December 2007, whichever is earlier.</p>

<p>The Board approves the appointment of Mr. Michael Ruffner as the non-voting, neutral Vice-Chair of the Finance and Operational Performance Committee (the "FOPC") for the remainder of his predecessor's term.</p>

The Board approves the Policy for Disclosure of Reports Issued by the Inspector General, set out in Annex 3 to the Report of the Finance and Audit Committee GF/B16/8.

<p>The Board extends the deadline for the signing of grant documentation for the proposals listed in Table 1 for three months to 20 May 2011.</p><p>Table 1: Extension of grant signing deadline for four grants in three countries</p><table class="table" dropzone="copy"><tbody><tr><td style="cursor: default;">No </td><td style="cursor: default;"> Country, Disease, Round</td><td style="cursor: default;"> Grant information</td><td style="cursor: default;">Deadline for signature </td></tr><tr><td style="cursor: default;"> 1</td><td style="cursor: default;">Central African Republic, TB, Round 9</td><td style="cursor: default;"><p>Principal Recipient: Ministry of Public Health, Population and the fight against HIV/AIDS</p><p>Total approved amount: Euros 20,972,227 over five years</p><p>Phase 1 approved upper ceiling: Euros 8,961,795</p></td><td style="cursor: default;">20 May 2011</td></tr><tr><td style="cursor: default;"> 2</td><td style="cursor: default;">Nigeria, TB, MDR-TB Component, Round 9</td><td style="cursor: default;"><p> Principal Recipient: IHVN</p><p>Total amount: US$ 113,332,101 over five years</p><p>Phase 1 (total): US$ 31,515,160</p><p>Phase 1 (MDR TB component): US$ 9,002,945</p></td><td style="cursor: default;">20 May 2011</td></tr><tr><td style="cursor: default;"> 3</td><td style="cursor: default;">Democratic Republic of Congo, Round 9 TB/HSS <br/>(2 grants)</td><td style="cursor: default;"><p>Principal Recipients: i) Ministry of Health and ii) CARITAS</p><p>Total amount (over 5 years): US$ 275,383,647</p><p>Phase 1: US$ 100,261,325</p></td><td style="cursor: default;">20 May 2011</td></tr></tbody></table>

<p>The Board refers to its decision at the Fourteenth Board Meeting (GF/B14/DP7) to establish the Rolling Continuation Channel as an alternative funding channel for strongly-performing grants that are reaching the end of their funding terms ("expiring grants").</p> <p>As an interim measure, pending the implementation of the outcomes of the review of the Rolling Continuation Channel architecture, the Board:</p> <ol> <li>Decides to revise the Rolling Continuation Channel policy and procedures in regard to the role of the TRP and the avenues for recourse available to a CCM whose proposal is not recommended for funding after the first submission of a Rolling Continuation Channel proposal by: <ol type="a"> <li>amending paragraph 12 of the decision point (GF/B14/DP9) entitled 'Establishment of a Rolling Continuation Channel' ("RCC decision point") as follows:<br /><br />12. All rolling continuation proposals shall undergo an independent technical review by the TRP. Such review shall ensure that only technically appropriate interventions are funded, with consideration to the fact that the proposal is intended to ensure continued funding for expiring grants that have met the qualification requirements set out in paragraph 3 above.</li> <li>amending paragraphs 7 and 8 of the Board Decision-Making Procedure for the Rolling Continuation Channel (GF/B15/DP19) as follows:<br /><br />7. The effect of a Board decision to approve a TRP recommendation shall be as follows:<br /><br />a. If the Board approves a TRP recommendations to fund a RCC proposal, that decision will constitute an approval of the entire term of such RCC proposal, with a financial commitment for the initial three (3) years of the RCC proposal, with funding for the second phase subject to the approval of the Board based on a mid-term review;<br /><br />b. If, after an initial submission of a given proposal under the RCC, the Board approves a TRP recommendation that the CCM resubmit a revised version of this proposal in the next wave of RCC proposals, the CCM shall have the option to:<br /><br />i. revise its proposal based on the issues identified by the TRP during the initial review of the proposal, and submit the revised proposal in the next wave of Rolling Continuation Channel proposals ("revised proposal"); or<br />ii. file an appeal as described in paragraph c. below<br /><br />If the CCM submits a revised proposal, the procedure described in paragraphs 2-6 above will be followed.<br /><br />c. If the Board approves a TRP recommendation not to fund a proposal, the CCM may file an appeal of the decision not to approve the proposal in accordance with the Global Fund's Rules and Procedures for Appeals as the final avenue for recourse for the unsuccessful RCC proposal.<br /><br />8. If the Board decides not to approve a TRP recommendation to fund, the decision making process that applies following a Board objection to a TRP funding recommendation under the Phase 2 Decision-Making Policies and Procedures, as amended from time to time, will be followed. If the Board objects to a TRP recommendation not to fund, then the matter will be referred to the Board at its next Board meeting.</li> </ol> </li> <li>Amends the description of 'Category 3' recommended proposals set out in Part 2 of Attachment 1 to the Terms of Reference of the Technical Review Panel by splitting 'Category 3' into two parts as follows<br /><br />Category 3a: (Applicable only upon initial submission) Not recommended for funding based on technical merit but strongly encouraged to resubmit a revised proposal, taking into account the issues raised by the TRP, for consideration in the next wave of Rolling Continuation Channel proposals.<br /><br />Category 3b: (Applicable only upon re-submission) Not recommended for funding based on technical merit but encouraged to resubmit through the Rounds-Based Channel following major revision</li> <li>Approves all 'Category 3' recommendations in the Wave 1 TRP Report as if such recommendations were designated 'Category 3a' and requests the Secretariat to notify the relevant CCMs promptly of this decision and the option to resubmit in time for the third wave of RCC proposals</li> <li>Delegates authority to the Secretariat to modify the Rolling Continuation Channel application forms and guidelines to give effect to these modified principles</li> <li>Approves the procedure for providing additional funding ("Rolling Continuation Channel Bridge Funding") for expiring grants as set out in Attachment 1 to Annex 3 of document GF/B16/6.</li> </ol>

<ol> <li>In accordance with paragraph 15.2 of the Global Fund’s Board and Committee Operating Procedures (‘Operating Procedures’) and after the approval of the Coordinating Group on 13 January 2014, the Board leadership decides to appoint Marc de Santis from the Canada/Switzerland constituency to serve as a member of the Audit and Ethics Committee (‘AEC’) to fill a current vacancy.<br /><br /></li> <li>Mr de Santis shall serve on the AEC for a two year term or until the appointment of his successor. This appointment is effective on 14 January 2014.</li> </ol>

<p>The agenda for the 36th Board Meeting (GF/B36/01) is approved.</p>

<p>The Board approves the Memorandum of Understanding with Roll Back Malaria attached as Annex 3 to the Report of the Governance and Partnership Committee (GF/B9/7), and requests the Secretariat to provide periodic reports on cooperation between the Fund and RBM under the agreements.</p><p>There are no material budgetary implications of this decision.</p>

<p>The Board approves the amendments to the Operating Procedures of the Board and Committees of the Global Fund as set forth in Annex 1 to GF/B40/ER08 which shall enter into force upon the approval of this electronic decision point.</p>

<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2’ proposals with composite index 3 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14:</p> <ul> <li>Brazil (Malaria) -- Euro 20,659,117;</li> <li>Colombia (Malaria) -- Euro 16,997,092;</li> <li>Serbia (HIV) -- Euro 3,766,988;</li> <li>Cape Verde (HIV) -- USD 5,321,184;</li> <li>Dominican Republic (Malaria) -- USD 4,492,517;</li> <li>Ecuador (Malaria) -- USD 8,374,965;g) Indonesia (Malaria) -- USD 73,453,889; and</li> <li>Nicaragua (HIV) -- USD 31,385,337.</li> </ul> <p>Phase 1 Upper Ceiling amounts: Prior to any reduction arising from the adjustment for efficiency applicable to Phase 1 of Round 8 in accordance with Decision Point GF/B18/DP13.The USD equivalent of proposal amounts requested in Euro is based on the UN official exchange rate effective at 1 March 2009 of USD 1= Euro 0.782.</p>

<ol> <li>Based on the recommendation of the Chair and Vice-Chair of the Board (the “Board Leadership”), in consultation with the Ethics and Governance Committee (the “EGC”), the Board: <ol type="a"> <li>Notes its responsibilities with regard to the recruitment process of the Executive Director as set out in Article 36 of the Operating Procedures of the Board and Committees of the Global Fund to Fight AIDS, Tuberculosis and Malaria (“BCOP”);</li> <li>Notes the consultations of the Board Leadership and the EGC in relation to this process, including with respect to the establishment of the nomination committee referred to in the BCOP and the selection of an executive search firm, in accordance with Global Fund procurement regulations, to provide support to the nomination committee in carrying out its mandate; and</li> <li>Approves the terms of reference of the 2017 Executive Director Nomination Committee, as set out in Annex 1 to GF/B36/ER10.</li> </ol> </li> <li>The Board requests the Board Leadership to submit a Chair, Vice-Chair and the membership of the nomination committee to the Board for approval.</li> </ol>

<p>The agenda for the 38th Board Meeting (GF/B38/01) is approved.</p>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B43/ER01 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

The Board endorses the recommendation of the Policy and Strategy Committee, as part of the strategic issue of "Optimizing Grant Performance", that the Technical Review Panel (TRP) clarification and Local Fund Agent assessment processes begin prior to Board approval of the proposals submitted by the Country Coordinating Mechanisms ("CCMs"). The Board therefore requests the Portfolio Committee to recommend for approval to the Board specific conditions for the application of this decision in time for it to apply to the next round of proposals. These conditions shall include, but not be limited to, a statement to the CCM by the Secretariat that a TRP recommendation shall only result in the Global Fund awarding a grant if the recommendation is approved by the Board, which retains the sole authority to make such approvals.

<p>The Board refers to the Quality Assurance Policy for Pharmaceutical Products (the “QA Policy”) (as last approved and amended in GF/B22/DP9), and the requirement set forth therein that Global Fund grant funds may only be used to purchase Finished Pharmaceutical Products which comply with the QA Policy.</p> <p>The Board grants an exception to the quality standards set forth in the QA Policy such that sufficient quantities of ritonavir 100mg may be procured under existing Global Fund grants in Cuba to avoid a treatment disruption.</p> <p>This exception is valid until a source of ritonavir 100mg that is compliant with the quality standards of the QA Policy is available for the Global Fund Cuba programs, and if such a source becomes available and a procurement of ritonavir 100mg can be made from that source in time to avoid a treatment disruption in Cuba, that procurement should be made and this exception should not be applied.</p> <p>The Secretariat shall take appropriate measures to minimize and address any quality risks associated with the procurement authorized by this decision, including:</p> <ol> <li>Requiring that, at a minimum, the manufacturing site of the ritonavir 100mg procured must, at the time of the procurement, be in compliance with Good Manufacturing Practices as verified by the WHO Prequalification Programme, a Stringent Drug Regulatory Authority, or a regulatory authority participating in the Pharmaceutical Inspection Cooperation Scheme; and</li> <li>Applying the notification/confirmation and systematic quality control testing as described in paragraphs 9 and 31 of the QA Policy to such procurement.</li> </ol>

<p>The Board decides to change its policy on quality assurance approved at the Third Board Meeting on "option (c)" by replacing the decision on Agenda Item 10(B)(4)(b)(c) with the following and eliminating the last sentence of that decision on the "option (c)" time limit:</p> <ul> <li>Once there are two or more equivalent pharmaceutical products that meet the standards in Option (a) or Option (b), then Option (c) is not applicable. Contracts entered into on or beforeApril 30, 2005with suppliers for products that qualified for purchase under Option (c) may be honoured by the Principal Recipient until they expire. No new purchase contracts or contract extensions for such products will be allowed afterApril 30, 2005.</li> <li>If the Principal Recipient determines that there is only one or no equivalent pharmaceutical product that meets the standards in Option (a) or Option (b) OR if the Principal Recipient determines that the products that meet these standards are unavailable[1] and represents the same to the Global Fund Secretariat, and the Secretariat does not object, then Global Fund resources may be used to procure other equivalent pharmaceutical products, provided that the products are selected in accordance with the following, in order of priority: <ol> <li>(i) the manufacturer has submitted an application for product approval to the WHO Prequalification Program or a stringent regulatory authority AND is manufactured at a site that is compliant with standards of Good Manufacturing Practice (GMP), as certified after inspection by the WHO or a stringent regulatory authority;</li> <li>(ii) the product is manufactured at a GMP-compliant manufacturing site as certified after inspection by the WHO or a stringent regulatory authority. <br /><br />A Principal Recipient shall inform the Global Fund Secretariat if it procures under provisions (i) or (ii), after having followed the above process. In turn, the Secretariat, working with technical partners, shall contract an independent third-party to conduct random quality analysis of products being procured<br /><br />according to these criteria to ensure their quality in the absence of the Option (a) or Option (b) standard. <br /><br />In the event that (a) the submitted application for product approval is no longer under consideration; or (b) the independent third party finds the quality of the product to be unacceptable, then the Principal Recipient shall promptly terminate the contract with the supplying manufacturer.</li> </ol> </li> </ul> <ul> <li>In all cases, products purchased with Global Fund resources are subject to the monitoring product quality standards prescribed by the Fund as specified in Section 6 of the Report of the Third Board Meeting.</li> </ul> <ul> <li>Procurement of products according to criteria (i) or (ii) should be time limited and Principal Recipients should defer to Options (a) or (b) as soon as possible.</li> </ul> <p>The Secretariat will monitor implementation of this decision and report to the Board at the Fourteenth Board meeting.</p>

The report of the Seventh Board Meeting is approved.

The Board approves the recommendation of the selection sub-group in relation to the appointment of the Inspector General and requests Heidrick &amp; Struggles to conclude negotiations with the selected candidate as soon as possible.

<p>The Board:</p> <ol> <li>Notes the consolidation of Pakistan’s Round 8 (PKS-809-G09-T) and Round 9 (PKS-910-G11-T) tuberculosis grants (the “Constituent Grants”) into one Single Stream of Funding (“SSF”) grant with the National Tuberculosis Control Program as Principal Recipient and a total budget amount for the implementation period comprised of the sum of the Board-approved budgets of the Constituent Grants, as set forth in Table 2; and</li> <li>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), funding in the amount listed for the interim-applicant SSF grant in Table 2 (the “Additional Amount”), which will be in addition to the total budget amount of the Constituent Grants for the implementation period. The Additional Funding increases the upper-ceiling amount available for commitment rather than the final funding amount for the implementation period and is subject to the provision that continued funding for the SSF grant shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 8,000,000 for the following grant: PKS-T-NTP</p>

<p>Decision Point 1:</p> <p>The Board revokes, until the Thirteenth Board meeting, Decision 3* of Agenda Item 5 of the Seventh Board Meeting (reference GF/B8/2), and decides that Phase 2 decisions shall be made by the Board in accordance with the processes and subject to the policies set out in Annex 3 to Board Document GF/B9/8. </p> <p>The Board approves, until the Thirteenth Board meeting, the amendments to the Bylaws and Board Operating Procedures set out in Annex 4 to Board Document GF/B9/8.</p> <p>Budgetary implications for this decision point:</p> <p>The additional cost of this decision point is estimated at US$140,000, reflecting assumptions around the need for a) some level of periodic Fund Portfolio Manager effort to work with CCMs and grant recipients to answer questions and provide clarifications to the Board in response to situations where the Board does not endorse Secretariat recommendations for Phase 2 funding; and b) costs incurred to handle the communications protocol described above, including the development of the web pages to hold the Phase 2 materials, the compilation and posting of all materials in a timely manner, and the correspondence with Board constituencies as required by the process.</p> <p>Decision Point 2:</p> <p>The Board approves, at the final Board Meeting of each year, a maximum amount for Phase 2 commitments during the next calendar year; and</p> <p>The Board asks the Secretariat to report back to the Board at every Board Meeting on the Phase 2 decisions taken since the previous Board Meeting, including the cumulative amount approved to date in the current calendar year.</p> <p>There are no material budgetary implications for this decision point. </p>

<p>The Board refers to its decision (GF/B16/DP14) and the decision of the Board of the Roll Back Malaria ("RBM") Partnership at its meeting on 28-29 November 2007 inviting the Global Fund to take on full responsibility to host and manage the Affordable Medicine Facility - malaria ("AMFm").</p> <p>The Board agrees to have the Secretariat prepare to host and manage the AMFm as a business line within the Global Fund:</p> <ul> <li>based on the AMFm design and business plan set out in the Secretariat Report to the Policy and Strategy Committee (GF/PSC9/03); and</li> <li>subject to final approval at the Eighteenth Board Meeting of a policy framework and implementation plan that incorporates the principles set out in Annex 1 to this Decision Point and offers practical solutions, in consultation with technical partners, to remaining technical issues (including identification of strategies to maximize access to ACTs by the most vulnerable and poorest and ensuring patient safety).</li> </ul> <p>The Board acknowledges the work and recommendations of the RBM Task Force on the AMFm design, as endorsed by the RBM Executive Committee, and joins the RBM Executive Committee in asking the RBM partnership and the AMFm Task Force to continue to contribute to the development of the AMFm and to pursue all options to maximize access (including targeting the poorest through free distribution of ACTs through public and NGO channels).</p> <p>The Board requests that the Secretariat continue to work with the RBM Partnership, UNITAID, endemic countries, and other relevant stakeholders and develop and present to the Board at its Eighteenth Meeting for decision:</p> <ol type="i"> <li>The policy framework and implementation plan for managing the AMFm, including the calendar for phasing in the AMFm and monitoring and evaluation (M&amp;E) arrangements;</li> <li>Recommended arrangements for the ongoing governance of the AMFm;</li> <li>A statement of the resources available for launching the initial phase of the AMFm;</li> <li>The organizational and budgetary requirements for managing the AMFm in its initial phase of operation; and</li> <li>Any required technical changes to the AMFm design and business plan.</li> </ol> <p>To oversee and guide the work by the Secretariat, the Board decides to establish an ad-hoc committee of the Board: the "AMFm Ad-hoc Committee". The ad-hoc committee should include relevant partners, and potential donors, including UNITAID. The Board invites nominations for the members of the AMFm Ad-hoc Committee and requests the submission of nominations to the Board Chair and Vice Chair by no later than May 15, 2008. Membership of the AMFm Ad-hoc Committee shall not apply towards the two-committee limit set out in Section 23 of the Board Operating Procedures.</p> <p>The Board requests the Finance and Audit Committee to work with the AMFm Ad-hoc Committee to review the AMFm design and business plan with regard to 1) the plan's policy and strategy issues relating to finance, 2) implications for the Fund's budget for Operating Expenses, and 3) the Fund fiscal management policies and processes. This review should particularly consider elements of the plan that would involve the Secretariat entering into contractual arrangements with implementers of the AMFm, any additional risk this may pose to the Fund, and how this plan will fit within the forthcoming risk management framework of the Fund and its model as a financing institution, not an implementing agency.</p> <p>The Board calls upon the FAC and the PSC, as part of its ongoing work, to provide analysis on elements of the AMFm policy framework, implementation and business plan that may potentially change the Global Fund framework document and bylaws. In particular, the FAC and the PSC should further review how the various tasks induced by the management of the AMFm should be shared between the Global Fund and its partners. The Board notes the need for extensive consultation with Board members on any proposed substantive change to the Fund's Framework Document of Bylaws.</p>

#

<ol><li> The Board, determined to scale up the Global Fund's response to HIV, Tuberculosis and Malaria, decides in principle to announce, after the Seventeenth Board Meeting, that there will be an extra Call for Proposals for funding in 2008.</li><li> The Board requests the Secretariat to prepare to issue a Call for Proposals for Round 9, which shall employ the same proposal form and guidelines as Round 8, on or about 1 October 2008, and to provide for review of those proposals in time for approval at the Nineteenth Board Meeting in April 2009.</li><li> The Board decides that in Round 8 and 9:<ol type="a"><li>Applicants whose initial proposal receives a Category 3 recommendation may resubmit a revised version of the same proposal in the next Round for consideration by the TRP in time for the Board to make a decision at its next Board Meeting.</li><li>When the TRP comments on initial Category 3 proposals, it is encouraged to recommend the types of changes that need to be made to strengthen the proposal for resubmission.</li><li>Within a week of the Board being informed of the TRP's recommendations and comments, each applicant should be informed by the Secretariat of the TRP's recommendation and comments regarding its proposal.</li></ol></li><li> The Board recognizes that this decision point has implications for the Secretariat, the TRP, and applicants. The Secretariat is requested by no later than 15 May 2008 to submit to the Board, for approval by email, a final decision on announcing Round 9, together with a description of resources available and forecasted and proposed changes to existing policies necessary to implement this decision point.</li><li> The Board calls on its members and RBM, along with the STOP TB Partnership and UNAIDS Co-sponsors, to provide support to implementers to develop high-quality proposals and to manage efficient programs, to ensure the effectiveness of Global Fund resources. </li><li> The Board also calls on implementing partnerships, donor countries, and technical partners to prioritize their efforts to develop and agree on a shared approach by which national strategies can be validated, as a basis for the Global Fund to approve funding requests through national strategy applications, and to accelerate the development of robust country-level national strategies. The Board recognizes that national-strategy applications could provide the most sound basis for the scaling-up of programs to prevent, control and treat HIV, tuberculosis and malaria, and could be the most effective way to streamline the ability of country-level partnerships to earn Global Fund resources. </li></ol>

<p>The Agenda for the 46th Board Meeting (GF/B46/01_Rev1) is approved.</p>

<p>The report of the Thirtieth Board Meeting (GF/B31/02) is approved.</p>

<p>The Board amends the Continuity of Services Policy (GF/B14/DP11) by amending paragraph v as follows:</p> <p>v. The Secretariat will review the Extraordinary Request, and provide a funding recommendation to the Board for its approval if incremental funding is needed. If incremental funding is not required because there are sufficient funds remaining under the ending grant to cover the Extraordinary Request, the Board authorizes the Secretariat to approve the Request, on the same conditions and subject to the same limitations as set out in this policy. The Secretariat will take into account performance issues, as appropriate, and shall make any adjustments to existing implementation arrangements necessary to ensure the effective use of Global Fund financing.</p>

<p>The Board takes note of the challenges in operationalizing the Rolling Continuation Channel ("RCC")<a id="_ftnref1" name="_ftnref1">1</a> as set out in the Policy and Strategy Committee document GF/PSC8/05. The Board further notes that the Policy and Strategy Committee has requested the Secretariat to analyze further and develop a Quarterly Application Schedule architecture. It is expected that such long-term architecture changes will be presented to the Board for decision at the Seventeenth Board Meeting.</p><p>As an interim measure to address the specific challenges faced in operationalizing the RCC, the Board approves the procedure for providing additional funding for affected well-performing grants for a time-limited period as set out in Annex 1 (entitled "Interim Bridge Funding for Expiring Grants") to the Report of the Policy and Strategy Committee (GF/B16/6). This interim measure shall apply for relevant grants that fail to qualify for the RCC during the period from initial implementation of the RCC until the adoption by the Board, and full operationalization by the Secretariat, of long-term architectural changes which will address such RCC implementation challenges and that would otherwise experience a funding gap as a direct result of such failure to qualify for the RCC. </p>

<ol> <li>The Board thanks the High-Level Independent Review Panel (HLP) and its support team for their hard work in delivering to the Board the report titled "Turning the Page from Emergency to Sustainability" dated 19 September 2011 (the "HLP Report").<br /><br /></li> <li>The Board adopts the HLP Report and accepts the underlying analysis, noting that it presents a compelling case for a rapid and urgent transformation of the Global Fund. The HLP acknowledges the achievements of the Global Fund over the past decade, and the importance of ensuring its success.<br /><br /></li> <li>The Board acknowledges that the Global Fund has significant weaknesses of fiduciary control and financial oversight, as identified in the HLP Report, and the Board is determined to take the necessary corrective actions to address these weaknesses. The Board takes note that the Executive Director and the Inspector General also agree with the HLP Report findings.<br /><br /></li> <li>The Board recognizes that implementation of the HLP's recommendations will require a detailed implementation plan, and that this should be informed by best-practice and draw on available experience.<br /><br /></li> <li>To take forward the recommendations of the HLP, the Board decides to execute the following action plan immediately:<br /><br />5.1 - Consistent with Recommendation 6.3 of the HLP Report ("Consolidate the Reform Agenda") the Board Chair and Vice-Chair, with the Secretariat and the Office of the Inspector General (OIG), will develop a single, time-bound and costed Consolidated Transformation Plan which integrates other reform work streams currently underway with recommendations by the HLP into one single plan, which will include prioritized action items, deliverables, timelines, and parties responsible for the delivery of each item in a logical, coherent, manageable, efficient and timely manner;<br /><br />5.2 - A draft of the Consolidated Transformation Plan will be circulated to the full Board for comment by 31 October 2011, and a final draft will be transmitted to the Board by 10 November 2011 for formal adoption at the Twenty-Fifth Board Meeting; and<br /><br />5.3 - The Coordinating Group (see Paragraph 6.3.1.2 below) will be responsible for monitoring, tracking and reporting to the Board on progress of this Consolidated Transformation Plan until all action items are completed.<br /><br /></li> <li> Acknowledging that they will be important components of the Consolidated Transformation Plan that will be approved in November 2011, the Board decides that the following key actions shall commence immediately, with status reports or decision points, as appropriate, being presented at the Twenty-Fifth Board Meeting:<br /><br />6.1 - The Secretariat and OIG will commence implementation of Recommendation 1 of the HLP Report ("Turn the Page from Emergency to Sustainable Response"), in close consultation with the Board Chair, Vice-Chair and Finance and Audit Committee (FAC);<br /><br />6.2 - The Board, Secretariat and OIG will commence implementation of Recommendation 2 of the HLP Report ("Define a Doctrine of Risk and Manage to It"), except Recommendations 2.3.iii.a-b of the HLP Report. The Board will give further consideration to Recommendations 2.3.iii.a-b of the HLP Report, taking into account the clarification provided by the HLP during the Twenty-Fourth Board Meeting;<br /><br />6.3 - The Board Chair and Vice-Chair, as part of their leadership of the Governance Reform process, will integrate Recommendation 3 of the HLP Report ("Strengthen Internal Governance") into the Board Governance Plan they will finalize. To accelerate implementation of the Governance Reform process the Board:<br /><br /> <ul> <li>6.3.1 - Adopts Recommendation 3 of the HLP Report ("Strengthen Internal Governance") with the following modifications to commence from 1 December 2011:<br /><br /> <ul> <li>6.3.1.1 - The existing four standing committees will be replaced by three standing committees titled and composed as follows:<br /><br /> <ul> <li>i. Strategy, Investment and Impact: ten voting members, five from the donor bloc and five from the implementer bloc, with a chair from the donor bloc;<br /><br /></li> <li>ii. Finance and Operational Performance: ten voting members, five from the implementer bloc and five from the donor bloc with a chair from the implementer bloc; and<br /><br /></li> <li>iii. Audit and Ethics - seven members, with four independent members, one of whom will be the Chair;<br /><br /></li> </ul> </li> <li>6.3.1.2 - There will be a Coordinating Group comprised of Board and committee chairs and vice-chairs;<br /><br /></li> <li>6.3.1.3 - The Board leadership will have a casting vote on two of the committees, as follows:<br /><br /> <ul> <li>i. For the Strategy, Investment and Impact Committee, the Chair of the Board will have a casting vote; and<br /><br /></li> <li>ii. For the Finance and Operational Performance Committee, the Vice Chair of the Board will have a casting vote;<br /><br /></li> </ul> </li> <li>6.3.1.4 - The terms of reference of the three committees will include the duties as recommended by the HLP Report and will be further developed under the leadership of the Board Chair and Vice-Chair. Ethics-related matters will be included in the terms of reference of the Audit and Ethics Committee; and<br /><br /></li> <li>6.3.1.5 - To optimize their performance, the committees can include ex-officio members of the Board and will have the ability to delegate operational matters to the Secretariat.<br /><br /></li> </ul> </li> <li>6.3.2 - Requests the Chair and Vice-Chair to seek nominations from Board constituencies for the three Board Member seats of the Audit and Ethics Committee, and to identify three appropriately qualified persons as member-designates. The Board further requests the three member-designates to commence an open and transparent process to identify the four independent members of that committee, for recommendation to the Board for approval at the Twenty-Fifth Board meeting.<br /><br /></li> </ul> 6.4 - The Policy and Strategy Committee (PSC) and its Strategy Development Working Group will include Recommendation 4 of the HLP Report ("Institute a New Grant-Approval Process") into the five-year Strategy that will be finalized and submitted to the Board for approval at the Twenty-Fifth Board Meeting; and<br /><br />6.5 - The Secretariat, in close and regular consultation with the Chair and Vice-Chair of the Board, FAC, PSC and OIG, will implement Recommendation 5 of the HLP Report ("Empower Middle-Management's Decision-Making") and Recommendations 6.1 and 6.2 of the HLP Report ("Measure Outcomes, Not Inputs" and "Focus on Quality and Value, Rather Than Quantity" respectively), and provide a progress report to the Board at the Twenty-Fifth Board Meeting.<br /><br /></li> <li>In implementing these actions and recommendations, the Board expects the Global Fund Secretariat to pursue the overall objectives of aid-effectiveness,1 to stabilize staff levels and to avoid any increase in general administrative overheads without the prior approval of the Board.</li> </ol>

His Excellency Ambassador Patrice Debré from France’s constituency is designated as rapporteur for the Twenty-Fourth Board Meeting.

<p>The Board notes that the Policy and Strategy Committee discussed (a) establishing fixed dates for the launch and approval of rounds to make progress towards greater alignment of Global Fund processes with country cycles and greater harmonization with partners' actions; and (b) ideas to develop a more flexible system whereby funding by the Global Fund of some grants or proposals might move away from rounds-based timing.</p><p>For those proposals that remain on a rounds-based system, the Board endorses the recommendation of the Policy and Strategy Committee that the Board establish and announce to the public, with significant advance notice, a fixed set of dates for future rounds of funding.</p><p>The Board decides the following:</p><ol start="1" type="1"><li>The Secretariat shall issue a minimum of one Call for Proposals in each calendar year, which it shall issue at approximately the same date(s) each year;</li></ol><ol start="2" type="1"><li>The Global Fund Board shall, with significant advance notice, announce the dates for the next two Calls forProposalsand the dates when the Board foresees it will approve proposals;</li></ol><ol start="3" type="1"><li>The Secretariat shall issue Calls forProposalsat least four months earlier than the due date for such proposals;</li></ol><ol start="4" type="1"><li>The Global Fund Board shall continue to make all decisions regarding the funding of proposals through a round at Board meetings; and</li></ol><ol start="5" type="1"><li>In accordance with the Comprehensive Funding Policy, the Secretariat will announce a forecast of the resources available for the round at the time it issues each Call forProposals.</li></ol><p>The Board requests that at the appropriate times the Secretariat propose the appropriate dates for the next Call for Proposals and for Board approval of such proposals. These dates should take into account the schedules of recipients, partners, donors and the Secretariat.</p>

<ol> <li>Based on the recommendation of the Finance andOperational Performance Committee, the Board approves the amended and restatedComprehensive Funding Policy, as set forth in GF/B31/04 – Annex 1 (the “Amendedand Restated CFP”). </li> <li>The Amended and Restated CFP supersedes all priorversions of the Comprehensive Funding Policy, and any related decisionspreviously adopted by the Board or its Committees that are inconsistent withthe Amended and Restated CFP. </li> </ol>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 1 of GF/B42/ER01 (“Table 1”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<p>The Board:</p> <p>Approves,in accordance with its decision to launch the transition to the New FundingModel (GF/B28/DP5), funding in the amount listed for the early-applicant grantsin Table 1 (the “Total Incremental Funding Recommendation”). The TotalIncremental Funding Recommendation increases the upper-ceiling amount availablefor commitment for the relevant implementation period and is subject to theavailability of funding and to the provision that the approved funding for eachgrant shall be committed in annual tranches.</p> <p>See attached tabledetailing total recommended funding amount of US$ 55,629,879. for thefollowing: Eurasian Harm Reduction Network (EHRN) (HIV/ AIDS), The RegionalMalaria Elimination Initiative in Mesoamerica and Hispaniola - EMMIE (Malaria)and Philippines (TB).</p>

The Board adopts The Global Fund Documents Policy, subject to refinement as appropriate based on legal review. As outlined in the policy, the Board will operate under a principle of maximum transparency and openness; subject to the restrictions outlined in the policy, the Board will make public all documents and records. As outlined in the policy, the Fund and the Board will not release any document or otherwise disclose information which is for discussion (“deliberative“) or “pre-decisional“ in order to encourage dialogue among Board members and other units of the Fund. As outlined in the policy, deliberative information will only be shared with the members of constituencies who need to provide input to the Board member. As outlined in the policy, all Board decisions, actions, or other final statements will be made public under the general principle of openness and transparency.As outlined in the policy, in extremely limited and sensitive circumstances, such as personnel actions, business proprietary information, or resource mobilization and other strategies, the Fund will not release information to the public.

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 99,032,607 for the following grants: BAN-202-G11-H-00 ; BAN-202-G12-H-00 ; BAN-202-G13-H-00 ; LBR-810-GO7-H ; SUD-T-UNDP</p>

<ol> <li>Based on the recommendations of the Strategy, Investment and Impact Committee, as set forth in GF/B33/ER10, the Board decides the Global Fund’s strategy should cover a period that aligns the start of each strategy cycle to the start of a replenishment and allocation period.</li> <li>Accordingly, the Board decides the next strategy should cover the six-year period that begins on 1 January 2017 and ends on 31 December 2022, with a mid-point review of progress and implementation alongside replenishment.</li> </ol>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy <span>(GF/B20/DP9).</span>⁵</p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of US$ 53,026,371 for the following grants: BTN-607-G03-H ; BTN-607-G04-T ; IND-607-G06-M ; ZIM-509-G10-H ; ZIM-509-G08-T</p>

<ol><li>The Board approved the suggested organizational structure of the Secretariat in principle, stressing the importance of the in-coming Executive Director having a possibility to fine-tune the structure.</li><li>The Board approved the workplan and budget for a five month period (not exceeding USD 9,8 million) and the Board requested the Executive Director to present a revised budget at the Board at the next Board Meeting</li></ol>

The Board notes the work already conducted by the Finance and Audit Committee to develop an overall assurance framework for the Global Fund and acknowledges that such effort involves considerations that extend beyond the OIG. The Board requests that the Finance and Audit Committee continue to develop its recommendation for documenting the overall assurance framework of the Global Fund in consultation with the Policy and Strategy Committee, the Secretariat and the Inspector General for presentation to the Board for its approval at the Sixteenth Board Meeting.

<ol> <li>The Board acknowledges the nomination of members for the 2017 Executive Director Nomination Committee (the “Nomination Committee”).</li> <li>Accordingly, the Board approves the appointment of the following individuals to serve as members of the Nomination Committee as described below, in accordance with the terms of reference of the Nomination Committee approved under decision point GF/B36/EDP11 and set out in Annex 1 to GF/B36/ER10: <ol type="a"> <li>Michèle Boccoz, Chair of the Nomination Committee;</li> <li>Vinand Nantulya, Vice- Chair of the Nomination Committee;</li> <li>Ala Alwan, Member;</li> <li>Sarah Boulton, Member, EGC Member;</li> <li>Joanne Carter, Member;</li> <li>Julie Essiam, Member;</li> <li>William Steiger, Member;</li> <li>Peter Felix, Independent Member</li> <li>Reinhard Tittel-Gronefeld, Independent Member</li> </ol> </li> <li>The Board requests the Nomination Committee to start the 2017 recruitment process for the next Executive Director.</li> </ol>

<p>The Board:</p> <ol> <li>Expresses continuing concern about the public health crisis in Venezuela, a country that has been made eligible for Global Fund funding for malaria only for the 2020-2022 allocation period, under GF/B41/EDP06, and its adverse impact on the fight against HIV, tuberculosis and malaria in Venezuela and the region;</li> <li>Acknowledges the new proposal for exceptional funding presented by the Secretariat, and developed in consultation with partners and civil society, in accordance with the approach for potential engagement with non-eligible countries in crisis approved by the Board through GF/B39/DP04;</li> <li>Recognizes that the emergency circumstances in Venezuela continue to require unique implementation and management arrangements, which differ substantially from the standard Global Fund funding model and applicable policies, as described in GF/B41/ER10 and Annex 1;</li> <li>Accepts that the proposed implementation and management arrangements continue to entail unique risks, as described in GF/B41/ER10 and Annex 1, including that the Office of the Inspector General will not be able to provide the Board with assurance, whether through audit or investigation work, over the funds disbursed under the proposed funding arrangements and that civil society oversight may not be able to provide adequate assurance as envisaged in GF/B41/ER10 and Annex 1;</li> <li>Based on the recommendation of the Strategy Committee, approves the investment and terms set forth in Annex 1, to provide an additional USD 6,000,000, for the year 2020, to support the procurement of critical HIV, TB and malaria health products for Venezuela and social monitoring of the investment; and</li> <li>Calls for continuous engagement from relevant partners, donors and other stakeholders to further support a regional response to the health crisis in Venezuela.</li> </ol>

<p>The Board decides that the Global Fund shall discontinue the Administrative Services Agreement with the World Health Organization not later than December 31, 2008 (the "End Date"). Administrative and employment arrangements that will be in effect after that date shall be determined in accordance with the principles, processes and timelines that are described in Annex 2 to the Report of the Finance and Audit Committee GF/B16/8. </p><p>Pursuant to the above, the Board requests the Secretariat to propose a new cash balance pension scheme that shall provide safeguards for the interests of staff, to which Global Fund staff can be affiliated beginning on the date of termination of the WHO Administrative Services Agreement (the "GF Pension Fund"), and delegates authority to the Finance and Audit Committee to approve it by its March 2008 meeting.</p><p>The Secretariat shall notify the United Nations Joint Staff Pension Fund through the WHO that the Global Fund wishes to negotiate a transfer agreement between the UNJSPF and the GF Pension Fund, for submission to the July 2008 session of the UNJSPF Board.</p><p>The Board takes note of the need to further clarify the relationship and partnership with the WHO and the UN system after a discontinuation of the administrative services agreement with WHO, based on a true public/private identity as an efficient and attractive financing instrument and the role of the UN, including its normative role and function. It requests that a draft policy statement on the relationship and partnership with the WHO and the UN system, linked to the broader PSC review of partnership relations, is presented at the 17th Board Meeting.</p>

The Board extends the deadline for the signing of the Round 8 Haiti Malaria Proposal to 11 February 2011.

<p>The agenda for the 44th Board Meeting (GF/B44/01 – Revision 1) is approved.</p>

<p>The Board reaffirms its commitment to the principles of alignment and harmonization - in particular to further alignment of the Global Fund with national strategies, systems, and structures, and further harmonization with the procedures of international partners, as a means to achieving increased impact.</p><p>To provide greater support for country programs, the Board decides, in principle, to establish new procedures that will allow applicants to submit national strategies for HIV/AIDS, tuberculosis or malaria for Global Fund financing under conditions that differ in some respects from existing application requirements ("National-Strategy Applications").</p><p>The Board endorses the following principles for National-Strategy Applications¹:</p><ul><li>National-Strategy Applications must be based on inclusive, costed, comprehensive and prioritized national strategies (which include a workplan and budget) that have undergone a rigorous technical certification by an independent review mechanism ("IRM")²;</li></ul><ul><li>National-Strategy Applications shall comprise the certified national strategy and minimal additional information, which should include a specification of financial contributions to the national strategy received from existing sources, the amount of funding requested from the Global Fund, and the results to which this funding is expected to contribute;</li></ul><ul><li>The IRM that certifies national strategies shall meet certain conditions - to be defined and endorsed by the Board at a later stage - such as appropriate technical expertise and the capacity to carry out certifications functions rapidly, efficiently and transparently;</li></ul><ul><li>The IRM shall assess the technical soundness and feasibility of national strategies based on rigorous criteria that will be developed jointly with relevant partners, so the outcome of the certification is useful beyond the Global Fund's own specific needs. The Global Fund shall contribute to the development of the criteria the standards the Board requires for the certification to fulfill the Global Fund's core principles, including but not limited to programmatic and financial accountability; and</li></ul><ul><li>The implementation of National-Strategy Applications should be consistent with the core principles of the Global Fund, including performance-based funding, financial and programmatic accountability, and additionality.</li></ul><p>The Board requests the Policy and Strategy Committee to recommend to the Board for approval at its Sixteenth Meeting a plan and policies for bringing into operation a National-Strategy Applications procedure, based on the principles set forth in this decision. Such recommendations shall also address</p><p>the role of Country Coordinating Mechanisms and the Technical Review Panel, the inclusion of non-governmental entities in the National-Strategy Applications process, and the possibility of more frequent funding decisions for National-Strategy Applications, which the Board believes could provide benefits in terms of alignment and harmonization. The Policy and Strategy Committee shall also identify any modifications to existing Global Fund policies that would be necessary in order to bring into operation the National-Strategy Applications procedure.</p><p>In the spirit of the underlying principles of the Global Task Team and the Paris Declaration, the Board calls upon all partners to develop a shared certification approach for national strategies and to allow, where relevant, the use of certified strategies as the basis for applications for funding.</p>

<p>The Board refers to its approval of the establishment of a funding channel ("rolling continuation channel") that provides an opportunity for Country Coordinating Mechanisms (CCMs) to apply for continued funding for grants reaching the end of their funding terms under conditions different from those available for proposals submitted as part of new rounds of financing ("rounds-based channel").¹</p> <p>The Board considers that, in order to conduct technical reviews of proposals submitted under the rolling continuation channel, it will be necessary to build additional flexibility into the staffing and procedures of the Technical Review Panel ("TRP"). For that purpose:</p> <p>1. The Board requests the Portfolio Committee to propose amendments of the Terms of Reference of the TRP for approval at the Fifteenth Board Meeting. Such amendments shall reflect the following principles:</p> <p>a. No change shall be made to the current procedures and membership principles of the TRP for the purpose of review of proposals received through the rounds-based channel.</p> <p>b. The Chair and Vice Chair of the TRP shall, acting together, have the authority to convene ad hoc groups for the purpose of reviewing and making recommendations on proposals received through the rolling continuation channel.</p> <p>c. Such ad hoc groups may include TRP members, alternate members, members of the TRP support group, and former members of the TRP. The Chair and Vice Chair of the TRP, acting together, shall determine the appropriate number and composition of reviewers in each group, based on their fields of expertise and the content of the proposals.     </p> <p>2. The Board requests the TRP Chair and Vice Chair to review rolling continuation channel proposals based on the principles set forth in this decision point and decision point "Establishment of a Rolling Continuation Channel" (GF/B14/DP9) if any such proposals are received before the Board has amended the terms of reference of the TRP.</p>

<p>The Board adopts the following decisions: </p><p><b>Decision 1 </b> </p><ol type="a"><li>Following TRP renewal, approximately one-quarter of the TRP members will be rotated each Round.</li><li>Members appointed from 2003 onwards will be appointed to serve a term of up to four Rounds.</li><li>After each Round, the Chair and Vice Chair of the TRP will recommend with specific explanation to the selection panel the members whom should be asked to remain on the TRP (up to a maximum of four Rounds' service for each TRP member).</li><li>The selection panel will select replacement TRP members from among the TRP Support Pool.</li></ol><p><b>Decision 2</b> </p><p>For the Fourth and subsequent rounds of applications to the Global Fund: </p><ol type="a"><li>Countries classified as "Low Income" by the World Bank are fully eligible to apply for support from the Global Fund.</li><li>Countries classified as "Lower-Middle Income" by the World Bank are eligible to apply for support from the Global Fund but must meet additional requirements, including co-financing, focusing on poor or vulnerable populations and moving over time towards greater reliance on domestic resources.</li><li>Countries classified as "High Income" by the World Bank are not eligible to apply for support from the Global Fund.</li><li>Regional proposals that include <b>a majority </b> of eligible countries may submit applications to the Global Fund.</li></ol><p><b>Decision 3:</b> </p><p>The Board approves Option One for Round Four. </p><ol type="a"><li>Option 1:Countries classified as "Upper-Middle Income" by the World Bank are eligible to apply forsupportfrom the Global Fund only if they face very high current disease burden. This is defined (based on technical input from WHO and UNAIDS) for each disease as follows:<br/><ol type="i"><li>HIV/AIDS: if the country's ratio of adult HIV seroprevalence (as reported by UNAIDS, multiplied by 1000) to GNI per capita (Atlas method, as reported by the World Bank) exceeds 5;</li><li>Tuberculosis: if the country is included on the WHO list of 22 high-burden countries, or on the WHO list of the 36 countries that account for 95% of all new TB cases attributable to HIV/AIDS;</li><li>Malaria: if the country experiences more than 1 death due to malaria per 1000 people (as reported by WHO).</li></ol></li><li>Eligible countries must meet additional requirements, including co-financing, focusing on poor or vulnerable populations, and moving over time towards greater reliance on domestic resources.</li><li>The Board requests that the PMPC review the issue of future applications focusing exclusively on vulnerable populations that do not receive significant funding from domestic or external sources from Upper-Middle Income countries ineligible under Option 1.</li><li>The PMPC will present recommendations to the Board for consideration at the Seventh Board Meeting.</li></ol><p><b>PROCUREMENT AND SUPPLY MANAGEMENT</b> </p><p><b>Decision 4: </b> </p><p>National Drug Regulatory Authorities (NDRA) laboratories or laboratories recognized by the NDRA should be used for quality monitoring by the PR. To ensure the respective laboratories have adequate capacity for full pharmacopoeial testing, they must meet one of the following criteria: </p><ol type="a"><li>Acceptance for collaboration with WHO pre-qualification project;</li><li>Accredited in accordance with ISO17025 and/or EN45002;</li><li>Accepted by a stringent authority. For the purposes of this policy a stringent drug regulatory authority is defined as a regulatory authority in one of the 28 countries which is either a Pharmaceutical Inspection Cooperation Scheme and/or International Conference on Harmonization.</li></ol><p><b>Decision 5:</b> </p><ol type="a"><li>The principles for procurement and quality assurance of pharmaceuticals that were adopted during the Third Board meeting of the Global Fund apply to diagnostics and other non-pharmaceuticals: namely that a Principal Recipient (PR) is responsible for procurement, and is required to conduct competitive purchasing in order to obtain the lowest possible price for products of assured quality:</li><li>For non-durable products, the same principles as for pharmaceuticals should be followed, namely that a PR is required to select from lists of pre-qualified products, where they exist, or products accepted by stringent regulatory agencies or products accepted by national standards.</li><li>For durable products the lowest possible price should take into account the Total Cost of Ownership (TCO), including the cost of reagents and other consumables as well as costs for annual maintenance.</li><li>Procurement methods for durable products may include either lease or purchase. The PR must provide a plan for service and maintenance of the products.</li><li>The Secretariat will work with technical partners such as WHO, UNAIDS and bilateral agencies to ensure availability of information to recipients in regards to quality assurance and procurement systems related to high priority consumables and durables such as condoms, HIV rapid testing kits, CD4+ T cell monitoring, bed nets, microscopes, etc.</li></ol><p><b>Decision 6</b> </p><ol type="a"><li>The Board recognizes the potential role of in-kind donations in significantly expanding the impact of the GF and in making a significant contribution to resource mobilization efforts through providing leverage for cash resources. In-kind donations also constitute a significant means by which the private sector may be involved with the Global Fund and contribute to achieving its goals, thus reflecting the public - private partnership principles upon which the Global Fund is based.</li><li>The Board recognizes the considerable challenges to be confronted in operationalizing in-kind donations. There are different issues involved in managing in-kind donations in the form of services, non-health products, or health products, particularly pharmaceuticals, at both the global and country level.</li><li>The Board requests that the PMPC, on the basis of input from the PSM-AP, and working jointly with other Committees, particularly with the Resource Mobilization Committee, to consider further the different operational <b>and other</b> issues surrounding in-kind donations of services, non-health, and health products. These general issues include, inter alia: <ul><li>Guarding against conflicts of interest;</li><li>Potential legal liabilities;</li><li>Long term sustainability;</li><li>Valuation of contribution. </li></ul></li><li>The Board requests that, on the basis of work done by the private sector and others, the PSMAP will propose strategic options, capturing issues relating to the diversity of products and services, the managerial capacity of the Global Fund Secretariat and Principal Recipients, and the advantages/costs of channeling donations through the Global Fund vis-à-vis other existing mechanisms.</li></ol><p><b>Decision 7:</b> Board refers to the Governance and Partnership Committee the issue of potential conflict of interests when products are manufactured in a state-owned laboratory and the Principal Recipient is a public entity and when products are manufactured or purchased in a state-owned structure and the state is responsible for quality. </p>

<ol><li>The Board refers to the Mozambique Round 8 Health Systems Strengthening grant (MOZ-809-G08-S) which has not begun implementation more than 24 months from the original Board approval of the proposal.</li><li>Noting that the Country Coordinating Mechanism has requested a material re-programming of the program, the Board approves the grant to be re-launched with additional funding of up to USD 5,653,933 and with one additional year of implementation, subject to the approval of the Technical Review Panel (‘TRP’) to the re-programming and any clarifications which the TRP may require, so that the program will be implemented for a total of three years from the date of the re-launch.</li></ol>

<p><b>Decision Point 1:</b> </p><p>The Board approves for funding the proposals recommended by the Technical Review Panel, and according to the categories listed below, with the clear understanding that budgets requested are upper ceilings rather than final budgets and the Secretariat should report to the Board the results of the negotiations with Principal Recipients on the final budget for acknowledgement (Report of the Technical Review Panel and the Secretariat on Round Four Proposals: Annex II).</p><ul><li>Category 1: Recommended proposals with no or minor clarifications, which should be met within 4 weeks and given the final approval by the TRP Chair and/or Vice-Chair.</li><li>Category 2: Recommended proposals provided clarifications are met within a limited timeframe (the initial reply to TRP clarifications should be received within 6 weeks of the applicant's receipt of the initial decision of the Board, and any further clarifications should be completed within 4 months from the receipt of the initial reply from the applicant). The TRP Chair and/or Vice-Chair shall give final approval based on consultations with the primary and secondary reviewers</li><li>Category 3: Not recommended in their present form but are encouraged to resubmit.</li><li>Category 4: Not recommended for funding.</li></ul><p><b>Decision Point 2:</b> </p><p>The Board acknowledges the lessons learned by the Secretariat and the TRP during the Round 4 process and requests the PMPC to further consider the Report of the TRP and to recommend specific actions to address the issues raised by the TRP, and to address the length of time TRP members are permitted to serve on the TRP at the Ninth Board Meeting.</p>

<p>The Board approves the Report of the Thirty-Third Board Meeting, as set forth in GF/B33/24.</p>

<p>The Board approves the following proposal:</p><ol><li>The list of persons selected for the TRP by the PMPC and the Executive Director (as in Annex 2).</li><li>The launch of the TRP renewal process for 2004, on the basis of the recommendations and lessons learned contained in the PMPC report (GF/B5/9).</li><li>Add a TB specialist to the TRP.</li></ol>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Annex 1 to GF/B33/ER01;</li> <li>Approves the reinvestment of newly identified existing funds for the Ukraine TB/HIV program and its constituent grants and its resultant total program budget, as listed in Table 2 of Annex 1 to GF/B33/ER01;</li> <li>Acknowledges each country disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Fund policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.</p> <p>Annex: Armenia TB - Ministry of Health of the Republic of Armenia (ARM-T-MOH), Bhutan - TB - Ministry of Health of Bhutan (BTN-T-MOH), Costa Rica - HIV - Humanist Institute for Cooperation (HIVOS) (CRI-H-HIVOS), Eritrea - Malaria - Ministry of Health of Eritrea (ERI-M-MOH), Iraq - TB - UNDP (IRQ-T-UNDP), UKR-C-AUA, UKR-C-AUN, UKR-C-UCDC.</p>

<ol> <li><span>The Board approves the revised Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as revised and set forth in Annex 1 to GF/B39/ER15 (the “Terms of Reference”), which shall enter into force upon the commencement of the term of the next Chair and Vice-Chair of the Board.</span></li> <li><span>The Terms of Reference shall supersede any and all prior versions of terms of reference of the Board Chair and Vice-Chair previously approved by the Board.</span></li> </ol>

<p>The Board approves for funding, in the amounts indicated, the following Round 5 proposals that were recommended by the Internal Appeal Panel in its Report to the Twelfth Board Meeting (GF/B12/8) and could not be approved for funding at the Twelfth Board meeting due to resource constraints:</p><p>i. Equatorial Guinea (Malaria) -- US$ 12,906,111</p><p>ii. Philippines (Tuberculosis) -- Euro 11,709,434</p><p>iii. Sudan (HIV/AIDS) -- US$29,424,335</p><p>iv. Sudan (Tuberculosis) -- US$6,830,013</p><p>The Board's approval is made with the clear understanding the amount listed for each proposal is an upper ceiling rather than the final Phase 1 Grant amounts.</p>

<p>The Board recognizes that the Global Fund, as a financing agency, is both a part of, and heavily dependent on, a partnership model in a range of its strategic functions including to an extent for the success of countries in developing, managing and implementing grants in countries. The Board supports consideration of the recommendations set forth in Parts 5.8-5.10 of the Report of the Comprehensive Working Group GF/B23/13 in the Strategy Process. The Board requests that the Secretariat move on the following two items in the near term, and report on its progress and implementation of these actions at the Twenty-Fourth Board Meeting:</p> <ol> <li>Strengthen country-level mechanisms to build on goodwill-based partnerships through formalized agreements between in-country stakeholders to ensure effective technical cooperation, country support, and capacity building in areas that have been identified as gaps, e.g., in technical, financial, and operational management. <br /><br /></li> <li>Use flexible funding models, where agreed by the Country Coordinating Mechanisms (CCMs) and Principal Recipients (PRs), to utilize existing grant budgets to improve financing of partner support for grant implementation, particularly in bottleneck situations.</li> </ol>

<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)^[1].</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 140,505,542 for the following grants: ZAR-708-G06-H ; ETH-708-G08-H ; GNB-708-G05-H ; HND-102-G04-H-00 ; MDG -708-G10-M ; MLW-708-G06-T ; MON-102-G01-T-00 ; MON-202-G02-H-00 ; RWN-304-G03-M ; STP-708-G03-M ; TNZ-708-G10-M</p>

The Board acknowledges the formation of the Global Fund Staff Council in November 2005 and notes the intention of the Board Chair, the Vice Chair, and the Staff Council to meet prior to every Board meeting.

Ms Elisabeth Mataka of the Developing Country NGO constituency is elected as Vice Chair of the Board for the period commencing upon the adjournment of the Fifteenth Board meeting until the adjournment of the first Board meeting of 2009.

<p>The Board decides to reorganize the Board Committees by canceling the GPC,</p><p>MEFA, PFSC, PMPC, RMCC and constituting the following three committees:</p><ol><li> The Policy and Strategy Committee (PSC)</li><li> The Portfolio Committee (PC)</li><li> The Finance and Audit Committee (FAC)</li></ol><p><b>Decision Point 2:</b> </p><p>The Board adopts Option 1 with regard to Committee structure and Membership. </p><p><b>Decision Point 3:</b> </p><p>The Board adopts the Committee Rules and Procedures in GF/B10/11, Annex 3, as amended by the Board at its 10^th meeting.</p><p>The Board adopts the Terms of Reference in GF/B10/11, Annex 2, as amended by the Board at its 10^th meeting.</p><p><b>Decision Point 4:</b> </p><p>The Board decides to amend Section 23 and Section 25 of the Board Operating Procedures as follows: </p><p><b>23. Size and Membership of Committees</b> </p><p><s>Committees will have a maximum of seventeen members</s>. The Board Chair and Vice Chair, in consultation with the committee chair, <s>and the Executive Director</s>, will propose the constituencies to be included on each committee, based on applications made by constituencies for committee seats, for full Board approval. There will be no more than one member per constituency on any single committee. Each constituency may participate in a maximum of <s>three</s>two committees. Membership on the Ethics Committee shall not count toward this <s>three</s> two-committee limit, nor shall membership on other ad-hoc committees where the Board specifically provides that membership shall not apply toward this limit. Where demand for committee seats exceeds the maximum, priority will be given to ensuring balance.</p><p>Constituencies will designate an individual to represent them on a given committee. While it is preferable that constituencies choose Board Members or Alternate Members to serve on committees, they are free to choose any individual to represent them.<s> While substitutes should be discouraged, committee members will be able to send substitutes as an exception without the approval of the committee chair. Only committee members (or their substitute) will attend committee meetings, unless other individuals are invited to do so by the committee chair</s>. Because committee chairs must chair the committee meeting without prejudice, they may bring an additional representative of the constituency to participate as a member of the committee. Where considered necessary by the committee chair, the vice chair of a particular committee may be permitted to bring an additional representative of the constituency to participate as a member of the committee. </p><p><b>25. Ethics Committee</b> </p><p>The Ethics Committee shall be a permanent committee of the Board. The Ethics Committee shall consist of four members. <s>The Board Vice Chair shall be a member of, and shall Chair, the Ethics Committee</s>.</p><p>The Ethics Committee shall operate under these Board Operating Procedures, the committee guidelines of the Board, and the Ethics Committee procedures and rules, as may be adopted and amended from time to time by the Board. In circumstances where these Ethics Committee procedures and rules conflict with these Board Operating Procedures or the committee guidelines of the Board, the Ethics Committee procedures shall govern.</p>

<p>The Board acknowledges the lessons learned by the Technical Review Panel (TRP) and Secretariat during the Round 6 proposals process as presented in the Report of TRP and the Secretariat on Round 6 Proposals (GF/B14/10), and delegates authority to the Portfolio Committee to:</p><p>a. approve appropriate revisions to the Proposal Form and Guidelines for future Rounds by 1 March 2007; and</p><p>b. approve appropriate revisions to the process for screening and clarification of proposals prior to submission to the TRP.</p>

<p><b>Decision Point 1</b> </p><p>The Board of the Global Fund agrees to reappoint Dr. Richard Feachem as Executive Director of the Global Fund.</p><p><b>Decision Point 2</b> </p><p>Terms of reference for the Executive Director will be developed and presented for decision at the Eighth Board Meeting.</p><p><b>Decision Point 3</b> </p><p>The Board will establish an annual performance review process for the Executive Director.</p>

<p>The Board approves the following decisions:</p><p><b>Decision Point 1</b> </p><p>Phase 2 grant renewal decisions will be made according to clear criteria for satisfactory grant performance, financial accountability and contextual considerations, subject to Global Fund resource availability. The decision will be based on systematically collected information, which will be made transparently available by the Global Fund through Grant Fact Sheets and Grant Score Cards.</p><p><b>Decision Point 2</b> </p><p>A Request for Continued Funding, up to a maximum of the original approved Proposal less funds spent during the initial grant period (years 1-2)<a id="_ftnref1" name="_ftnref1">^[1]</a>, will be reviewed and may be adjusted for reasonableness. Program objectives for phase 2 are expected to be broadly consistent with the original approved Proposal, with reprogramming subject to review.</p><p><b>Decision Point 3</b> </p><p>The Board delegates the authority to make phase 2 grant commitments to the Secretariat according to the policies and review and decision process set forth in this document. The Board will confirm all decisions to discontinue funding based on reviews by the Secretariat and the TRP. The Secretariat will regularly report on phase 2 grant commitments to MEFA and PMPC. The PMPC Chair will inform the Board at each Board meeting. The Technical Evaluation Reference Group (TERG) will regularly review and report on the soundness of the phase 2 review and decision process to the Board through MEFA.</p><p>The phase 2 decisions will be taken 20 months after the start date for grant programs with exceptions for <i>force majeur</i> situations. The decision may be taken earlier in cases of (i) accelerated implementation; or (ii) severe exchange rate fluctuations.</p><p>For Rounds 1 and 2 grants, the start date of each grant program may be adjusted to reflect program realities. This will be achieved through negotiations between the Secretariat and the PR.</p>

The Board approves additional funding up to US$ 4,998,103 for the Phase 2 period of the Round 7 Lesotho HIV grant (LSO-708-G05-H) to improve the quality and scale of PMTCT activities, subject to TRP clarifications and conditions within a limited timeframe. The Board approves the revised Phase 2 incremental amount up to US$ 20,247,629 which includes an additional sum of US$ 4,998,103 allocated for PMTCT activities. This funding may also be subject to additional conditions to be cleared by the Secretariat as part of its risk management function.

<p>The Board approves the Quality Assurance Policy for Pharmaceutical Products ("QA Policy") as set out in Annex 1 to the Report of the Portfolio Committee (GF/B18/5). The QA Policy shall come into effect on 1 July 2009 and shall replace the Global Fund's previous policy for the quality assurance of pharmaceutical products (as approved at the Third Board meeting and amended at subsequent Board meetings). </p><p>The Board authorizes the Secretariat to request the World Health Organization (WHO) to host the Expert Review Panel described in the QA Policy, and to conclude the necessary arrangements with the WHO.</p><p>The Board delegates to the Portfolio Committee the responsibility for overseeing the implementation of the QA Policy, including the establishment of the Expert Review Panel. The Board requests the Secretariat to provide the Portfolio Committee with an update to review the implementation of the QA Policy at the Portfolio Committee's final meeting in 2009, and thereafter, as requested by the Portfolio Committee. </p><p>The Board also requests the Secretariat, under the oversight of the Portfolio Committee, to review the current status of quality assurance for diagnostic products and make recommendations. The Board requests the Portfolio Committee to report the findings of this review at the Board's final meeting in 2009. </p>

<ol> <li>The Board: <ol type="i"> <li>Recalls its decision (GF/B38/DP05) on the Integration of Additional Public Donors into the Global Fund Governance Structure and Amendment of the Global Fund Bylaws;</li> <li>Notes the requirement of the Operating Procedures of the Board and Committees pursuant to which each constituency of the Board must be represented in at least one Standing Committee of the Board; and</li> <li>iii. Notes the recommendation of the Ethics and Governance Committee, as set forth in GF/B39/ER02, to create an additional non-voting committee seat within the Strategy Committee.</li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board approves the creation of an additional non-voting seat in the Strategy Committee and, to this effect, amends Section C., article 3, paragraph e. of the Charter of the Strategy Committee, as set forth in Annex 1 to GF/B39/ER02.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B43/ER03 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol> <li> <p>The Board endorses the Technical Review Panel (TRP) Recommendation Categories for the Transitional Funding Mechanism (TFM) as set forth in the GF/B26/ER 07.</p> </li> <li> <p>The Board approves all TFM proposals recommended for funding by the TRP as Categories 1, 2, and 3 as indicated in Annex 1 of GF/B26/ER 07, subject to all applicable clarifications or conditions outlined in TRP review forms. The aggregate total of the maximum upper ceilings of funding for Category 1, 2 and 3 TFM proposals is US$ 419.8 million.</p> </li> <li> <p>Applicants whose proposals are recommended for funding as "Category 3" shall:</p> <ol type="a"> <li> <p>provide an initial detailed written response to the requested TRP clarifications no later than four (4) weeks after the applicant's receipt of notification in writing by the Secretariat of this Board decision; and</p> </li> <li> <p>conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than eight (8) weeks after the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment.</p> </li> </ol> </li> <li> <p>The Board conditionally approves all TFM proposals which are recommended for funding by the TRP as "Category 4" as indicated in Annex 1 of GF/B26/ER 07 subject to review and approval by the TRP of the revised TFM proposals. The Board notes that applicants whose proposals are recommended for funding as "Category 4" submitted proposals in need of substantial revision despite risks of disruption of essential prevention, treatment and/or care services during the TFM eligibility period of 1 January 2012 and 31 March 2014. The aggregate total of the maximum upper ceilings of funding for Category 4 TFM proposals is US$ 91.2 million.</p> </li> <li> <p>Applicants whose proposals are recommended for funding as "Category 4" shall:</p> <ol type="a"> <li> <p>submit a revised proposal, based on the parameters set out in the applicants' TRP review form; and</p> </li> <li> <p>complete the revised proposal review process, including anyclarification which the TRP may require, within the timeframe stipulated in the TRP review form resulting from such a review.</p> </li> </ol> </li> <li> <p>The Secretariat will notify the Board of the outcomes of all Category 4 proposals.</p> </li> <li> <p>The Board declines to approve for funding those proposals recommended by the TRP as "Category 5." These proposals are eligible to appeal this decision subject to the grounds and process for appeals as stipulated in the 'Rules Governing the Global Fund's Appeal Mechanism for Applications not Approved for Funding'.</p> </li> <li> <p>The Board notes that many applicants will face disruption during the second half of 2013 or in 2014, the latter stages of the TFM eligibility period. There may be circumstances where there are advantages to signing a TFM grant closer to the date of disruption, including circumstances created by the Board's decision to accelerate the implementation of the Global Fund Strategy (GF/B26/DP6). As such, the Board decides that TFM grants may be signed beyond the currently required 12-month period after Board approval of a proposal (GF/B8 Timeframes for Grant Agreements, Decision Point 2) and may have start dates that are beyond 15 or 18 months after Board approval, as applicable, in accordance with their respective disruption dates.</p> </li> <li> <p>The Board's approval of proposals is made with the clear understanding that the proposal amounts recommended for funding by the TRP, as set forth in Annex 1 - GF/B26/ER 07, are maximum upper ceilings rather than final approved grant amounts and are subject to reduction upon successful completion of TRP clarifications, TRP reviews of revised proposals, and grant negotiations.</p> </li> </ol>

<p>The Board:</p> <ol> <li>Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SC04/DP02;</li> <li>Approves the additional incremental funding recommended for certain UQD of the following country disease components: (i) Burundi Malaria, and (ii) Philippines TB, as listed in Table 2 of GF/B39/ER12, based on available funding approved by the Audit and Finance Committee;</li> <li>Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<ol><li>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.<br/><br/>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.<br/><br/></li><li>The Board approves the use of undisbursed grant funds under grant number IND-102-G01-T-00 listed in Schedule B to finance continuation of program activities under the Rolling Continuation Interim Bridge Funding policy, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on an understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendations set forth in the Qualification Score Card.<br/><br/><br/>SCHEDULE A (Phase 2 Recommendations)<br/><br/>Ghana, HIV – Round 5<br/>Grant Number(s) GHN-506-G06-H<br/>CCM Requested Amount (Total Phase 2 in US$): 65,468,580<br/>Approved Funding Amount (Incremental in US$): 65,468,580<br/>Recommendation Category: Go<br/><br/>Ghana, TB – Round 5<br/>Grant Number(s) GHN-506-G05-T<br/>CCM Requested Amount (Total Phase 2 in US$): 17,916,308(1)<br/>Approved Funding Amount (Incremental in US$): 16,924,238<br/>Recommendation Category: Go<br/><br/>Kenya, Malaria – Round 4<br/>Grant Number(s) KEN-405-G06-M<br/>CCM Requested Amount (Total Phase 2 in US$): 104,346,797<br/>Approved Funding Amount (Incremental in US$): 80,423,329<br/>Recommendation Category: Conditional Go<br/><br/>Kyrgyzstan, Malaria – Round 5<br/>Grant Number(s) KGZ-506-G03-M<br/>CCM Requested Amount (Total Phase 2 in US$): 1,733,735<br/>Approved Funding Amount (Incremental in US$): 1,733,735<br/>Recommendation Category: Go<br/><br/>Uganda, Malaria – Round 4<br/>Grant Number(s): UGD-405-G05-M<br/>CCM Requested Amount (Total Phase 2 in US$): 91,614,931<br/>Approved Funding Amount (Incremental in US$): 71,034,989<br/>Recommendation <br/>Category: Conditional Go<br/><br/>Zambia, HIV – Round 4<br/>Grant Number(s): ZAM-405-G12-H<br/>CCM Requested Amount (Total Phase 2 in US$): 21,687,283<br/>Approved Funding Amount (Incremental in US$): 13,390,445<br/>Recommendation<br/>Category: Conditional Go<br/><br/><br/>SCHEDULE B (RCC Interim Bridge Funding Recommendation)<br/><br/>Indonesia, TB – Round 1<br/>Grant Number(s): IND-102-G01-T-00<br/>Duration of Funding: 10 months<br/>CCM Requested Amount (Incremental in US$): 0<br/>Approved Funding Amount (Incremental in US$) 0</li></ol>

<ol><li>The Global Fund Board decided to adopt the decision points requested by the Working Group on Monitoring and Evaluation and ask the M.E.F.A Committee to report back to the Board on progress on their implementation at the meeting of the Board in January, 2003. <ol><li type="a">The Board instructed the Secretariat to prepare annual action plans for monitoring and evaluation of the Global Fund’s performance, and instruct the M.E.F.A. Committee to present a plan appropriate to its mandate as agreed by the Board;</li><li type="a">The Board endorsed the principles of transparency, consultation with stakeholders and coordination of monitoring and evaluation efforts to facilitate optimal use of existing partner capacity, while satisfying the needs of major donors and their internal auditing requirements;</li><li type="a">The Board reaffirmed the importance of linking results to an appropriate disbursement schedule and annual results reviews, and instructed the Secretariat to include results-reporting templates in grant agreements with PRs, ensuring PRs clearly understand the concept of Results Based Disbursement;</li><li type="a">The Board instructed the Secretariat to operationalize an approach for results reviews, which includes a provision for annual results reviews, review criteria, and a strengthening of information systems making this reporting feasible;</li><li type="a">The Board instructed the Secretariat to clarify the role and responsibilities of CCMs, PRs, LFAs and the Fund Secretariat regarding monitoring and reporting within the context of the fiduciary architecture of the Global Fund;</li><li type="a">The Board instructed the Secretariat to define quality assurance in the context of the Fund’s mission, and identify mechanisms for ensuring data quality;</li><li type="a">The Board endorsed the need to set budgetary parameters for monitoring and evaluation at the Fund level and to reconfirm the need for grant proposals to include budgets for monitoring and evaluation.</li></ol></li><li>The Board directs the M.E.F.A. Committee to review the recommendation that there be an independent secretariat in the field of monitoring and evaluation and to report on this matter to the January, 2003 Board meeting</li><li>The Board directs the M.E.F.A. Committee to consider the need for periodic focused external audits of the performance of the Global Fund, or aspects of the Global Fund, and to bring recommendations to the Board in January 2003.</li></ol>

<p>Siula Bulu from the Western Pacific Region constituency is designated as Rapporteur for the 35th Board Meeting.</p>

The Board approves a budget for US$400,000 in 2007 for support services to the Chair and Vice Chair of the Board.

1. The Board welcomes the invitation of the Government of Rwanda to host the Global Fund's<br/>37th Board Meeting on 03-04 May 2017.<br/><br/>2. Accordingly, the Board agrees to convene the 37th Board Meeting in Kigali, Rwanda.

<p>The Board authorizes the addition of 25 staff positions, representing US$ 1.8 million in staffing costs, and US$ 4.13 million in non-staffing costs to the approved 2011 Operating Expenses budget to accelerate the implementation of the Reform Agenda, as described in GF/B23/13.</p> <p>The budgetary implications of this decision for the 2011 Operating Expenses Budget are US$ 1.80 million in staff costs (prorated), reflecting an increase of 25 staff positions, and US$ 4.13 million in non-staffing costs.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b to GF/B40/ER06 (“Table 1a” and “Table 1b”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> </ol> <p>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</p>

The Board notes that the approach adopted by the OIG to develop its annual audit plan is an important strategic matter that reflects the Global Fund's risk management policy. The Board approves the approach for setting the annual OIG audit plan as described in Annex C of the OIG Progress Report (GF/B20/14).

The Board appoints Norbert Hauser as Chair of the Board and Aida Kurtovic as Vice -Chair of the Board to each serve a term starting from the adjournment of the Thirty-Third Board Meeting on 1 April 2015 and until the adjournment of the first in person Board Meeting in 2017.

<p>The Board emphasizes the urgency of providing more room for youth leadership and involvement in the response to HIV/AIDS, tuberculosis and malaria. The Board recognizes the diversity and special needs of young people and stresses the importance of protecting young people's health and human rights, especially for the 5.4 million young people who are living with HIV and the millions who are at risk, in particular young women and girls; but also those who are marginalized, including but not limited to young sex workers and people who use drugs; lesbian, gay, bisexual and transgender youth; and young migrants. </p><p>The Board asks constituencies and the Secretariat to consider how they can better include young people, facilitate youth-led action at global and national level and ensure that their ideas and perspectives are better reflected in the work of the Global Fund and the Board and report back to the Board within 2 years.</p>

<p>The Board:</p><ol><li>Approves extension of the current implementation periods of SAF-910-G09-H, SAF-H-NACOSA, SAF-304-G04-H, and SAF-H-NDOH to 30 September 2013; and</li><li>Approves the commitment of up to USD 26,831,949 in additional funding from the indicative amounts of grant funds available, but not yet approved or committed, for the next implementation periods to fund extensions for SAF-910-G09-H, SAF-H-NACOSA and SAF-H-NDOH, as set forth in Table 1.</li></ol>

<p>Referring to its earlier decision on 19 December 2011 (B25/EDP/02), the Board:</p> <ol> <li>Notes that a transcription error was made in the reporting of the amounts requested and the Secretariat’s recommendation for incremental funding for the Phase 2 period for the Zimbabwe grants numbered ZIM-809-G14-S and ZIM-809-G13-M listed in decision point B25/EDP/02;</li> <li>Decides to amend its funding decision for the two Zimbabwe grants numbered ZIM-809-G14-S and ZIM-809-G13-M, by replacing the earlier approved amounts with the corrected funding amounts as set out in Table 1, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).^[1]</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each of affected proposals shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$282,752,190 for the following grants: BLR-809-G03-H ; BRN-809-G07-H ; IND-809-G13-M ; IND-809-G14-M ; KAZ-809-G04-T ; NIC-809-G06-H ; PHL-202-G09-M ; PHL-202-G11-T ; SOM-809-G06-H ; ZIM-809-G14-S ; ZIM-809-G13-M</p>

<p><b><i>1. The Board acknowledges the nominations for membership of the Board's Audit and Finance Committee (the "AFC"), Ethics and Governance Committee (the "EGC"), and Strategy Committee ("SC"), as set forth in GF/B35/ER02".</i></b> </p> <p><b><i>2. Accordingly, the Board approves the appointment of the following individuals to serve as voting members of the Committees listed below, representing the Board constituencies listed by their name:</i></b> </p> <p><b><i>a. Audit and Finance Committee</i></b> </p> <p><b><i>i. Gregoire Lacoin, European Commission Constituency;</i></b> </p> <p><b><i>ii. Sylvie Bourdenet, France Constituency;</i></b> </p> <p><b><i>iii. Erika Satterwhite, Private Sector Constituency;</i></b> </p> <p><b><i>iv. Anthony Richard Garnett, United Kingdom Constituency;</i></b> </p> <p><b><i>v. Michael Ruffner, United States Constituency;</i></b> </p> <p><b><i>vi. Soltan Mammadov, Eastern Europe &amp; Central Asia Constituency;</i></b> </p> <p><b><i>vii. Thamer Al Hilfi, Eastern Mediterranean Constituency;</i></b> </p> <p><b><i>viii. Grace Rwakarema, Eastern and Southern Africa Constituency;</i></b> </p> <p><b><i>ix. Sugata Ghosh Dastidar, South East Asia Constituency; and</i></b> </p> <p><b><i>x. Han Mengjie, Western Pacific Region Constituency.</i></b> </p> <p><b><i>b. Strategy Committee</i></b> </p> <p><b><i>i. Philippe Meunier, France Constituency;</i></b> </p> <p><b><i>ii. Heiko Warnken, Germany Constituency;</i></b> </p> <p><b><i>iii. Eiji Hinoshita, Japan Constituency;</i></b> </p> <p><b><i>iv. Lennarth Hjelmaker, Point Seven Constituency;</i></b> </p> <p><b><i>v. Kieran Daly, Private Foundations Constituency;</i></b> </p> <p><b><i>vi. Rico Gustav, Communities Constituency;</i></b> </p> <p><b><i>vii. Jorge Saavedra, Developing Country NGOs Constituency;</i></b> </p> <p><b><i>viii. Vinand Nantulya, Eastern and Southern Africa Constituency;</i></b> </p> <p><b><i>ix. Joel Mayowa, West and Central Africa Constituency; and</i></b> </p> <p><b><i>x. LV Fan, Western Pacific Region Constituency.</i></b> </p> <p><b><i>c. Noting that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group serve as non-voting members of the Strategy Committee, the Board appoints the following individuals to serve as additional non-voting members of the Strategy Committee, representing the Board constituencies listed by their name:</i></b> </p> <p><b><i>i. Sheikh Mubashar, WHO Constituency; and</i></b> </p> <p><b><i>ii. Melanie Renshaw, Partners Constituency.</i></b> </p> <p><b><i>d. Furthermore, the Board appoints Alexandru Cebotari to serve as a non-voting member of the Audit and Finance Committee</i></b> , <b><i>representing the World Bank, and notes that the remaining non-voting member of the Audit and Finance Committee that will represent one of the non-voting, ex-officio members of the Board will be subsequently appointed.</i></b></p> <p><b><i>3. Additionally, the Board approves the appointment of the following individuals, with their nominating Board constituency listed by their name, to serve in their personal capacity as voting members of the Ethics and Governance Committee:</i></b> </p> <p><b><i>a. Jacques Mader, Canada Switzerland Australia Constituency;</i></b> </p> <p><b><i>b. Sarah Boulton, United Kingdom Constituency;</i></b> </p> <p><b><i>c. Sandy Thurman, United States Constituency;</i></b> </p> <p><b><i>d. Jason Wright, Developed Country NGOs Constituency;</i></b> </p> <p><b><i>e. Archil Talakvadze, Eastern Europe &amp; Central Asia Constituency; and</i></b> </p> <p><b><i>f. Mirta Roses Periago, Latin America and Caribbean Constituency.</i></b> </p><p> <b><i>4. The Board notes each Committee Member appointed under this decision point shall begin their term upon approval of this decision point and serve for two years or until the appointment of their respective successor.</i></b></p>

<p><b><i>Protecting Grants from the Impact of Exchange Rate Fluctuations</i></b> </p><p><b>Decision Point 1</b> </p><p>That in cases where a funding shortfall caused by an adverse currency fluctuation is jeopardizing the viability of the grant supported program, the CCM may apply for Phase 2 funding on an accelerated basis in order to permit the program to continue uninterrupted without curtailing program activity.</p><p><b>Decision Point 2</b> </p><p>That the Secretariat evaluate the implications of the Global Fund offering top-up grants and multi-currency denominated grants as further means of protecting grants from the impact of exchange rate fluctuations and to present its analysis and recommendations to the Board in June 2004.</p><p><b>Decision Point 3</b> </p><p>To mandate the Secretariat and the MEFA Committee to study possible stabilization mechanisms, including topping-up grants and multi-currency grants, aimed at protecting grants from the impact of exchange rate fluctuations. The MEFA Committee will present its analysis and recommendations to the Board at the Eighth Board Meeting.</p><p><b><i>Criteria for Considering Promissory Notes as Assets</i></b> </p><p><b>Decision Point 4</b> </p><p>That the Global Fund shall consider as assets for the purposes of entering into grant agreements, promissory notes or similar obligations issued by the government of a sovereign state (or its designated depository) which shall be non-negotiable, non-interest bearing and payable at par value to the account of the Fund in the designated depository on demand or in accordance with an encashment schedule agreed between the contributor and the Secretariat.</p>

<p>The Global Fund Board recognizes that the health-related Millennium Development Goals are interlinked. Achieving MDG 6 (combating HIV, malaria and TB and other diseases), MDG 4 (reducing child mortality) and MDG 5 (improving maternal health) can only be approached in an integrated manner and the success of one MDG depends on progress on all others.</p> <p>The Board acknowledges that HIV, tuberculosis and malaria place a heavy burden on the health of women and children. In sub-Saharan Africa, HIV is responsible for 46 per cent of all deaths among women of reproductive age. HIV, TB and malaria are among the most common indirect causes of maternal deaths. All three diseases heavily impact on the health of children: Children account for more than 80 per cent of malaria, and over 2 million children are living with HIV, 90 per cent of them living in sub-Saharan Africa. </p> <p>The Board notes the efforts of a broad range of partners who are working to accelerate action and to scale up integrated services, and especially applauds the efforts of MCH advocates, who have been tireless in their efforts to improve the health and save the lives of women and children.</p> <p>The Board is encouraged by the contributions of the Global Fund in financing country-led programs that improve maternal and child health, including scaling up PMTCT services, malaria prevention and treatment, anti-retroviral therapy, integration of sexual and reproductive health services with HIV/AIDS programmes and support for children orphaned by HIV/AIDS. The Global Fund investments are also strengthening health and community systems, and supporting a range of interventions to promote gender equality and equity, as articulated in the Gender Equality Strategy (Decision Point GF/B18/DP18).</p> <p>The Board supports the efforts of countries to integrate MCH within their HIV/AIDS, TB and malaria programmes, and strongly encourages CCMs to look at opportunities to scale up an integrated health response that includes MCH in their applications for HIV/AIDS, TB, malaria and HSS. </p> <p>However, the Board notes that despite support for integrated MCH services through the current Global Fund portfolio, some areas along the continuum of care in maternal and child health will not be addressed by 2015. These areas, as outlined in the Consensus for Maternal, Newborn and Child Health, include comprehensive family planning, skilled care for women and newborns during and after pregnancy and childbirth. </p> <p>The Board encourages countries and partners, as a matter of urgency, to work together in the context of opportunities presented through grant reprogramming, Round 10, and changes to the Global Fund grant architecture to urgently scale up investments in MCH in the context of the Global Fund's core mandate. </p> <p>The Board strongly encourages CCMs to identify opportunities to scale up an integrated health response that includes MCH in their applications for HIV/AIDS, tuberculosis, malaria and HSS.</p> <p>The Board agrees to work with partners in exploring ways to further enhance and integrate the Global Fund's contributions in this area within the context of national strategies and integrated approaches.</p> <p>The Board requests the Secretariat to review and elaborate the potential options and their implications for enhancing the contributions of the Global Fund to MCH, recognizing the urgent need for additional and sufficient financing for MCH as well as for AIDS, tuberculosis and malaria, and exploring how this will impact on existing Global Fund policies, partnerships, resource mobilization, procedures, and operations, including CCMs, TRP and staffing at the Secretariat. The Board further requests the Secretariat to report on this matter at the 14th Policy and Strategy Committee meeting for its recommendation to the Twenty-Second Board Meeting.</p>

<p>The agenda for the Extraordinary Board Meeting (GF/EB01-2021) is approved.</p>

<p>The Board amends the Board Operating Procedures by inserting the following text as Section “G” and renumbering the remaining text accordingly:</p><p><span></span></p><p>G. PROCEDURES FOR APPOINTMENT AND ASSESSMENT OF THE EXECUTIVE DIRECTOR</p><p><span></span></p><p>26. Appointment of the Executive Director</p><p><span></span></p><p> No later than six months prior to the end of the term of the incumbent Executive Director, the Board shall, in accordance with Article 8.1 of the Bylaws and this Section of the Board Operating Procedures, decide on a procedure for the appointment of the next Executive Director. </p><p><span></span></p><p> At this time, the Board shall normally launch a competitive recruitment process, publicly inviting applications for the position of Executive Director. Where the incumbent Executive Director has not served more than one term of office, the Board shall invite him or her to re-apply, together with other candidates, for such position and publicly announce such invitation. Where appropriate the Board may launch such a recruitment process without inviting the Executive Director to re-apply for the post or, based on a satisfactory performance appraisal and if the incumbent Executive Director has not served more than one term, extend the appointment of the Executive Director for a further term of three years without the normal recruitment process.</p><p><span></span></p><p>If the Board decides to launch a recruitment process, it shall be assisted by an ad hoc Nomination Committee. At least six months prior to the end of the term of the incumbent Executive Director, or at any other time decided by the Board, the Chair of the Board shall, notwithstanding the otherwise applicable procedures under these Board Operating Procedures and the Committee Rules and Procedures, recommend for Board approval the terms of reference of the Nomination Committee and nominate for Board approval a Chair and the membership of that Committee. Membership in the Nomination Committee shall not count towards the two committee limit referenced in Section 23 of these Board Operating Procedures.</p><p><span></span></p><p> The Chair of the Board may also recommend for Board approval updated terms of reference of the Executive Director and the criteria for his selection. Following approval of the membership of the Nomination Committee, the recruitment process is launched. </p><p><span></span></p><p>The Nomination Committee shall interview and rank candidates, and present the highest ranking candidates to the Board, which shall then select a candidate, consistent with the terms of office of the Executive Director that are stated in Section 17 of these Board Operating Procedures.</p><p><span></span></p><p>The mandate of the Nomination Committee shall expire upon the appointment of the Executive Director.</p><p><span></span></p><p>27. Assessment of the performance of the Executive Director</p><p><span></span></p><p>The Chair of the Board shall ensure that the performance of the Executive Director is assessed each year based on best practices. All documentation related to such assessment shall be provided to the Board not later than the end of the first quarter of the calendar year. </p>

<ol> <li>The Board approves the appointment of Mr. Mohamed Abdellatif as an independent member of the Audit and Ethics Committee (the “AEC”) to fill one current vacancy.</li> <li>Mr. Mohamed Abdellatif shall serve on the AEC until the end of his predecessor’s term.</li> </ol>

<p>The Board approves revised Terms of Reference for the Executive Director as set out in Annex 1 to Electronic Report B26/ER/05, which shall be used as the basis for the recruitment of a new Executive Director.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2013 Annual Financial Report, which includes the 2013 Consolidated Financial Statements that have been audited by Ernst &amp;amp; Young Ltd, as set forth in GF/B31/ER02 Annex 1.</p>

<ol><li>There should be a balance between chairs from developed and developing countries. There should be one chair per committee. The committee chair shall appoint a vice chair of the committee.</li><li>Committee chairs will preferably be either Board members or alternates. The Board will also approve any vice chairs who are appointed by committee chairs. The Board Chair/Vice Chair will select the committee chairs and submit these names to the full Board for approval. The Board will also approve any vice chairs who are appointed by committee chairs.</li><li>The Board Chair/Vice Chair will be able to designate or replace committee chairs when necessary as, for example, when a committee chair is no longer available, or is not adequately fulfilling the role. The Board will approve the change of any committee chair.</li><li>Committees will have a minimum of six and a maximum of twelve members.</li><li>The Board Chair/Vice Chair, in consultation with the committee chair and the ED, will propose the constituencies to be included on each committee, based on applications made by constituencies for committee seats, for full Board approval. There will be no more than one member per constituency on any single committee.Each constituency may participate in a maximum of three committees. Where demand for committee seats exceeds the maximum, priority will be given to ensuring the balance of donors, recipient countries, NGOs, private sector and foundations.</li><li>Constituencies will designate an individual to represent them on a given committee. While it is preferable that constituencies choose Board members or alternates to serve on committees, they are free to choose any individual to represent them.</li><li>While substitutes should be discouraged, committee members will be able to send substitutes as an exception without the approval of the committee chair.</li><li>Only committee members (or their substitute) will attend committee meetings, unless other individuals are invited to do so by the committee chair.</li><li>Expert input should be provided at the discretion of committees and in consultation with the Executive Director and may take the form of a panel of independent experts. The committee chair and vice chair, in conjunction with the ED, will then choose the panel of independent experts from the list of nominations submitted by the committee. The Board will not need to approve the specific list of individuals selected. These independent experts will be subject to the agreed conflict of interest provisions. When Board committees have designated an expert panel, the expert panel will be able to meet with the full committee, or (at the committee’s discretion) independently, with only the committee chair and/or vice-chair); in either case, Board/constituency members who are not members of the committee will not attend these expert panel meetings, unless invited to do so by the committee. The committee will provide terms of reference for expert panels.</li></ol>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).²</p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of US$ 81,600,858<span> for the following grants: </span>BEN-708-G07-M ; BTN-708-G05-M ; CIV-607-G06-M ; LSO-708-G05-H ; NEP-708-G08-T ; NGR-708-G07-M ; MAL-607-G04-M ; MON-708-G05-H ; MWP-708-G07-T ; PRY-708—G03-T ; SNG-708-G07-M ; THA-708-G09-M</p>

<p><b>Decision Point 1:</b> </p><p> The Board requests the Chair to launch a process to produce a performance assessment of the Executive Director in time for the Thirteen Board Meeting.</p><p><b>Decision Point 2: </b> </p><p> The Board decides to establish a Committee, composed of the Chairs and Vice Chairs of the Policy and Strategy Committee, Finance and Audit Committee, Portfolio Committee and Ethics Committee, to prepare recommendations for the Thirteenth Board Meeting, which will include updated Terms of Reference for the position of Executive Director. </p><p><b>Decision Point 3: </b> </p><p> The Board decides to amend its By-laws and Board Operating Procedures for the appointment of the Executive Director to be in line with the text appearing below. The Board requests the Chair to work with WHO and the Global Fund's Legal Counsel and outside Swiss counsel to produce draft amendments for adoption at the Thirteen Board Meeting.</p><p>APPOINTMENT OF THE EXECUTIVE DIRECTOR</p><p><b>I. Term and Term Limits: </b> </p><p> The Board decides to amend Article 8.1 of its By-Laws. The Board selects the Executive Director for a period of four (4) years, renewable for a period of three (3) years. The Board will make this selection on a merit-based, non-political and open basis.</p><p><b>I I. Options for Board Decision</b> </p><p>At least six months before the end of the incumbent Executive Director's first term, the Board makes one of three decisions: </p><ol><li> Launch a recruitment procedure, and encourage the Executive Director to let his/her name stand for the post; </li><li> Reappoint the Executive Director, subject to performance appraisal; or</li><li> Launch a recruitment procedure, and do not encourage the Executive Director to let her/his name stand for the post.</li></ol><p>The norm is Option One. In that case, the Board will make public that it has invited the incumbent Executive Director to re-apply for the post.</p><p><b>III. Recruitment/reappointment procedure </b> </p><p>The Board decides to modify its Board Operating Procedures to include a recruitment procedure and a reappointment procedure, as decided in Paragraph 2 above. </p><p>3.1. Recruitment procedure ;</p><ol type="a"><li> At least six months before the end of the term of an incumbent Executive Director, or any other time decided by the Board, the recruitment process will be followed as below. The Board at that time approves updated Terms of Reference, including selection criteria, for the position of Executive Director. </li><li> The Board Chair nominates, and the Board approves, a selection committee.</li><li> The Board launches the recruitment process. </li><li> The selection committee interviews candidates, and presents the best-ranking candidates to the Board for decision. </li></ol><p>3.2. Reappointment procedure </p><p>On the basis of the performance assessments, the Board could decide to reappoint an Executive Director for one additional term of three (3) years, under the conditions in Paragraph One above.</p><p>Under this system, the annual performance assessment of the Executive Director would, of course, continue, in line with normal best practice. All material for the evaluation will be provided to the Board in the first quarter of the calendar year. </p>

<p><b>Decision Point 1:</b> </p><p>The Board decides to approve the following procedure for use, should it so decide, in processing proposals pending before it at its 10^th meeting:</p><p><b>Interim procedure for processing proposals pending before the Board at its 10^th meeting</b> </p><ol><li>The Board may decide to refer a proposal back to the CCM for further processing as a Revised Request for Continued Funding.</li><li>If the Board refers a proposal for further processing as a Revised Request for Continued Funding, the CCM will be provided with a summary of concerns raised and will be given one opportunity to address these and any other concerns raised during the Phase 2 process.</li><li> The CCM must deliver its Revised Request for Continued Funding to the Secretariat within two months of written notification of the opportunity to resubmit. The Secretariat shall review the Revised Request for Continued Funding solely for financial reasonableness, and shall pass both the submission and its financial comments to the TRP for review within one month of receipt from the CCM. The TRP shall provide a recommendation to the Board within one month of receipt from the Secretariat. </li><li> If the TRP recommends to discontinue funding, the recommendation shall be in the form of notification to the Board, no further funding shall be provided for the proposal and funding of the existing program shall terminate at the completion of its term. </li><li> If the TRP recommends to continue funding, the Board shall vote by e-mail on the TRP recommendation under its no-objection procedure. Votes must be received by the Secretariat no later than the 10th day following notification to the Board (inclusive of the day of notification).</li><li> If the TRP recommendation to continue funding is not approved by the Board, no further funding shall be provided for the proposal and funding of the existing program shall terminate at the completion of its term.</li></ol>

<p>Dr. Tedros Adhanom Ghebreyesus of the Eastern and Southern Africa constituency is elected as Chair of the Board for the period commencing on 6 July 2009 until the adjournment of the first Board meeting of 2011.</p><p>Mr. Ernest Loevinsohn of the Canada-Germany-Switzerland constituency is elected as Vice-Chair of the Board for the period commencing on 6 July 2009 until the adjournment of the first Board meeting of 2011.</p>

<ul><li>Direct the Secretariat to draft a Monitoring and Evaluation Plan, which will be reviewed by the MEFA Committee and presented to the Board for approval by the June Board meeting.</li></ul><ul><li>Direct MEFA torecommend to the Board for approvala qualified external auditor to audit the Global Fund's financial statements in time to report the audit findings at the June 2003 Board meeting.</li></ul><ul><li>Direct MEFA to discuss the advantages and disadvantages of an independent Monitoring and Evaluation unit versus the use of external auditors to assure objective evaluation and recommend to the Board the preferred method for independent review.</li></ul>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B40/ER04 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B45/ER10 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

The Board welcomes and supports the Executive Director's initiative to strengthen the Global Fund's relationship with its key partners in the fight against the three diseases. In this context, the Board expresses its satisfaction with and endorsement for the principles of the new memorandum of understanding with UNAIDS (the "UNAIDS MoU"), and requests the Executive Director to finalize and sign the UNAIDS MoU.

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for the grant listed in Table 2 of GF/B45/ER19 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board, taking into account the specific nature of Local Fund Agent (the “LFA”) services as described in GF/B38/ER01 decides to:</p> <ol> <li>Replace its prior decision on Re-tendering Local Fund Agent Contracts (GF/B15/DP50) with the Principles of the LFA Procurement Method: Differentiation; Ensuring value-for-money through monitoring LFA performance and cost; Encouraging the diversity of LFA service providers; and Unique contracting arrangements, as set forth in Part 6 of GF/B38/EDP01 (the “Principles of the LFA Procurement Method”);</li> <li>Delegate to the AFC the authority to approve modifications to the Principles of the LFA Procurement Method; and</li> <li>Delegate to the Secretariat the authority to approve the procedures for procurement of LFA services in accordance with the Principles of the LFA Procurement Method Budgetary implications: no additional resources required</li> </ol>

Mr. Rajat Gupta of the Private Sector constituency is elected as Chair of the Board for the period commencing upon the adjournment of the Fifteenth Board meeting until the adjournment of the first Board meeting of 2009.

The Board takes note of the end of year report by the Performance Assessment Committee (PAC) on the Corporate Key Performance Indicators (KPIs) 2006. It is fully satisfied with the indicators for which targets were met or exceeded. While it notes that there is a material shortfall in four KPIs, the Board accepts the reasons given as to why these targets were not met. Overall, the Board regards the results achieved in 2006 as a reflection of the performance based culture of the Global Fund and is pleased with the significant progress achieved in embedding this culture throughout all Global Fund activities.

The report of the Seventeenth Board Meeting (GF/B18/2) is approved, as amended at the Eighteenth Board Meeting.

<p>The Board approves the 2006 operating expense budget in the amount of US$83,200,000 as set out in Annex 1 to the Report of the Finance and Audit Committee (GF/B12/7) and as recommended by the Finance and Audit Committee (FAC) and proposed by the Secretariat. </p><p>The Board notes that the budget includes envisaged cost savings and requests FAC to review actual expenditure and budgetary needs after the first half of 2006 and, if necessary, make further recommendations to the Board at that time.</p>

The Board approves the 2010 Operating Expenses Budget in the amount of USD 274 million as set out in Annex 1 to the Report of the Finance and Audit Committee (GF/B20/6).

<p>The EDP number (GF/B32/EDP09) is not in use.</p>

<p>The Board approves additional funding for the Phase 2 period of the Senegal grant (SNG-102-G01-H-OO) in the amount of USD 5,714,285, conditional on satisfaction of the conditions set forth in the Report of the Technical Review Panel on Honduras Round 1 HIV/AIDS Grant and Senegal Round 1 HIV/AIDS Grant Phase 2 Renewals (GF/B11/15, Revision 2). The Board specifies that the approved amount is an upper ceiling rather than a final funding amount, and that the final amount shall reflect the conditions and the responses to the clarifications requested by the Technical Review Panel.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of this grant shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy (GF/B20/DP9).⁴</p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount of US$ 56,401,349 for the following grants: CAM-607-G10-M ; MAW-607-G01-H ; HL-607-G08-H ; SLE-607-G04-H</p>

<p>#</p>

<p>The Board:</p><p>Declines approval of additional funding for the next implementation period for the Round 8 Congo malaria grants (COG-810-G03-M and COG-810-G04-M).</p><p><span style="font-size: 12px; line-height: 1.5;">See attached table.</span></p>

<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite index 6 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14.</p>

<p>1.The Board notes its review and discussion of the: </p><p>a.Office of the Inspector General 2015 Annual Opinion on Governance, Risk Management and Internal Controls of the Global Fund, as set forth in GF/B35/11 (the "OIG Annual Opinion"); and</p><p>b.Risk Management Report and Assurance Statement, as set forth in GF/B35/23.</p><p>2.Accordingly, the Board acknowledges that while in-country partnerships are in place and significant initiatives and measures have been implemented to improve programmatic, fiduciary and risk-management processes, immediate and heightened efforts are needed to accelerate progress and advance risk management systems and processes. </p><p>3.The Board requests the Secretariat to:</p><p>a. Present a detailed action plan to advance risk management and internal controls, with measurable and time-bound targets, and a report on progress to the Board in June 2016 through the standing committees that were established under Board decision point GF/B34/EDP07 (the "Standing Committees"); and</p><p>b. In the context of the differentiation initiative, review the business model in high-risk countries and present possible options to the Board after review by the Standing Committees at their second meetings in 2016.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER09 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </li> </ol>

<p><span><b>Revised Decision Point 4:</b> </span></p><p>The Board recognizes the importance of sustaining ongoing treatment, as well as prevention, care and support services.</p><p>The Board requests the Secretariat urgently to explore internal mechanisms and to work with partners to develop options for the continuity of services through broader country partnerships associated with common national strategic framework for the three diseases. The Board requests the Secretariat to report back to MEFA, PMPC and the Ethics Committee on these issues in time for the development of recommendations by the Ninth Board Meeting.</p><p>Up to the Ninth Board Meeting, Secretariat priority shall be given to addressing issues related to discontinuation of treatment within Global Fund grant programs</p><p>Budgetary implications of this decision point:</p><p>The additional cost of implementing this decision is approximately US $67,500.</p><p><b>Decision Point 5:</b> </p><p>With regard to the legal concerns and fiduciary policy constraints raised by some Board Constituencies, the Board decides to revisit the issue of approval authority of the agreed procedure for decision making on Phase 2 renewals.</p><p>MEFA, in cooperation with the PMPC, is requested to explore options for incorporating in the agreed Phase 2 renewal process provision for the exercise by the Board of an appropriate decision making role that meets legal and fiduciary policy requirements of Board constituencies and make recommendations to the Ninth Board Meeting.</p><p>As an interim arrangement, the Board authorizes the Secretariat to extend the terms of grants up to six months for those grants where Phase 2 decision is required prior to the Ninth Board Meeting, and to provide bridge funding for such grants as appropriate based on program needs during this extension period. The Board approves an amount of up to USD 30 million to be used for this purpose.<br/><br/><b>Decision Point 6:</b></p><p>The Board recognizes the urgent need to allow recipients to change to new, more expensive artemisinin-based combination therapy in line with the latest scientific evidence, following the recommendations of the malaria experts of the Technical Review Panel.</p><p>As an interim measure, the Board authorizes the Secretariat to commit as necessary up to USD 90 million for the projected costs of reprogramming 28 programs, which would be financed by utilizing resources from the Phase 2 renewal funding of these programs.</p><p>The Board requests PMPC to consider the issue of reprogramming in the context of changing scientific evidence, and report back to the Ninth Board Meeting.</p>

The Board approves the outstanding Category 2 of Indonesia Round 1 Proposals for HIV/AIDS and Malaria.

<p>The Board:</p> <ol> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Annex 1 to GF/B33/ER07.</li> </ol> <p>Annex: Abidjan-Lagos Corridor Organization (MAW-607-G01-H), Djibouti (DJB-613-G05-H), Guinea-Bissau (GNB-M-UNDP), Kosovo (KOS-711-G04-H), Nigeria (NGA-T-IHVN), Pakistan (PKS-M-DOMC PKS-T-NTP).</p>

<p>The Board notes that:</p> <ol> <li>In September 2011, the Board decided (GF/B24/DP3, entitled “High Level Independent Review Panel”) to form an Audit and Ethics Committee (“AEC”) comprised of seven members, four of whom would be independent of any constituency of the Board.<br /><br /></li> <li>In November 2011, the Board mandated the Coordinating Group (GF/B25/DP14, entitled “Appointment of Committee Leadership”) to provide nominations to the Board to fill the four independent member seats on the AEC, with one of those seats being for the Chair of the AEC.<br /><br /></li> <li>The Coordinating Group’s 27 March 2012 “Electronic Report” to the Board on the nominations process (GF/B25/ER11) recommended that the Board increase the number of independent AEC members from four persons to five in order to ensure that the AEC will have an appropriate level of expertise in its financial audit function, in addition to the three other necessary disciplines of forensic investigation, ethics, and legal and dispute resolution.</li> </ol> <p>The Board:</p> <ol> <li>Approves the increase in independent members of the AEC from four persons to five, to bring the full membership of the committee to eight.<br /><br /></li> <li>Amends the Charter of the Audit and Ethics Committee and the Board and Committee Operating Procedures in the manner set forth below with immediate effect:<br /><br /> <ol> <li>Amendments to the Charter of the Audit and Ethics Committee:<br /><br /> <ol> <li>the word “four” is deleted in each of paragraphs 3.i, 6 and 7, and is replaced with “five”; and<br /><br /></li> <li>a new paragraph is inserted immediately following paragraph 4, containing the following text: “In instances in which the Committee is unable to take a decision, the AEC Chair shall, in consultation with the AEC Vice-Chair, exercise an additional vote in order to resolve such impasse.”<br /><br /></li> </ol> </li> <li>Amendments to the Board and Committee Operating Procedures:<br /><br /> <ol> <li>Table 3.b of Annex 1 (“Expected Minimum Key Competencies and Responsibilities of Members of each of the Standing Committees of the Board”), is amended by striking out the whole of the text in bulleted item 1 in column three of that table (“Key Competencies of Audit and Ethics Committee Members”); and<br /><br /></li> <li>replacing it with the following text: “At least two voting members with financial audit experience, with professional accreditation in financial accounting (Committee Chair should be selected from amongst the independent members who hold professional accreditation in financial accounting)”.<br /><br /></li> <li>The word “four” is deleted in paragraph 44.1.3 and is replaced with “five.”<br /><br /></li> </ol> </li> </ol> </li> <li>Approves the appointment of the following individuals as independent members of the AEC to serve for two-year terms from the date of effect of this decision, or until the appointment of their respective successors:<br /><br /> <ol> <li>Graham Joscelyne (Financial audit competency) as member and Chair of the AEC</li> <li>Gabor Amon (Forensic investigation competency) as member of the AEC</li> <li>Veronica Charlesworth (Financial audit competency) as member of the AEC</li> <li>Wendy Harrison (Ethics competency) as member of the AEC</li> <li>Barry Metzger (Legal/dispute resolution competency) as member of the AEC<br /><br /></li> </ol> </li> <li>Acknowledges that the Finance and Operational Performance Committee will bring to the November 2012 Board meeting a comprehensive remuneration and honorarium strategy across the Global Fund’s governance and advisory entities, which will include a recommendation on the appropriate honorarium for independent members of the AEC having regard to their role and fiduciary obligations.<br /><br /></li> <li>Approves an honorarium for the period April to December 2012 of US$ 14,000 for the independent Chair of the AEC, and US$ 9,000 for other independent members of the AEC. The Board notes that the FOPC’s recommendations in November 2012 may include a recommendation to retroactively increase the honorarium of independent members of the AEC.<br /><br /></li> <li>Requests the Audit and Ethics Committee to provide recommendations into the Phase 2 Governance Reform process on revised “Criteria for Independent Members of the Audit and Ethics Committee” that takes into account lessons learned during the process of constituting the committee.</li> </ol>

The Board approves the amendments to the Policy on Ethics and Conflicts of Interest for Global Fund Institutions as set out in Annex 1 (Revision 1) to the Report of the Ethics Committee (GF/B18/8).

<p><b>Decision Point 1</b> </p><p>The Board decides to use the following language in its decisions for the approval of Category 1 and 2 proposals in order to recognize that the Secretariat may ask the Technical Review Panel to re-review proposals in the course of implementation:</p><p>"This approval is subject to re-review by the Technical Review Panel if, after consultation with the recipient but in the sole discretion of the Global Fund, changes in scientific evidence (as identified in collaboration with WHO and other technical partners) materially affect the proposal."</p><p>The Board further decides that following such re-review, should the TRP recommend that, in light of the new scientific evidence, the approach taken in the proposal should be changed, the Board should reconsider the approval of the proposal. The recipient will have the opportunity to submit a revised version of the relevant parts of the proposal prior to the Board's decision.</p><p>There are no material budgetary implications for this decision point. </p><p><b>Decision Point 2</b> </p><p>The Board expands the circumstances in which the Phase 2 decision-making process can be accelerated by modifying the existing decision on the Phase 2 process, as set forth in GF/B8/2, page 7, to read as follows:</p><p>"The decision may be taken earlier in cases of (i) accelerated implementation; (ii) severe exchange rate fluctuations; or (iii) additional financing needs resulting from changes in scientific evidence."</p><p> There are no material budgetary implications for this decision point.</p>

The Chair indicated that all comments on the Terms of Reference of the TRP had been duly noted by the Secretariat, and that a revised version of the TOR paper incorporating the agreed changes would be prepared and used as a basis for initiating the selection process for the Technical Review Panel.

The Board decides to amend the Phase 2 Decision Making Policies and Procedures by adding a new paragraph 19 to the Phase 2 Decision-Making Policy and Procedures as set out in Attachment 1, Section 3 of GF/B16/7.

#

<p><b>Decision Point:</b> </p><p>1.1 The choice of currency will apply only to new proposals submitted after 1 January 2005. Specifically:</p><p>1.2 Grants approved in Rounds 1 through 4 which have not been signed by 1 January 2005 will continue to be denominated in USD (i.e. the currency choice applies from Round 5 onwards)</p><p>1.3 Phase 2 renewals are not regarded as new proposals and hence will continue to be denominated in the currency chosen for Phase 1.</p><p>1.4 The currency choice must be made at the time of submission of the Proposal. Specifically, the applicant cannot change its chosen currency at any time after submission of the Proposal (including during implementation). </p>

Recognizing the need for equitable representation of HIV/AIDS, tuberculosis and malaria within the Global Fund, the Board decides that the follow up work and decisions on the Five Year Evaluation should include action to ensure the effective participation on the Global Fund Board of malaria and tuberculosis constituencies. The Board requests the PSC to discuss the issues and present outcomes at the Board Retreat in October 2008 so that a recommendation can be presented at the Eighteenth Board Meeting in November 2008.

<p>The Board expresses its appreciation to UNAIDS and the International Task Team on HIV-related</p><p>Travel Restrictions for their work and its strong support for the overarching goal of the Task Team, to eliminate HIV specific restrictions related to entry stay and residence based on HIV status.</p><p>The Board takes note of the recommendations contained in GF-B18-12 Annex 1 and decides:</p><p>1. That no Board, Committee meeting, or Partnership Forum will be held in a country with an HIV-specific restriction related to entry, stay or residence based on HIV status; and</p><p>2. To support country-led efforts to review and eliminate laws, policies and practices related to HIV-specific restrictions on entry, stay and residence, through leadership, advocacy and appropriate partnerships at international, regional and national levels.</p><p>3. To work with partners to ensure countries have access to the latest guidance and information from normative agencies on this issue of HIV specific restrictions on entry, stay and residence.</p><p>The Board requests the relevant committees, based on the Task Team Report to provide recommended actions to the Board at its Nineteenth Meeting, in particular on how the Global Fund, through its policies and procedures, can finance country interventions that support the elimination of HIV-related restrictions.</p>

<p>Birgit Pickel from the Germany Constituency is designated as Rapporteur for the 45th Board Meeting.</p>

<p>In accordance with the Board-adopted Global Fund Human Resources Policy Framework (GF/EDP/08/16 – Annex 1), any staff salary above CHF 245,000 requires Board approval. The Board authorizes the Secretariat to enter into a contract of employment with a new Chief Financial Officer within the Grade 09 level with an annual salary above CHF 245,000 and below the ceiling for Grade 09 salaries of CHF 349,800.</p>

<ol> <li>The Board approves the appointment of: <ol type="i"> <li>Michael Ruffner as Chair of the Audit and Finance Committee;</li> <li>Edward Ouko as Vice-Chair of the Audit and Finance Committee;</li> <li>Suomi Sakai as Vice-Chair of the Ethics and Governance Committee;</li> <li>Rico Gustav as Chair of the Strategy Committee; and</li> <li>Gunilla Carlsson as Vice-Chair of the Strategy Committee.</li> </ol> </li> <li>The Board notes each Committee Chair and Vice-Chair appointed under this decision point shall begin their term on 16 May 2020 and serve for two years or until the appointment of their successor.</li> </ol>

<p>The Board acknowledges that a significant percentage of the Operating Expenses Budget is denominated in Swiss Francs (CHF) whereas the budget is presented in United States Dollars (USD) and the reporting currency of the Global Fund is the USD.</p><p>To give greater certainty to the Board at the time of approving the USD budget, the Board decides to give the Secretariat authority to manage foreign exchange transactions in a manner which minimizes the exposure of the budget to volatility in the exchange rate between the USD and the CHF.</p><p>The Board further authorizes the Executive Director to take all necessary steps to manage this exposure.</p><p>The steps taken to manage this exposure will be under the oversight of the Finance and Audit Committee.</p>

The Board approves the Budget Framework as set out in Annex 3 to the Report of the Finance and Audit Committee (FAC) (GF/B17/6), which shall guide the formulation and consideration for approval of annual budgets for Operating Expenses of the Global Fund. The Board requests that FAC annually review the Framework, including the parameters, for three years, bearing in mind the desire to achieve economies of scale, and thereafter as needed, and report back to the Board, with recommendations for modifications as necessary. In conjunction with the PSC process that will recommend Secretariat KPIs for 2009, FAC shall explore how best to link the KPIs to the budget. The FAC shall also examine how to enhance its review of expenditure each year. 

<ol> <li>The Board appoints Mr. Mouhamadou Diagne to serve as the next Inspector General of the Global Fund for a six-year term to begin not later than 30 June 2015.</li> <li>The Board authorizes the Global Fund to enter into a contract of employment with Mouhamadou Diagne for an annual salary that is above CHF 245,000 and does not exceed CHF 310,000, and requests the Board Chair to facilitate that process.</li> </ol>

<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to Paragraph 7 of Annex 1 to the Decision Point Modification of Grant Renewals and Transition to New Funding (GF/B25/DP16).^[1]</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p><span style="font-size: 12px; line-height: 1.5;">See attached tabledetailing total recommended funding amount of US$ 146,478,569 for the following grants: BRN-809-G08-H ; ZAR-809-G07-M ; ZAR-810-G08-M ; ECU-809-G04-M ; ECU-809-G05-M ; PER-809-G06-T ; PER-809-G07-T</span></p>

<p>1. Recognizing the continued need for countries to maintain and scale up their national programs to fight HIV/AIDS, tuberculosis and malaria and reaffirming the Board's commitment for the new architecture for grant funding, the Board urges donors to make firm pledges at the Replenishment Meeting in October 2010 to meet the expected demand and to allow the scaling up of life saving treatment.</p> <p>2. With reference to its decision regarding the launch of the next Round of proposals (GF/B20/DP30), the Board requests the Secretariat to issue a Call for Proposals for Round 10, on or about 20 May 2010 with a submission date on or about 20 August 2010, and to provide for review of those proposals in time for approval at the Twenty-Second Board Meeting in December 2010.</p> <p>3. The Call for Proposals for Round 10 shall include a provision for a dedicated funding stream for proposals which focus only on Most at Risk Populations (GF/B21/DP18).</p> <p>4. In determining the amount of assets available to be committed for Round 10 at the time of approval of the proposals, only pledges to be received within (and for use within) the period up to and including 31 December 2011 shall be considered. Notwithstanding Article 3d of the Comprehensive Funding Policy, the determination of available assets as at 31 December 2011 will be updated at the end of the first quarter of 2011 in relation to new pledges. </p> <p>5. In the event that insufficient resources are available to approve all TRP recommended proposals, the provisions of Decision Point GF/B21/DP17 will apply.</p>

<p>The Board acknowledges the progress made on developing options for the strategic issues in Batch 1 as outlined in the Report of the Policy and Strategy Committee (GF/B13/7). In particular, the Board notes the agreed outcomes of the Policy and Strategy Committee set out in Annex 3 to the Report of the Policy and Strategy Committee (GF/B13/7).</p><p> In addition, the Board requests that the development of options continue, and that the Policy and Strategy Committee present to the Board the work on option development for Batches 2 and 3, as well as a draft strategy document, at the Fourteenth Board meeting.</p>

<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Table 2 and described in the Secretariat’s COS form, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements <span style="font-size: 12px; line-height: 1.5;">for such proposal consistent with the recommendations set forth in the Secretariat’s COS form.</span></p><p>See attached tabledetailing total recommended funding amount of US$8,317,359 for the following grant: SSD-405-G05-H</p>

<ul> <li>Set forth below is the Secretariat’s recommendation to approve funding up to an amount of US$ 2,317,504,873 and EUR 434,148,572; this includes country allocation funding as well as US$46,519,790 and EUR 1,782,000 of catalytic investments for matching funds.</li> </ul> <p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 to GF/B38/EDP02 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board approves the appointment of Ambassador Lennarth Hjelmaker as a voting member of the Strategy, Investment and Impact Committee for the remainder of his predecessor's two-year term, or until the appointment of his successor. </p>

<p>Tamaki Tsukada from the Japan constituency is designated as Rapporteur for the 39th Board Meeting.</p>

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.</p><p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p><p>SCHEDULE A </p><ol><li>Belarus, TB – Round 6<br/>Grant Number: BLR-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 7,488,285 <br/>Approved Funding Amount (Incremental in US$): 7,468,729 <br/>Recommendation Category: Go<br/><br/></li><li>Bosnia and Herzegovina, TB Round 6 <br/>Grant Number: BIH-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 3,088,672 <br/>Approved Funding Amount (Incremental in US$): 3,088,672 <br/>Recommendation Category: Go<br/><br/></li><li>Burkina Faso, HIV Round 6 <br/>Grant Number: BUR-607-G06-H Euro <br/>CCM Requested Amount (Total Phase 2 in US$): 23,770,535(1) <br/>Approved Funding Amount (Incremental in US$): Euro 19,780,000 = US$ 28,210,236(1) <br/>Recommendation Category: Go<br/><br/></li><li>Iraq, TB Round 6 <br/>Grant Number: IRQ-607-G01-T <br/>CCM Requested Amount (Total Phase 2 in US$): 8,110,000 <br/>Approved Funding Amount (Incremental in US$): 8,056,257 <br/>Recommendation Category: Go<br/><br/></li><li>Moldova, TB Round 6 <br/>Grant Number: MOL-607-G02-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,871,489 <br/>Approved Funding Amount (Incremental in US$): 5,500,000 <br/>Recommendation Category: Go<br/><br/></li><li>Papua New Guinea, TB Round 6 <br/>Grant Number: PNG-607-G03-T <br/>CCM Requested Amount (Total Phase 2 in US$): 16,267,739(2) <br/>Approved Funding Amount (Incremental in US$): 14,185,291 <br/>Recommendation Category: Go<br/><br/></li><li>Peru, HIV Round 6<br/>Grant Number: PER-607-G05-H <br/>CCM Requested Amount (Total Phase 2 in US$): 10,847,949 <br/>Approved Funding Amount (Incremental in US$): 9,256,222 <br/>Recommendation Category: Go<br/><br/></li><li>Romania, TB Round 6 <br/>Grant Number: ROM-607-G04-T Euro <br/>CCM Requested Amount (Total Phase 2 in US$): 4,050,099 (1) <br/>Approved Funding Amount (Incremental in US$): Euro 3,555,623 = US$5,071,030(1) <br/>Recommendation Category: Go<br/><br/></li><li>Thailand, TB Round 6 <br/>Grant Number: THA-607-G07-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,319,698 <br/>Approved Funding Amount (Incremental in US$): 4,334,035 <br/>Recommendation Category: Go<br/><br/></li><li>Thailand, TB Round 6 <br/>Grant Number: THA-607-G08-T <br/>CCM Requested Amount (Total Phase 2 in US$): 5,342,916 <br/>Approved Funding Amount (Incremental in US$): 4,514,102 <br/>Recommendation Category: Go<br/><br/></li><li>Tunisia, HIV Round 6 <br/>Grant Number: TUN-607-G01-H <br/>CCM Requested Amount (Total Phase 2 in US$): 7,013,846 <br/>Approved Funding Amount (Incremental in US$): 6,614,846 <br/>Recommendation Category: Conditional Go <br/><br/>Total US$96,299,420</li></ol>

<p>The Board approves the appointment of the following:</p><ol><li>Anupong Chitwarakorn (HIV/AIDS), Stephen Mills (HIV/AIDS), Anthony David Harries (Tuberculosis), Frank Adae Bonsu (Tuberculosis), Daniel Tarantola (Cross-cutting), Mari Nagai (Cross-cutting), Lev Khodakevich (Cross-cutting), Claudia Surjadjaja (Cross-cutting) and Lucie Blok (Cross-cutting) as Permanent Technical Review Panel (TRP) Members to serve for up to four Rounds commencing from Round 10;</li><li>In respect of Round 10, the twenty (20) persons identified as Alternate Members as presented in Annex 1 of this Report (B21/EDP/18); and</li><li>The membership of the Technical Review Panel Support Group (as presented in Annex 1 of this Report (B21/EDP/18)), comprising the pool of experts from which TRP membership will be replenished in the event of TRP vacancies as they may arise.</li></ol><p>Each Permanent TRP, Alternate and Support Group Member has been recommended by the Portfolio and Implementation Committee and the Executive Director of the Global Fund Secretariat.</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER11 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board refers to its decision made at the Twentieth Board Meeting on Secretariat Office Space (GF/B20/DP19). Having reviewed the draft development contract (GF/B21/6 - Annex 4) pertaining to the development of a building in which the Secretariat would lease office space, the Board requests the Finance and Audit Committee to approve the development contract for signature by the Secretariat once it is finalized and report on this issue to the Board at the Twenty-Second Board Meeting. </p>

<ol> <li>The Board: <ol type="i"> <li>Recalls its decision (GF/B38/DP05) on the Integration of Additional Public Donors into the Global Fund Governance Structure and Amendment of the Global Fund Bylaws;</li> <li>Notes the requirement of the Operating Procedures of the Board and Committees pursuant to which each constituency of the Board must be represented in at least one Standing Committee of the Board;</li> <li>Notes the Board decision (GF/B39/EDP02) to create an additional non-voting committee seat within the Strategy Committee; and</li> <li>Notes that the Additional Public Donors Constituency is not currently represented on a Standing Committee of the Board.</li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board appoints Kaltham Al-Assam, representing the Additional Public Donors Constituency, as a non-voting member of the Strategy Committee for a term that will expire in May 2020, or until the appointment of her successor.</li> </ol>

<p>The Board:</p> <ol> <li>Notes the Secretariat’s review of the items on the 2017- 2019 allocation period’s register of Unfunded Quality Demand (“UQD”) in accordance with the prioritization framework approved by the Strategy Committee through GF/SC04/DP02;</li> <li>Approves the additional incremental funding recommended for certain UQD of the following country disease component: (i) Pakistan malaria, as listed in Table 2 of GF/B40/ER02, based on available funding approved by the Audit and Finance Committee;</li> <li>Affirms the additional incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board thanks the Inspector General ad interim for his work on the development of the Global Fund Assurance Framework, and requests the incoming Inspector General to further develop the Assurance Framework for approval at the Seventeenth Board Meeting.</p><p>The Board requests the Secretariat to develop a Risk Management Framework in collaboration with the incoming Inspector General for review by the FAC in March 2008 (subject to the priorities to be established). </p><p>The Board requests the incoming Inspector General to develop a list of priorities for consideration by the Finance and Audit Committee for inclusion in the 2008 work plan of the Office of the Inspector General that will be presented to the Seventeenth Board Meeting. </p>

<ul><li>Adopts the Guidelines on Constituency Processes as a useful compilation of best practice.</li></ul><ul><li>Adopts the Constituency Operations Statement as a transparent tool for understanding the processes of stakeholder groups and requests Board Members to complete the statement for their constituency, understanding that this statement will be made public.</li></ul><ul><li>Notes the importance of the role of focal points and supports the facilitation of the attendance of focal points for recipient country constituencies in attending Board and Committee Meetings.</li></ul>

<ol start="1" type="1"><li>The Board approves the appointment of Ambassador Michèle Boccoz as a voting member of the Strategy Committee for a term that will expire on 26 May 2018, or until the appointment of her successor.</li></ol><p></p>

The Board extends the Phase 1 Ending Date of the Ghana Malaria Grant GHN-809-G08-M from 31 December 2011 to 31 December 2012, and subject to approval of Phase 2 of this Grant, authorises the extension of the Phase 2 Ending Date from 31 December 2014 to 31 December 2015.

<p>The Board approves the Report of the 45th Board Meeting, as set forth in GF/B45/22.</p>

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund’s 2017 Statutory Financial Statements, which have been audited by KPMG SA, as set forth in GF/B39/06 Annex 2.</p>

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B38/EDP17 (“Table 2”); and</li> <li>Affirms that any additional funding provided to fund the revised budget (a) shall increase the upper-ceiling amount that may be available for the relevant implementation period for each grant listed in Table 2, and (b) is subject to the availability of funding. </li> </ol>

<p>The Board recognizes that:</p><p>i. the Round 3 Russian Federation HIV/AIDS grant to Open Health Institute entitled "Stimulating an Effective National Response to HIV/AIDS in the Russian Federation" (RUS-304-G01-H) (the "OHI Grant") expired on 31 August 2009;</p><p>ii. in addition to provision of treatment services, the OHI Grant has provided support for lifesaving prevention services for populations in the Russian Federation that are vulnerable to HIV/AIDS through the work of non-governmental organizations;</p><p>iii. under the current income eligibility policies of the Global Fund, the Russian Federation is not eligible for funding for HIV/AIDS funding; </p><p>iv. the income eligibility policies of the Global Fund will be reviewed by the Portfolio and Implementation Committee in 2010 for approval by the Board at its second meeting in 2010; and</p><p>v. the Russian Federation has contributed USD$ 225,852,403 to the Global Fund, and has supported other programs for HIV in Russia.</p><p>The Board recognizes the role of the Russian government leadership in developing efficient national policies and providing a long term, sustainable response to HIV, and calls on the Russian Federation to expand investment in these life-saving, evidence-based services to vulnerable populations.</p><p>In recognition of the emergency situation of the lifesaving prevention activities supported by the OHI Grant being discontinued, the Board approves:</p><p>a. an extension, on an extraordinary basis, to 31 December 2011 of the term of the OHI Grant (the "Extension Term"); and</p><p>b. continued emergency funding for lifesaving prevention services in an amount of up to USD$ 24 million for the Extension Term, in order to continue the same activities as currently being implemented under OHI Grant. </p><p>The Board requests that the Secretariat continues discussions with the government of the Russian Federation on the HIV epidemic in Russian and their role as a donor to the Global Fund. </p>

<ol type="A"><li><u>Country Coordinating Mechanisms: </u><ol><li>The Board approved the principle of sub-regional Country Coordination Mechanisms for small countries, based on the small islands state classification of the United Nations.</li><li>The Board approved the eligibility of sub-national proposals provided that they are consistent with nationally formulated policies and that there is evidence of a legal framework for the sub-national entity stating its autonomy.</li><li>The Board confirmed that regional proposals can be accepted, provided that they clearly add value beyond the national level, include appropriate NGO and other civil society partners, and that they are supported by national Country Coordination Mechanisms."</li><li>Confirming that CCMs should be inclusive, involving members of civil society and the private sector as partners in preparation, approval and implementation of proposals, in accordance with the guidelines of proposals and stressing the importance of improving their effectiveness and capacity, the Board: – recognized the Secretariat as the lead advisor to the TRP and to the Board on CCM confirmation, as necessary;– noted the importance of linking this to the development and leverage of partnerships at the country level.</li></ol></li><li><u>Proposals: </u><ol><li>The Board adopted a three-year approach to balancing the portfolio between regions, diseases and interventions, subject to a mid-term review of balancing after the third round and after ongoing reviews and drawing on existing data from technical partners as well as recommending use of a needs assessment instrument.</li><li>The Board adopted an approach regarding the balance of prevention, care, support and treatment whereby if a given proposal can explain and document that a particular intervention is available through other arrangements it is not necessary that this intervention be a part of the proposal. The most appropriate balance of interventions will differ according to country contexts.</li></ol></li><li><u>Eligibility Criteria: </u><ol><li>The Board reaffirmed the decision that priority be given to proposals from countries in greatest need, as determined by level of poverty and disease burden and that proposals from members of the OECD’s Development Assistance Committee (DAC) are not eligible for funding by the Global Fund.</li><li>The Board confirmed that proposals from eligible countries in lower need situations will be considered for funding, but will be given lower priority and lower overall allocation relative to those with greater need</li><li>The Board decided that proposals from eligible countries whose overall needs are of lower priority but which focus on particularly vulnerable populations will be considered as specified in the above decision.</li><li>The Board decided that multi-year proposals can be approved. The Fund will allocate funds for a two-year period with funding for the third and following years contingent on a satisfactory performance assessment and the Fund’s available resources at that time.</li></ol></li><li><u>Approval guidelines: </u><ol><li>The Board decided that multi-year proposals can be approved. The Fund will allocate funds for a two-year period with funding for the third and following years contingent on a satisfactory performance assessment and the Fund’s available resources at that time.</li><li>The Board endorsed the importance of additionality with regard to resources made available by the Global Fund relative to other sources of funding.The Board agreed that there is a need to further clarify the questions of funding ranges, resource gaps, percentage justification and additionality.</li><li>Noting the desire to ensure economies of scale, to have maximum impact, and not to overburden the operations of the Secretariat and the TRP, the Board agreed to the principle of a lower limit of total requested funds by a single applicant. The Board asked that exceptions to this limit be considered by the TRP on a case-by-case basis.</li><li>It was decided that the Secretariat would continue to work on the development of specific guidelines and report back to the Board at its next meeting.</li></ol></li><li><u>Emergency decision:</u> The Board decided that in the case of complex emergencies – identified by the Secretariat referencing international declarations such as those of the UN Office for the Coordination of Humanitarian Affairs – specific decisions on eligibility in each case should be made by the Executive Director in consultation with the Board to avoid delays in proposal review.</li><li><u>Next steps:</u> Recognizing the need to ensure high quality proposals from countries in greatest need and noting the existing availability of resources from current partners to work with countries at the local level, the Board requested the Secretariat to recommend at its next meeting specific ways for the Global Fund to support countries where capacity to prepare proposals is less strong both by leveraging existing partnerships and possibly catalyzing new processes.</li><li><u>Communication guidelines:</u><br/><ol><li>The Board authorized the Secretariat to share information on the reasoning behind the different decisions taken on proposals only with their authors, other groups that are part of the proposal (e.g. all members of a CCM listed on the CCM certification sheet), and Board Members and their representatives. All others making inquiries about specific proposals would be informed of these guidelines and directed to make their inquiries directly to the proposals’ authors.</li><li>The Board authorized the Secretariat to share information related to the review process so long as proposal-specific deliberations remain confidential</li><li>The Board requested the Secretariat to send a regular e-mail to Board members listing all inquiries made by Board members on information related to the review of specific proposals</li><li>The Board asked the Secretariat to make the arrangements for posting information of the approved proposals on the web site" <br/><br/></li></ol></li></ol>

The Board approves the Action Plan for the Selection of the Executive Director of the Global Fund, as presented by the Nomination Committee on 1 December 2006.

The agenda for the 35th Board Meeting (GF/B35/01 - Revision 3) is approved.

<ul><li>Adopts the revisions to the Board Operating Procedures as proposed, except for paragraphs 22 and 23.</li></ul><ul><li>The Board has recognized the need for a revision of the By Laws and asks the Governance and Partnership Committee and Secretariat to review the By Laws and report back to the Board at their June 2003 meeting.</li></ul>

<ol> <li>Based on the recommendation of the Strategy Committee, the Board approves the revisions for Key Performance Indicators 3, 5, 6a, 6b and 9b as presented in GF/B44/ER04.</li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the 2021 target for Key Performance Indicator 12b as presented in GF/B44/ER04; and</li> <li>Based on the recommendation of the Audit and Finance Committee, the Board approves the revision of the formula for Key Performance Indicator 7a as presented in GF/B44/ER04. </li> </ol>

The Board approves the Annual Report as presented in GF/B23/16.

<ol><li>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.<br/><br/>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.<br/><br/>SCHEDULE A (Phase 2 Decision)<br/><br/>Rwanda, HSS – Round 4<br/>Grant Number(s): RWN-505-G05-S<br/>CCM Requested Amount (Total Phase 2 in US$) 19,622,213<br/>Approved Funding Amount (Incremental in US$) 19,622,213<br/>Recommendation Category: Go2. <br/><br/>South Africa, HIV/TB – Round 2<br/>Grant Number(s): SAF-202-G05-C-00<br/>CCM Requested Amount (Total Phase 2 in US$) 17,563,541(1)<br/>Approved Funding Amount (Incremental in US$) 15,986,220<br/>Recommendation Category: Conditional Go3. <br/><br/>Swaziland, HIV – Round 4<br/>Grant Number(s): SWZ-405-G04-H<br/>CCM Requested Amount (Total Phase 2 in US$) 34,273,541(1)<br/>Approved Funding Amount (Incremental in US$) 29,442,921<br/>Recommendation Category: <br/>Conditional Go<br/><br/></li><li>The Board approves Exceptional Extension Funding for the proposal listed in Schedule B in the amount and period indicated for the proposal, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount.<br/><br/>SCHEDULE B (Exceptional Extension Funding Decision)<br/><br/>Burundi, Malaria – Round 2<br/>Grant Number(s): BRN-202-G05-M<br/>Duration of Funding: 5 months<br/>CCM Requested Amount (in US$) 3,492,712<br/>Approved Funding Amount (Incremental in US$) 1,267,367<br/><br/></li><li>The Board approves the use of undisbursed grant funds under grant number TMP-304-G02-T to finance the continuity of services listed in Schedule C and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on an understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.<br/><br/>SCHEDULE C (Continuity of Services Decision)<br/><br/>Timor Leste, TB – Round 3<br/>Grant Number(s): TMP-304-G02-T<br/>CCM Requested Amount (in US$) 36,560<br/>Approved Funding Amount (Incremental in US$) 0</li></ol>

<p>Mary Isaac from the Latin American and Caribbean constituency is designated as Rapporteur for the 42nd Board Meeting</p>

<ol> <li>Based on the rationale provided in GF/B46/ER06, the Board: <ol type="a"> <li>Approves that any additional 6th Replenishment pledges received through 30 September 2022 will be used to support the COVID-19 Response Mechanism (C19RM);</li> <li>Approves that any additional C19RM funds may be awarded through 31 March 2023;</li> <li>Approves to revise the thresholds for Board approval of C19RM awards set out in paragraph 5.d of GF/B44/EDP18 based on the total additional C19RM funding made available, as follows: <ol type="i"> <li>If up to US$ 1 billion of additional funding for C19RM is made available, the Board approval threshold will increase to US$ 45 million, and the Secretariat will have delegated authority to increase Board-approved C19RM awards by up to US$ 15 million, where such increases scale-up interventions approved by the Board;</li> <li>If more than US$ 1 billion of additional funding for C19RM is made available, the Board approval threshold will increase to US$ 55 million, and the Secretariat will have delegated authority to increase Board-approved C19RM awards by up to US$ 20 million, where such increases scale-up interventions approved by the Board; and</li> <li>Threshold amounts will continue to be measured in aggregate by country, not including any amounts awarded under the fast-track approach or C19RM funds awarded in 2020;</li> </ol> </li> <li>Agrees that all other parameters of C19RM under GF/B44/EDP18 remain unchanged; and</li> <li>Approves that the Secretariat may continue to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing (as originally approved under paragraph 3 of GF/B42/EDP10) through 31 December 2023.</li> </ol> </li> </ol>

The Board requires that resource mobilization and the replenishment process be included as an agenda item at each Board meeting, and that the Finance and Audit Committee will develop a resource mobilization strategy to be discussed at the Thirteenth Board meeting.

Dr. Helene D. Gayle from the Private Foundations Constituency is designated as Rapporteur for the Eleventh Board Meeting.

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B41/ER05 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and<br />Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

The agenda for the Twenty-Second Board Meeting (GF/B22/1, Revision 1), as amended, is approved.

<p>The Board:</p> <ol> <li>Approves the revised budget recommended for each grant listed in Table 2 of GF/B41/ER09 (“Table 2”);</li> <li>Affirms the additional funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, and (b) is subject to the availability of funding; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The agenda for the February 2017 Board Retreat (GF/BR2017/01- Revision 5) is approved.</p>

<p>Dr Regina Rabinovich from the Private Foundations Constituency is designated as Rapporteur for the First Special Board Meeting.</p>

The Board approves the appointment of Ambassador Louis Charles Viossat of the France and Spain constituency as Chair of the Finance and Audit Committee to serve for the unexpired term of Ambassador Mark Dybul.

<p>The Board endorsed the document - Guidelines on the Purpose, Structure, and Composition of the Country Coordinating Mechanisms - (Annex 3 of the Report of the Governance and Partnership Committee), and:</p><ol><li>Approved the guidelines on CCMs as presented.</li><li>Requested the Governance and Partnership Committee to continue to monitor the issue of CCMs.</li><li>Requested the Secretariat to report back on the case studies when the findings of these studies become available.</li></ol>

<p>The Board:</p> <ol> <li>Approves bridge funding for the grants listed in Table 2 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts and are approved for the continuation of essential programs up to the period of the Transitional Funding Mechanism (GF/B25/DP16 Annex 2).</li> </ol> <p>See attached tabledetailing total recommended funding amount of USD 1,745,524 for the following grants: RUS-304-G01-H ; RUS-506-G05-H</p>

<p>The Board approved the following changes to the Bylaws:</p><p>1. Article 20: Representation</p><p>The Chair and Vice Chair (for matters which are within the responsibility of the Foundation Board) and the Executive Director (for matters which are delegated to him/her) are entitled to represent the Foundation in all dealings with third parties.</p><p>(Option 2) Between Board meetings, the Chair and the Vice Chair acting together, are empowered to take on behalf of the Foundation any decision within the responsibility of the foundation which they consider must be taken urgently without recourse to other procedures as provided in the Bylaws and the Board Operating Procedures. In case no consensus is reached between the Chair and the Vice Chair, the Chair shall take the decision. </p><p>2. Article 12: The Chair and the Vice Chair of the Board</p><p>(Option 1)The Foundation Board members will select the Chair and the Vice Chair of the Foundation Board from among their own voting members, provided, that the two positions will alternate between voting groups described in Article 15. The Chair and the Vice Chair will each be elected for a period of two years. </p><p>The Board also:</p><p>Confirmed that the terms of office of the incumbent Chair and Vice Chair, at the date of entry into force of these amended bylaws, shall have commenced on the date of their respective election. This decision of the Board is subject to approval of the Bylaws by the Swiss Supervisory Authority.</p><p>The Board decided to defer the approval of 20.3 Election Procedure of the Board Operating Procedures until the next Board meeting.</p>

<p>1. The Board acknowledges the work carried out by the Secretariat to review the Global Fund's employee grievance and dispute resolution system, as well as the decisions reached by the Management Executive Committee (MEC) to strengthen internal components of this system (GF/B36/ER03).<br /><br />2. Regarding mechanisms for final resolution of employee grievances, the Board notes the review carried out by the Secretariat on the recognition of the jurisdiction of the International Labour Organization Administrative Tribunal (ILOAT), as compared with other available mechanisms.<br /><br />3. Noting the outcome of this review, and upon recommendation from the Audit and Finance Committee (AFC), the Board requests that the Secretariat continue its work in this area, specifically to (i) further explore available mechanisms for final resolution of employee disputes; and (ii) review the feasibility of implementing alternatives to the current system within the Global Fund's context. The Staff Council will be consulted as part of this exercise.<br /><br />4. Provided an alternative model is identified which is both feasible and considered by MEC to present advantages over the current ILOAT model, the Board requests that the Secretariat develop such an alternative model and present it to the AFC for review and decision at its October 2017 meeting. As part of its presentation to the AFC, the Secretariat will include an analysis of the projected costs of any proposed alternative model, as compared with the current ILOAT model.</p>

The agenda for the Twenty-Eighth Board Meeting (GF/B28/1) is approved.

#

Mr. Maksut Kulzhanov from the Eastern Europe and Central Asia constituency is designated as rapporteur for the Twenty-Third Board Meeting.

<p>1. The Board approves for funding, subject to paragraphs 3 and 4 below, the proposals recommended by the Technical Review Panel ("TRP") and as listed in Annex VI to the Report of the TRP and the Secretariat on Round 5 Proposals (GF/B11/6) as:</p><ul><li>"Recommended 1 Proposals";</li><li>"Recommended 2A Proposals with Composite index 8"; and</li><li>"Recommended 2A Proposals with Composite index 6".</li></ul><p>The Board's approval is for the amount indicated as "Total 2 Years" in such Annex, and is made with the clear understanding that such amounts are upper ceilings rather than final Phase 1 Grant amounts.</p><p>2. The remaining proposals recommended for funding by the TRP as "Category 2" will be approved, subject to paragraph 4 below, through Board confirmation by e-mail, as funds become available under the terms of the Comprehensive Funding Policy, but no later than June 30, 2006. Approval will be based on their composite ranking, following the Prioritization in Resource Constrained Environments principles (approved by the Board at its 7th meeting).</p><p>3. The proposal applicants in Category 1 shall provide any adjustments or clarifications requested by the TRP no later than four weeks after notification in writing by the Secretariat to the applicant of the Board's decision. The Board's approval is conditional on the final approval of the TRP Chair and/or Vice Chair. This process shall proceed immediately after the 11th Board meeting.</p><p>4. The proposal applicants in Category 2 shall provide an initial reply to the clarifications requested by the TRP no later than six weeks after notification in writing by the Secretariat to the applicant of the Board's decision. Any further adjustments and clarifications shall be completed within four months from the receipt of the initial reply from the applicant. The Board's approval is conditional on the final approval of the TRP Chair and/or Vice Chair based on consultations with the TRP primary and secondary reviewers. This process shall proceed immediately after the 11th Board meeting.</p><p>5. The Board declines to approve for funding the proposals indicated as Category 3 in Annex II to the Report of the TRP and the Secretariat on Round 5 Proposals (GF/B11/6), but the applicants are encouraged to re-submit a proposal for any possible future rounds of funding.</p><p>6. The Board declines to approve for funding the proposals indicated as Category 4 in Annex II to the Report of the TRP and the Secretariat on Round 5 Proposals (GF/B11/6).</p><p>7. The situation and progress in the approvals process for Round 5 proposals will be further considered, if necessary, at the Thirteenth Board Meeting</p>

<p>Part 1 - Key principles of Market-Shaping Strategy</p> <p>1. The Board acknowledges the critical role of the Global Fund in shaping markets to maximize global access to health products in accordance with the applicable Global Fund quality assurance requirements at affordable and sustainable prices and further emphasizes its desire for the Global Fund to more actively shape the markets for health products to optimize price, quality, design, and sustainable supply.<br /><br />Part 2 - Market-shaping strategy</p> <p>2. The Board approves the market-shaping strategy of the Global Fund set out in Annex 1 to the Report of the Market Dynamics and Commodities Ad-hoc Committee ("MDC") to the Board (GF/B23/9 Revision 1) ("Market-Shaping Strategy"). The Board requests the MDC to oversee the refinement and implementation of the Market-Shaping Strategy, including through relevant non-material changes to Annex 1.<br /><br />Part 3 -Market-shaping interventions for Anti-Retroviral medicines (ARVs)</p> <p>3. The Board approves the strategic interventions for ARVs in accordance with the Market-Shaping Strategy ("Strategic Interventions") as recommended by the MDC and described in Annex 1 to the MDC Report to the Board (GF/B23/9 Revision 1).</p> <p>4. The Board requests the Secretariat to implement the Market-Shaping Strategy and relevant Strategic Interventions under the oversight of the MDC. The Board requests that an implementation framework and appropriate policies and procedures be developed to effectively implement the Strategic Interventions with appropriate consultation. The Board requests the MDC to report back on progress at the Twenty-Fourth Board Meeting.</p> <p>5. Recognizing the risk of supply disruption to pediatric ARVs for certain Global Fund grant programs due to the phase-out of the UNITAID pediatric ARV program, as identified by the MDC and outlined in Table 1 of the MDC Report to the Board (GF/B23/9 Revision 1), the Board requests the Secretariat to prioritize the implementation of the Strategic Interventions set out in Section 5.2.2 of the Market-Shaping Strategy. Further, the Board requests the Secretariat, in consultation with UNITAID and other relevant partners, to facilitate the provision of support to principal recipients to sustain pediatric ARV treatment. The Board further requests the Secretariat to prioritize the execution of the appropriate policy and procedural changes to enable the Secretariat to use the Voluntary Pooled Procurement mechanism ("VPP") to strategically manage demand for pediatric ARVs to ensure the consistent and timely availability of these products purchased through the VPP.</p> <p>6. The Board requests the Secretariat and MDC to provide an update on progress in refining and implementing the Market-Shaping Strategy and the Strategic Intervention for ARVs at the Twenty-Fourth Board Meeting. The Board also requests the MDC to oversee an independent evaluation of the strategy after an appropriate period of implementation.</p> <p>Part 4 - Budgetary Implications</p> <p>7. The Board recognizes that implementation of the proposed Strategic Interventions for ARVs have budgetary implications for the Secretariat‟s operating expenses budget starting in 2011 as described in Table 1 of the MDC Report to the Board (GF/B23/9 Revision 1). The estimated implications for 2011 amount to USD 350,000 for provision of market-shaping tools and implementation of Strategic Interventions, including 4 Full Time Equivalents ("FTEs") starting on or about October 2011.</p> <p>8. The Board requests the Finance and Audit Committee ("FAC") to consider and approve the budgetary implications of this Decision Point within the framework of the 2011 administrative budget review, which is scheduled for June 2011.</p> <p>9. The Board further requests the FAC to consider the budgetary implications of market-shaping strategies including the continued cost of the 4 FTEs for 2012 and later years as part of the regular budgeting cycle.<br />Part 5 - MDC authority to approve implementation of subsequent Strategic Market Interventions</p> <p>10. Recognizing the MDC‟s technical competency, the Board authorizes the MDC to approve the implementation of other Strategic Interventions for health products procured using Global Fund financing, without requiring further approval or authorization from the Board, provided that such Strategic Interventions:</p> <p>a. will not increase the Operating Expenses Budget of the Global Fund beyond the matters referred to in Part 4 above;</p> <p>b. will not contravene, or require an amendment to, a Decision Point or policy approved by the Board; and</p> <p>c. are consistent with the principles set out in the Market-Shaping Strategy.</p> <p>11. The MDC shall notify the Board through the relevant MDC Reports to the Board of:</p> <p>a. any subsequent Strategic Interventions approved by the MDC for implementation in accordance with this Decision Point; and</p> <p>b. the progress of the implementation of such Strategic Interventions, including the phase-out of Strategic Interventions in accordance with the Market-Shaping Strategy.</p> <p>Part 6 - MDC Authority Extends to Any Successor</p> <p>The Board agrees that at its Twenty-Fourth Meeting it will request the Policy and Strategy Committee to recommend a course of action about the continuation of the MDC. Consequently, the Board determines that the authority and responsibilities conferred on the MDC in this Decision Point as applicable, shall apply with such necessary and consequential changes to any successor body or panel that may be approved by the Board to replace the role and responsibilities of the MDC in respect of this Decision Point.</p>

<ol> <li>The Board acknowledges the Audit and Ethics Committee's second stage policy proposals as set forth in document GF/B33/15 - Revision.</li> <li>Accordingly, the Board: <ol type="a"> <li>Approves the Code of Ethical Conduct for Governance Officials contained in Annex A to GF/B33/15 - Revision 2; and</li> <li>Notes that the Code of Ethical Conduct for Governance Officials will be reviewed following appointment of the Ethics Officer. This review will be conducted by the Board Leadership in collaboration with the Committee responsible for ethics matters (the "Committee"). The findings of the review will be presented to the Board for discussion and potential revisions to the Code of Ethical Conduct as applicable.</li> </ol> </li> <li>In addition, the Board: <ol type="a"> <li>Notes the Board's decision to approve the reporting arrangements for the Ethics Officer described in GF/B33/DP09;</li> <li>Endorses, in principle, the Terms of Reference of the Ethics Officer contained in Annex B to GF/B33/15 - Revision 2; and</li> <li>Requests that the Terms of Reference of the Ethics Officer be further developed by the Board Leadership in collaboration with the Committee, with the support of the Office of the Inspector General, through a comprehensive consultation process and submitted to the Board through the Committee for approval by June 2015.</li> </ol> </li> <li>Following approval by the Board of the Terms of Reference of the Ethics Officer in June 2015, the recruitment process will be launched.</li> </ol>

<ol> <li>The Board approves the amended policy on “Eligibility Criteria,Counterpart Financing Requirements and Prioritization of Proposals for Fundingfrom the Global Fund”^[1]as set out in GF/B30/6 – Revision 1, Attachment 1 (the “Amended Policy”). TheAmended Policy, “The Global Fund Eligibility and Counterpart Financing Policy,”is effective upon the date of this decision and applies to all subsequenteligibility determinations.<br /><br /></li> <li>The Board requests the Strategy, Investment and Impact Committee and the Secretariat to initiate a process that by the end of 2014 will provide options and recommendations to the Board to refine the Global Fund’s approach to transitioning countries. This approach shall include consideration of appropriate public health indicators to measure progress in sustaining and enhancing gains against the three diseases.</li> </ol> <p> </p>

<p>The Board approves the following amendments to the Board Chair and Vice-Chair nomination and election process:</p><p>1. The incumbent Board Chair and Vice-Chair shall launch the nomination process three months ahead of the Board meeting at which the election is scheduled to take place.</p><p>2. Any individual nominated by a voting constituency, with the attributes stipulated in the Terms of Reference of the Board Chair and Vice-Chair, may stand for office.</p><p>3. The Board Chair and Vice-Chair shall, upon election, become ex-officio members of the Board during their tenure, independent of any constituency, and shall not hold voting rights.</p><p>These amendments are reflected in the excerpts of the revised By-laws, Board Operating Procedures and Terms of Reference of the Board Chair and Vice-Chair contained in Annex 4, Revision 1 of the PSC's report to the Twenty-Second Board (GF/B22/4).</p>

The Board requests the Policy and Strategy Committee to work with the Secretariat and the Finance and Audit Committee to develop a roadmap for future collaboration with UNITAID and present it for approval by the Board at the Fifteenth Board Meeting. 

<p>The Board amends the Committee Rules and Procedures, Section C. paragraph 1 a. and b. as follows:</p><p>C. Size</p><p>Committees will be limited to a maximum membership as follows:</p><p>a. Policy and Strategy: 20 members (plus one representative of each of the World Bank, the World Health Organization, the Partners constituency and UNAIDS in a consultative, non-voting role)</p><p>b. Portfolio and Implementation: 12 members (plus one representative of each of UNAIDS, the Partners constituency and the World Health Organization in a consultative, non-voting role).</p>

<p>The Board refers to the Chair's Summary of the Third Global Fund Voluntary Replenishment (2011-2013) Preparatory Meeting (the "Preparatory Meeting") noting that participants at the meeting "without at this stage taking any collective positions on the substance of the issue - encouraged the Board to review the comprehensive funding policy." The Board also refers to the briefing note entitled "Use of Promissory Notes and Similar Obligations as a Means of Contributing to the Global Fund," prepared by the Secretariat at the request of participants of the Preparatory Meeting.</p><p>The Board requests the Finance and Audit Committee to conduct a review of the Global Fund Comprehensive Funding Policy, with the support of the Secretariat and through a balanced and inclusive process. Considering the relevance of this review for the Third Voluntary Replenishment, the Board requests the FAC to provide to the Board its analysis and recommendations on the use of promissory notes and similar obligations and its impact on the Comprehensive Funding Policy prior to 30 June 2010. Any proposed changes to the Comprehensive Funding Policy would be considered by the FAC after 30 June 2010 and recommendations would be provided by the FAC to the Board before the Twenty-Second Board Meeting. </p>

<ol> <li>As outlined in GF/B23/DP24 and reiterated in GF/B23/DP28, the Board continues to work with a full commitment to transparency and to endeavor to uphold the independence of the Office of the Inspector General (the “OIG”) within the Global Fund. In order to further promote this independence, the Board decides to supersede GF/B23/DP28 in its entirety with this decision point (GF/B32/DP04).</li> <li>The Board recognizes the need to have clear, consistent and contextualized information regarding the status of recoveries related to non-compliant expenditures identified within grant programs financed by Global Fund resources.</li> <li>With respect to non-compliant expenditures identified from OIG audits and investigations, the Board requests the Global Fund Secretariat to prepare a Recoveries Report (the “Report”) for the periods ending 30 June and 31 December of each year. The Report will detail, among other items: <ol type="a"> <li>the amounts reported by the OIG as being non-compliant and/or as constituting financial loss;</li> <li>the amounts deemed recoverable by the Secretariat based on the OIG’s findings, including an explanation of the method and process employed for the determination of such amounts; and</li> <li>progress on outstanding recovery actions, including a description of the context within which recovery-related processes are being handled by the Secretariat and any lessons learned.</li> </ol> </li> <li>The Board requests the AEC to: <ol type="a"> <li>review the Report;</li> <li>engage with the Finance and Operational Performance Committee (the “FOPC”) on matters within the FOPC’s mandate that relate to the process of developing and updating the Report; and</li> <li>present any recommended amendments to this decision point to the Board for approval.</li> </ol> </li> <li>Following the review of the Report by the AEC, the Secretariat shall submit the Report to the Board.</li> <li>Furthermore, the Board directs the Secretariat to develop, for AEC approval, a methodology and format for future reporting within the Report, which describes measures taken with respect to recoverable amounts identified in the due course of grant management operations.</li> </ol> <p>The Board requests the OIG to report independently on the Secretariat’s progress on matters related to recoveries as part of the OIG’s Report to the Board or as otherwise determined by the AEC.</p>

<p>The Board refers to its decision<a id="_ftnref1" name="_ftnref1"></a>1 to authorize the Secretariat to modify the application of existing policies to the extent necessary to consolidate grants on a pilot basis. Noting the update on the Secretariat's progress set out in the Policy and Strategy Committee document GF/PSC8/06, the Board reaffirms its commitment to achieving simplification and cost-efficiency in managing grants, and alignment with country systems, while maintaining adherence to the principle of performance-based funding. The Board accordingly delegates to the Secretariat the authority to:</p> <ol start="1" type="1"> <li>work with countries, on a voluntary basis, to consolidate existing and new grants where doing so would be consistent with the principles listed above;</li> <li>exercise flexibility in the application of existing policies, including but not limited to the Phase 2 Decision-Making and the Rolling Continuation Channel policies and procedures,<a id="_ftnref2" name="_ftnref2" target="_self"></a>where necessary, revising requirements that could inhibit grant consolidation; and</li> <li>approve bridge funding, in limited cases and for a period of no longer than nine months, by employing Phase 2 funds not yet approved by the Board, where necessary to allow for the alignment of end dates of grants that are being consolidated, provided that the amount of such bridge funding is reported to the Board on each occasion that it is approved.</li> </ol> <p>The Board requests the Portfolio Committee to ensure that application forms and guidelines allow for the submission of consolidated applications through the Rounds-Based Channel and Rolling Continuation Channel.</p> <p><a id="_ftn1" name="_ftn1"></a></p>

<p>Based on the updated Demand Scenarios and Resource Forecasts, the Board decides to establish a balanced Working Group with participation by Dr. Peter Godfrey-Faussett, the outgoing Chair of the TRP, to review the current policies that guide both resource mobilization and resource allocation and to develop a framework for managing the tension between resource demand and supply in a resource-constrained environment.</p><p>Upon the recommendation of the Board Chair and Vice-Chair, the Board approves the appointment of the following members of the Working Group:</p><table class="table" dropzone="copy"><tbody><tr><td>Name</td><td>Constituency</td><td> </td></tr><tr><td>1.</td><td>Peter van Rooijen, as Co-Chair</td><td>Developed Country NGO</td></tr><tr><td>2.</td><td>Dr. Sigrun Mögedal, as Co-Chair</td><td>Point 7</td></tr><tr><td>3.</td><td>Javier Hourcade Bellocq</td><td>Communities</td></tr><tr><td>4.</td><td>Dr. Agnes Binagwaho</td><td>Eastern and Southern Africa</td></tr><tr><td>5.</td><td>Simon Bland</td><td>UK/Australia</td></tr><tr><td>6.</td><td>Amb. Patrice Debré</td><td>France/Spain</td></tr><tr><td>7.</td><td>Michelle Moloney-Kitts</td><td>USA</td></tr><tr><td>8.</td><td>Bill Parr</td><td>Western Pacific Region</td></tr><tr><td>9.</td><td>Sujatha Rao</td><td>South East Asia</td></tr><tr><td>10.</td><td>Todd Summers</td><td>Private Foundations</td></tr><tr><td>11.</td><td>Dr. Ernest Messiah</td><td>Latin America and the Caribbean</td></tr><tr><td>12.</td><td>Enrico Vicenti</td><td>Italy</td></tr></tbody></table><p> </p><p>The Working Group is requested to:</p><p>1. provide recommendations for amendments of existing policies regarding prioritization for funding technically sound proposals in a resource-constrained environment, subject to review at the appropriate times;</p><p>2. provide recommendations, if possible, on future resource allocation policies, to be followed-up by the appropriate Board committee(s); and</p><p>3. present options for an increased and urgent resource mobilization effort.</p><p>The Working Group is requested to seek appropriate input during its deliberations, consult with PC, PSC and FAC, and report to the Board before its Twentieth Board Meeting in November 2009. </p>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period[1] for the grants listed in Table 1 in the amounts indicated for each grant, based on the understanding that the amounts approved are upper ceilings rather than final funding amounts for that period and that the Secretariat shall pursue on-going implementation arrangements for each grant consistent with the recommendations set forth in the Grant Score Card for each grant. Approval is also subject to the provision that funding for renewals of existing grants shall be committed in annual tranches, subject to the availability of funding (GF/B25/DP16, para 7 of Annex 1).</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of each grant shall be the sum of the amount set out in Table 1 of this Decision for that grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either undisbursed funds or cash balances held by recipients under the grant.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 130,325,572 for the following grants: BLR-304-G01-H ; BRN-910-G09-M ; BRN-910-G10-M ; CPV-810-G01-H ; CPV-810-G02-H ; PRK-810-G02-T ; SLV-910-G08 ; SLV-910-G07-T ; ERT-910-G07-M ; FJI-T-MOH ; LSO-809-G07-H ; MDG-810-G13-T ; MDG-810-G14-T ; MNT-910-G03-H ; NIC-202-G05-T-00 ; PRY-910-G06-S ; SER-910-G06-T ; SER-910-G07-T ; SLB-810-G01-T ; SWZ-809-G08-S ; TAJ-304-G02-T</p>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Table 1 of GF/B40/ER07 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board notes with concern the current shortfall regarding funds availability for Round 5.</p><p>The Board calls upon participants of the Replenishment Conference, and all other potential donors, to take urgent action to ensure that Round 5 is fully funded.</p>

<p>The Board approves the Report of the 34th Board Meeting, as set forth in GF/B34/25.</p>

The Board approves the document entitled "Phase 2 Decision-Making Policies and Procedures" included as Annex 1 to the Report of the Portfolio Committee (GF/B12/6) and as amended at the 12th Board Meeting and revokes all previously approved versions of such document. 

<p>The Board decides to revise the current eligibility criteria for proposals for funding and approves the income level and cost-sharing eligibility criteria for Global Fund funding as set out in Attachment 1, Section 2 of GF/B16/7. The Board delegates to the Portfolio Committee the responsibility to oversee the implementation of the Income Level and Cost-Sharing Eligibility Criteria and to make decisions to facilitate such implementation within the parameters of the policy. The Board further requests technical partners to work with the PC to review how the availability of data for concentrated epidemics in HIV/AIDS will impact access to Global Fund financing. </p><p>The Board decides to review the Income Level and Cost-Sharing Criteria in three years' time. </p>

<ul><li><b>(Deferred)</b> The PMPC recommends that the Board endorse upper and lower limits for proposals submitted to the Global Fund.<br/><br/><ul><li>The PMPC recommends that the Board endorse the strongly preferred recommendation to use a lower limit of US$2 million per year per proposal.</li><li>Alternatively, the minority option supports the use of a lower limit of US$2 million per year per proposal on all CCM applications, and a lower limit of $1 million per year per proposal on all non-CCM applications.</li></ul></li></ul><ul><li>The Board encourages the Secretariat, working with the Portfolio Management and Procurement Committee, to include in the revised Guidelines for Proposals for the Third Round language regarding the preferred scale of grant applications. This should provide guidance to applicants to ensure that proposals are neither excessively large, in view of both national programmatic capacity and the limited resources of the Global Fund, nor excessively small, in view of both the Global Fund's goal to scale-up country responses and the administrative costs of processing applications.</li></ul><ul><li><b>(Not Approved)</b> The PMPC recommends that the Board endorse the strongly preferred recommendation to use a lower limit of US$2 million per year per proposal. Alternatively, the minority option supports the use of a lower limit of US$2 million per year per proposal on all CCM applications, and a lower limit of US 1 million per year per proposal on all non-CCM applications. The PMPC recommends that the Board endorse an upper limit on all proposals of US$50 million per year and of 50% of total public health sector expenditure per year (whichever figure is the lower).</li></ul>

The Board requested that representatives from the Private Sector and Italy chair a working group on governance and that the findings of this working group be presented at the Third Board Meeting.

<p>The Board acknowledges the work of the Policy and Strategy Committee and Secretariat in reviewing the architecture issues related to the current financing model of the Global Fund.</p> <p>The Board recognizes that certain key improvements may be implemented immediately, while other potential improvements require further consideration and development.</p> <p>A. Endorsement of a "single stream of funding per Principal Recipient per disease" model:</p> <p>The Board endorses, in principle, the recommendation that future architectural changes shall be based on a "single stream of funding per Principal Recipient per disease" model, recognizing that:</p> <ol> <li>The Secretariat will present to the Policy and Strategy Committee, at its first meeting in 2009, a detailed design for implementation of this model, including an analysis of all necessary changes to Global Fund policy required to implement this model; and</li> <li>The Policy and Strategy Committee will present the model for Board approval at the Nineteenth Board Meeting.</li> </ol> <p>B. Changes to be implemented beginning in Round 10:</p> <p>Recognizing that the Board has made the following previous decisions in order to progress towards greater alignment of Global Fund processes with country cycles:</p> <ul> <li>To announce, with significant advance notice, a fixed set of dates for future rounds of funding (GF/B14/DP12) and to call for two rounds of funding in 2008 (GF/B17/DP23);</li> <li>The opportunity for applicants to re-submit a revised version of the same proposal that was recommended by the TRP as a 'Category 3' proposal (GF/B17/DP23); and</li> <li>The opportunity for the TRP to recommend RCC proposals for funding conditional upon the removal of a limited set of specific elements from the disease proposal (GF/B14/DP9).</li> </ul> <p>The Board now decides to reflect the above decisions in future rounds, commencing with Round 10, as follows:</p> <ol> <li>The Secretariat shall issue a minimum of two Calls for Proposals in each calendar year, which shall be issued at dates that fall 6 months after each other, and on as close to the same dates each year as is practicable;</li> <li>Applicants whose proposals are recommended as 'Category 3' proposals by the TRP, shall be entitled to re-submit, in the next round, a revised version of the same proposal that was recommended by the TRP as a 'Category 3' proposal;</li> <li>The TRP may, when recommending proposals as 'Category 1' or 'Category 2' (including 'Category 2B' proposals), recommend relevant proposals for funding conditional upon the removal of a limited set of specific elements from the disease proposal (which removal is not subject to a right of appeal); and</li> <li>The Board requests the Secretariat to prepare amendments to the TRP Terms of Reference as necessary to implement the decisions described above.</li> </ol>

<p>The Board acknowledges the letter from the Roll Back Malaria ("RBM") Partnership, dated August 16, 2007 requesting the Global Fund to consider hosting the Affordable Medicines Facility - malaria ("AMFm").</p><p>Based on the information provided to date, the Board supports in principle:</p><ul type="disc"><li>the objectives and principles of AMFm; and</li><li>the idea of investigating with no presumptive decision the appropriateness of hosting the AMFm as a Global Fund business line, considering the complementarities and synergies of the Global Fund's objectives and business model with many design elements of the AMFm.</li></ul><p>To facilitate a final Board decision on hosting the AMFm, the Board requests the Secretariat, under the oversight of the PSC, to develop and present to the Board at its Seventeenth Meeting a report and a possible business model and plan for hosting the AMFm within the Global Fund, taking into account operational and architectural considerations and consultations with the RBM Taskforce, UNITAID, key recipient countries and other relevant stakeholders. The intended mechanism should seek to increase broad access to ACTs especially among those at highest risk.</p>

<p>The Board refers to its decision (GF/B20/DP24) to review the findings of the Independent Evaluation of the Affordable Medicines Facility - malaria (AMFm) Phase 1 and make a recommendation on whether to "expand, accelerate, modify, terminate or suspend the AMFm business line" in pilot countries.</p> <p>The Board:</p> <ol> <li>notes the findings of the Independent Evaluation ("IE"), as detailed in the Strategy, Investment and Impact Committee ("SIIC") Report to the Board (GF/B28/04), on the effectiveness of the AMFm in the eight pilot programs and, in particular, notes the results regarding the "upstream" success parameters recommended in 2010 by the Technical Evaluation Reference Group ("TERG").<br /><br /></li> <li>recognizes that the successes of the AMFm are due to the co-payment system, consisting of price negotiations with manufacturers and direct co-payments from the Global Fund to manufacturers on behalf of approved first-line buyers, and the use of supporting interventions.<br /><br /> </li> <li>notes that the results of the IE and the TERG's interpretation of those findings indicate there is sufficient evidence to approve a modified approach to support countries in achieving the Roll Back Malaria targets of universal coverage of malaria treatment if coupled with efforts to improve access to diagnostic testing.<br /><br /></li> <li>recognizes the importance of ensuring access to affordable diagnostic testing and treatment for malaria and the role of the private sector in delivering this access.<br /><br /></li> <li>notes the role of the Global Fund in helping to ensure sustainable affordable pricing for health commodities through innovative strategies and initiatives, including through engagement of the private sector.<br /><br /></li> <li>thanks countries, partners, donors and manufacturers for their participation and support in AMFm.</li> </ol> <p>The Board decides to modify the existing AMFm business line by integrating the lessons learned from the operations and resourcing of Phase 1 of the AMFm into Global Fund grant management and financial processes by:</p> <ol> <li>requesting the Secretariat to establish and operationalize a co-payment system through which the Global Fund will make direct payments to manufacturers on behalf of in-country buyers and at negotiated prices for countries which request the use of approved grant funds for a private sector subsidy to achieve their malaria case management targets and utilize supporting interventions; and<br /><br /></li> <li>Acknowledging the need for an assessment by technical partners of the feasibility to include diagnostic testing into the co-payment system, which would inform the operationalization of the co-payment system.</li> </ol> <p><u>2013 Transition by AMFm Pilot Countries to Full Integration</u>:</p> <p>The Board:</p> <ol> <li>notes that the integration of a co-payment system into Global Fund grant management and financial processes will mean that, following a responsible Transition, co-payments for anti-malarial drugs will no longer be available through a separate funding mechanism hosted by the Global Fund.<br /><br /></li> <li>decides that, during the Transition in 2013 to operationalizing the integration of a co-payment system, the pilot countries will have a defined funding allocation to support private sector co-payments, subject to availability of dedicated resources for such payments, and that each country will determine the parameters, such as the use of demand levers, under which that funding is utilized.<br /><br /></li> <li>requests the Secretariat to report to the FOPC and SIIC prior to the end of 2012 on the outcome of resource mobilization efforts undertaken to finance the co-payments for the Transition.<br /><br /></li> <li>authorizes the Secretariat to deploy remaining resources from malaria grants in Phase 1 for supporting interventions, which is separate from co-payment funds.</li> </ol>

The Board endorses the Risk Management Framework of the Global Fund as set out in Attachment 3 to the Finance and Audit Committee Report to the Board (GF/B20/6).

<p>The Board approves the appointment of Ms. Beatrijs Stikkers as a voting member of the Finance and Operational Performance Committee (the "FOPC") for a term that will expire on 1 May 2016, or until the appointment of her successor.</p>

<p>1. The Board notes its January 2016 approval (GF/B34/EDP07) of the amended and restated Operating Procedures of the Board and Committees, which become effective upon the conclusion of the 35th Board Meeting in April 2016.<br /><br />2. Based on the recommendation of the Transitional Governance Committee, the Board approves the amendments to Articles 15, 16, 20, 22 and 36 of the Operating Procedures of the Board and Committees, as set forth in Annex 1 to GF/B34/ER15 (the "Amended Provisions"), which become effective upon the date of this decision and will be incorporated into the amended and restated Operating Procedures of the Board and Committees.</p>

<ol> <li>The Board acknowledges that the Global Fund, as a whole, needs to move forward thoughtfully with the implementation of the overall comprehensive reform agenda, and asks that the Secretariat and incoming Chair and Vice-Chair of the Board take on and advance the operational and governance reforms recommended in the Report of the Comprehensive Working Group (CRWG Report, GF/B23/13).<br /><br /></li> <li>The Board notes that strategic priorities will need to be set in anchoring the operational reforms in the Secretariat‟s current workplan. The Board encourages the Secretariat to engage with the Chair, Vice-Chair, and Finance and Audit Committee (FAC) regarding resource implications for successful implementation of these reforms.<br /><br /></li> <li>The Board acknowledges that consultations with direct implementers have been conducted in Ukraine, Kenya, Thailand, El Salvador and Senegal as part of the comprehensive reform process, and that those inputs should be taken into consideration during the implementation of reforms.<br /><br /></li> <li>The Board acknowledges that it will be accountable for the successful implementation of the comprehensive reform agenda. The Board requests the Executive Director and incoming Chair and Vice-Chair to jointly submit a report at Twenty-Fourth and Twenty-Fifth Board Meeting, which outlines overall progress in relation to the nine reform objectives.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the appointment of the following individual to the Strategy, Investment and Impact Committee (‘SIIC’), to replace one out-going member:<br />a. Ambassador Philippe Meunier, representing France.</li> <li>Notes that Ambassador Philippe Meunier shall serve on the SIIC until the end of his predecessor’s term.</li> </ol>

<ol> <li>The Board notes that a portion of sources of funds may be excluded from the allocation to Country Bands for future utilization towards initiatives that are not adequately accommodated through the allocation of resources to Country Bands (Annex 1 to GF/B27/DP7) (the “Special Initiatives”). </li> <li>Based on the recommendation of the Strategy, Investment and Impact Committee (the “SIIC”), the Board decides that up to USD 100 million will be available over the 2014 – 2016 allocation period for the following Special Initiatives, as described in GF/B31/08A – Revision 1, in the amounts listed below: <ol type="a"> <li>USD 30 million for the Humanitarian Emergency Fund;</li> <li>USD 17 million for Country Data Systems; </li> <li>USD 29 million for Technical Assistance for Strong Concept Notes and PR Grant-making Capacity Building; </li> <li>USD 15 million for Technical Assistance on Community, Rights and Gender; and</li> <li>USD 9 million for Enhancing Value for Money and Financial Sustainability of Global Fund Supported Programs.</li> </ol> </li> <li>The funds available for Special Initiatives may be reallocated by the Secretariat among the Special Initiatives set forth under paragraph 2 above, upon the SIIC’s approval, in consultation with the Finance and Operational Performance Committee (the “FOPC”), of an updated budget and plan to implement such initiatives.</li> <li>The Secretariat shall recover investments towards Special Initiatives from funding provided through grant programs whenever possible.</li> <li>With respect to the use of funds available for the Special Initiatives, the Board requests the Secretariat to report to the FOPC on the financial implications and to the SIIC on the operational and strategic implications. </li> </ol>

<p>The Board refers to its decision (GF/B15/DP17) on National Strategy Applications ("NSAs"), requesting that the Policy and Strategy Committee (PSC) recommend to the Board a plan and policies for bringing into operation a National-Strategy Applications procedure, based on the principles set forth in that decision. The Board reiterates its commitment to the development of a credible, shared validation approach for national strategies, which will form the basis of the NSA procedure once it becomes available.</p> <p>To learn lessons with regard to other aspects of the NSA procedure, the Board authorizes the Secretariat to bring it into operation through a phased roll-out, which shall begin with a first wave of NSAs ("the First Learning Wave") in a limited number of countries. The First Learning Wave shall be aimed at drawing policy and operational lessons to inform a broader roll-out of the NSA procedure.</p> <p>The principles underlying the Board's decisions on:</p> <ul> <li>"dual-track financing" (as described in GF/B15/DP14);</li> <li>the strategic approach to health systems strengthening (as described in GF/B15/DP6); and</li> <li>the Comprehensive Funding Policy (GF/B15/DP27)</li> </ul> <p>shall be applied to the First Learning Wave.</p> <p>The initial funding of grants in the First Learning Wave shall be approved by the Board for a period that shall not exceed two years.</p> <p>The Board authorizes the Secretariat to make exceptions to existing policies and procedures to the extent necessary to implement the First Learning Wave. Such exceptions may relate, but are not limited, to the following:</p> <ol type="a"> <li>The type and format of information to demonstrate eligibility of the NSAs;</li> <li>The submission and review procedures and policies for applications for Global Fund financing (including the timing of submission and the format of applications);</li> <li>The Technical Review Panel (TRP) terms of reference, including TRP procedures, compensation arrangements for TRP members, criteria for review of NSAs (including the national strategy itself) and interaction with CCM members and other relevant stakeholders during review; and</li> <li>The Phase 2 review (including the timing of the Phase 2 review and renewal decision).</li> </ol> <p>Any exceptions to existing policies and procedures made in connection with the First Learning Wave shall be consistent with the Framework Document of the Global Fund.</p> <p>In implementing the First Learning Wave, the Secretariat shall take into account the outcome of the deliberations of the UNAIDS Programme Coordinating Board at its meeting in December 2008, the IHP+ consultations on the validation process and other relevant stakeholder consultations.</p> <p>The Secretariat shall report to the PSC at its first meeting in 2009 on progress of implementation of the First Learning Wave. The TRP-recommended applications emanating from the First Learning Wave shall receive the same funding priority as proposals submitted under the Rounds-Based Channel (provided that, in a resource-constrained environment, precedence is given to previously approved but unfunded rounds-based proposals).</p> <p>The Secretariat will also propose to the PSC, once they have been identified, modifications to existing Global Fund policies that would be necessary to launch a broader roll-out of the NSA procedure.</p> <p>The authority granted to the Secretariat under this decision point will continue for the duration of the grants approved within the First Learning Wave.</p>

<p>The Board delegates authority to the Portfolio and Implementation Committee (PIC) to approve changes to the "Guidelines and Requirements for Country Coordinating Mechanisms". </p><p>However, if the PIC considers that material changes to any of the six CCM eligibility requirements are needed, the PIC will make a recommendation to the Board for approval.</p>

<ol> <li>The Board refers to its decision on "TRP Recruitment 2010-2012" (B21/EDP/18) appointing the membership of the Technical Review Panel (TRP) Support Group, comprising the pool of experts from which TRP membership will be replenished in the event of TRP vacancies as they may arise. The Board also notes that each of the TRP Support Group members (as presented in Annex 1 of the Report B21/EDP/18) have been recommended by the Portfolio and Implementation Committee and the Executive Director of the Global Fund Secretariat. The Board authorizes the TRP Chair and TRP Vice-Chairs to appoint replacements for vacancies in the Permanent TRP and Alternate members from members of the TRP Support Group.<br /><br /></li> <li>The Board authorizes the TRP Chair and TRP Vice-Chairs to add members to the TRP as required for a given round of proposals. Such additional members shall be selected from Alternate Members, and where necessary due to member unavailability, from former TRP Members.<br /><br /></li> <li>When additional members are added to the TRP, the TRP leadership shall report such additions to the relevant Board Committee.<br /><br /></li> <li>The Terms of Reference of the TRP shall be amended accordingly.</li> </ol>

Mr. Carsten Staur from the Point Seven Constituency is designated as Rapporteur for the Thirteenth Board Meeting.

The Board approves the 2012 Annual Report of the Global Fund, as set forth in GF/B29/11.

<p>The Global Fund Board decided on the following measures related to procurement and supply management:</p> <p>A. PRODUCT SELECTION AND RATIONAL USE</p> <p><u>1. List of medicines to be procured</u></p> <p>Fund resources may be used only to procure medicines which appear in current national, institutional or World Health Organization (WHO) standard treatment guidelines (STGs) or essential medicines lists (EMLs). The relevant STG or EML should be included in the proposal submitted to the Fund. Unlisted products may be procured only with appropriate and specific rationale presented in the proposal, as judged by the Technical Review Panel (TRP).</p> <p><u>2. Plans for preventive, diagnostic and other public health products</u></p> <p>Proposals for purchase of medications must be accompanied in the proposal by a plan of enabling diagnostics and other major categories of supplies related to the provision of these medications.</p> <p><u>3. Adherence, drug resistance and monitoring adverse effects</u></p> <p>a) It is strongly recommended to Recipients that they implement mechanisms to encourage adherence to treatment (including but not limited to Fixed Dose Combinations (FDCs), once-a-day formulations, blister packs, and peer education and support), to monitor and contain resistance, and to monitor adverse drug reactions (ADRs) according to existing international guidelines and, if necessary, drawing on budgeted requests for financial support from the Fund.</p> <p>b) To help contain resistance to second-line TB drugs and consistent with the policies of other international funding sources, all procurement of medications to treat Multi Drug Resistant TB (MDR-TB) must be conducted through the Green Light Committee (GLC). [http://www.who.int/gtb/policyrd/DOTSplus.htm]</p> <p>B. QUALITY ASSURANCE</p> <p><u>4. Compliance with quality standards</u></p> <p>a) For any medicinal product to be eligible for purchase with Fund resources, its compliance with quality standards must be assured. For multi-source, off-patent products with available dosage from public pharmacopoeial quality standards, verification of product compliance with standards would be conducted in accordance with the existing national procedures of the Recipient’s country.</p> <p>b) Provided products are accepted by the national drug regulatory agency (NDRA)of the Recipient country (see 5 below), to be eligible for purchase with Fund resources any single or limited source product (that is, a medicinal product for which there are not publicly available quality assurance standards, analytic methods, and reference standards) must (a) have been found to be acceptable by the WHO-initiated UN Pilot Procurement Quality and Sourcing Project, or (b) have been authorized for consumption in its country by a stringent regulatory authority, [For the purposes of this policy a stringent drug regulatory authority is defined as a regulatory authority in one of the 28 countries which is either a PIC/S and/or ICH member] or (c) have been authorized by the national drug regulatory authority in the Recipient’s country. Option (c) is applicable only until December 31, 2004, after which suppliers must comply with one of the two standards as set out in (a) and (b) and in all cases are subject to monitoring product quality standards prescribed by the Fund as in 6.1.</p> <p><u>5. National drug registration</u></p> <p>a) Products procured with Fund resources are subject to authorization by the National Drug Regulatory Authority (NDRA) in the country in which they will be used, following its standard practices for drug registration for pharmaceutical products. For products that have passed the UN Pilot Procurement Quality and Sourcing Project review, as described in above, NDRAs are encouraged to expedite registration by accepting WHO pre-qualification inspection and supporting dossiers in lieu of national requirements.</p> <p>b) For products which have been authorized by stringent drug regulatory authorities, NDRAs are encouraged to expedite registration by accepting in lieu of national requirements the Executive Summary of the Common Technical Document (CTD) or Summary parts for quality, safety and efficacy together with all necessary information to perform quality control testing of products and necessary reference standards.</p> <p><u>6. Monitoring product quality</u></p> <p>a) Recipients, their procurement agents, or NDRA’s must systematically draw random samples of pharmaceutical products purchased with Fund resources for quality control testing to monitor compliance with quality standards. Testing may be budgeted in proposals, to be funded by the Fund. For multi-source off-patent products with available public standards, samples should be sent to WHO-recognized laboratories in cases where the NDRA have no capacity for this testing.</p> <p>b) For single- or limited-source products without public standards and pre-qualified by UN Pilot Procurement Quality and Sourcing Project, samples should be sent to WHO-recognized laboratories already participating in the WHO pre-qualification project in case the NDRA has no capacity. For single- or limited-source products that have been pre-qualified on the basis of authorization by a regulatory authority in an ICH and/or PIC/S member, testing shall be done by a laboratory identified by the purchaser as stated in the purchase contract. The laboratory should be a WHO-recognized laboratory, or a laboratory in ICH and/or PIC/S countries in case the country does not have identified laboratory capacity.</p> <p>C. PROCUREMENT AND PRICING</p> <p><u>7. Procurement practices</u></p> <p>The Fund will require that, as a minimum, Recipient procurement offices and any contracted agencies/services adhere to the Interagency Operational Principles for Good Pharmaceutical Procurement. [Operational Principles for Good Pharmaceutical Procurement (Interagency document). WHO, Geneva, 1999. WHO/EDM/PAR/99.5. www.who.int/medicines/library/par/who-edm-par-99-5/who-edm-par-99-5.htm] Where practices differ from the Interagency Guidelines, Recipients or their agents must demonstrate to the LFA comparable systems for competitive bidding within a group of pre-qualified suppliers, transparency and accountability to their practices, and their application of necessary quality assurance mechanisms. Recipients should also demonstrate the existence of a full set of contractual documentation to govern each transaction.</p> <p><u>8. Procurement responsibilities</u></p> <p>a) The Recipient is responsible for all procurement, with the use of contracted local, regional or international procurement agents being at the discretion of the Recipient. The exception to this would be for those product categories for which local procurement capacity is insufficient, as judged by the Procurement and Supply Management Assessment. For such product categories, Recipients would be required to use established regional or international procurement services and will be informed by the Fund on which mechanisms are available. </p> <p>b) Even for product categories for which Recipients have procurement capacity, the use of capable regional and global procurement services is encouraged wherever pooling of demand lowers prices for products of assured quality.</p> <p><u>9. Monitoring supplier performance</u></p> <p>Recipients are responsible for monitoring the performance of suppliers with respect to product and service quality and for submitting that information electronically for web publication through a mechanism established by or identified by the Fund. Reporting guidelines for supplier performance should be specified by the LFA, according to guidelines provided by the Secretariat of the Fund.</p> <p><u>10. Lowest possible price</u></p> <p>a) The Fund requests Recipients to use Good Procurement Practices, which includes competitive purchasing from qualified manufacturers and suppliers, as outlined in section B of these recommendations, to attain the lowest price of products. The Fund encourages Recipients to comply with national laws and applicable international obligations in the field of intellectual property including the flexibilities provided in the TRIPS agreement and referred to in the Doha declaration in a manner that achieves the lowest possible price for products of assured quality.</p> <p>b) The Fund encourages the voluntary efforts of pharmaceutical companies to expand current tiered or preferential pricing arrangements, among other mechanisms, to promote differential pricing.</p> <p>c) Disclosure of information on prices paid for purchases by Fund Recipients is a matter of principle and will facilitate a process leading to lower prices. The Fund will ensure that information on prices paid on products of assured quality with the same conditions (e.g., including other goods or services included in the contract) is made publicly available. The disclosure of this information will be pursued by the Fund. A methodology for assuring this transparency will be presented to the Board by January 2003.</p> <p>d) In the cases of this policy, price refers to DDU costs – delivered duty unpaid. The approach taken may be to publicly list average, minimum, maximum, and mode prices and/or prices for individual companies and/or Recipients. This choice requires further consideration by the Fund to identify or develop standard methods to ensure to the extent possible that price information is based on a consistent set of definitions. It is understood that price comparisons are indicative and must include special “add ons”/conditions included in the price and that actual prices will vary.</p> <p><u>[...]</u></p> <p>E. BUDGETING AND FINANCE</p> <p><u>17. Direct payment to suppliers upon delivery</u></p> <p>Prompt payment in compliance with the terms of payment of the contractual provisions encourages timely delivery of products and reduces transaction costs. Direct payment to suppliers by the Trustee, on confirmation of delivery, will be allowable upon request of the Secretariat if, as confirmed by the LFA, such payment arrangements are expected to reduce costs and to be consistent with necessary accounting requirements.</p> <p><u>18. Exemption from duties, tariffs and taxes</u></p> <p>a) The Fund strongly encourages the relevant national authorities in the Primary Recipient’s country to exempt from duties and taxes all public health products financed by the Fund to NGOs, groups of NGOs, or national authorities, or any other PRs.</p> <p>b) In any case, Fund resources may not be used to pay duties, tariffs, local or national taxes on public health products procured with Fund resources. If payment of such fees is required by relevant national authorities, such payment is the responsibility of the Recipient.</p> <p><u>19. Additionality of Fund resources and contribution to sustainability</u></p> <p>a) The Fund encourages Recipients to manage and to apply Fund resources as part of a sustainable long-term plan for local public health financing. Recipients will be required to declare in the original proposal to the Fund other international financing and product donation programs being utilized by Recipients. Ongoing indicators must show the magnitude of product financing supported by domestic versus international financing.</p> <p>b) Programs which include consumer cost recovery mechanisms are eligible for funding by the Fund when such programs are part of a pre-existing healthcare financing policy, which should be specified in the proposal to the Fund; in these cases, the budget request to the Fund must not duplicate costs to be reimbursed by consumers.</p> <p><u>[...]</u></p> <p><u>21. Prices used for budgeting proposals</u></p> <p>a) For budget requests for pharmaceutical products, proposals to the Fund must use the lessor of current procurement prices, firm offers from suppliers, or existing public price information sources specified by the Secretariat in the Guidelines for Proposals. A rationale for budgeting using prices other than those specified above should be described in the proposal. All prices should be expressed in standard trade terminology to allow transparent comparison.</p> <p>b) During implementation, these budgeted prices will not act as a defined reimbursable ceiling or floor to the full cost of products paid by the Recipient, provided that products are of assured quality and that procurement practices adhere to the policies of the Recipient and Fund.</p> <p>F. MONITORING AND EVALUATION</p> <p><u>22. Monitoring the performance of procurement and supply systems</u></p> <p>a) Prior to disbursement, Recipients must prepare a plan for monitoring the performance and sustainability of procurement and supply management systems. The monitoring plan should include tracking of procurement prices, distribution costs, additionality of Fund resources to domestic and other international sources, and other measures of procurement and supply system performance and sustainability. Indicators for monitoring should be agreed with the Fund and included in the Grant Agreement. The Secretariat of the Fund will make available a menu of existing international indicators with agreed methodology to support this process.</p> <p>b) Baseline data for agreed “core” indicators must be gathered before Fund-supported services and products may be delivered. The baseline survey should be done prior to the Grant Agreement as part of the Procurement and Supply Management assessments undertaken by the LFA.</p> <p><u>23. The Board also approved several follow-up items to be considered by the Portfolio and Procurement Committee (Reference numbers refer to the Report of the Task Force on Procurement and Supply Management) :</u></p> <p>a. Reference 2.1: Diagnostics and other major categories related to provision of medications;</p> <p>b. Reference 4.2.c): A study of the degree of intensity, the frequency, monitoring, and how frequent the testing and monitoring should be done, along with the costs involved;</p> <p>c. Reference 6.1: A study of :</p> <p>• the need to decide on how to make a judgment on NDRA capacity to proceed with analysis of multi-source products, and if required make a recommendation on this topic to the Board;</p> <p>• the potential conflicts of interest involved when products are manufactured in a state-owned laboratory and the Principal Recipient is a public entity;</p> <p>• the potential conflicts of interest involved when products are manufactured or purchased in a state-owned structure and the state is responsible for quality;</p> <p>d. Reference 8.1: Review the feasibility and options for partnering relevant global bidding mechanisms;</p> <p>e. Reference 8.2: Review the feasibility or necessity of global or regional procurement or bidding mechanisms for product categories for which such mechanisms do not currently exist. The Fund will not, in any case, take on such procurement responsibilities itself;</p> <p>f. Reference Annex IV, p. 7: Review specific recommendations on capacity building;</p> <p>g. Reference 10.1: Perform a feasibility study, including a full cost analysis, to develop a pricing reporting mechanism as outlined in the pricing section that will require that information on prices paid by Recipients is made publicly available through existing international pharmaceutical pricing services or be made public by the Fund. This includes determining who will publish the pricing information. Taking into account that it is a difficult matter, the Portfolio Management and Procurement Committee will study the best way of achieving this objective;</p> <p>h. Reference 12: Study and make recommendations regarding the issue of domestic production;</p> <p>i. Reference 18.1: Study the impact of the policy on duties, tariffs, and taxes, including specifically the impact on NGOs, and make appropriate recommendations to the January 2003 Board meeting; </p> <p>j. Explore the necessity for the continuation for a special Procurement and Supply Management Task Force and review the memberships of such a Task Force.</p>

<ol> <li>The Board decides to amend the Charters of the Audit and Ethics Committee (the "AEC") and the Finance and Operational Performance Committee (the "FOPC") to reallocate the advisory and oversight responsibilities related to the external audit of the Global Fund's annual financial statements between the AEC and FOPC, as set forth in Annexes 3 and 4 to GF/B27/07.</li> <li>The AEC and FOPC Charters, as amended and set forth in Annexes 3 and 4 of GF/B27/07, shall be effective as of the date of this decision.</li> </ol>

<ol> <li>The Board acknowledges the Strategy, Investment and Impact Committee’s (the “SIIC”) plan to develop recommendations for Board consideration at its March 2015 meeting on the Global Fund’s role in funding treatment of co-infections and co-morbidities of HIV/AIDS, tuberculosis and malaria, and directs the Secretariat to engage and collaborate with partners to support the SIIC’s development of such recommendations.</li> <li>As an interim measure until there is an outcome to those deliberations, where there is a currently approved budget for Hepatitis C virus (“HCV”) treatment within an existing Global Fund grant, the Global Fund may continue to fund such treatment up to the approved budget amount, as set forth in GF/B32/22, and may otherwise permit continuation of Global Fund funded HCV treatment programs during this interim period with new grants in these countries up to previously approved budgeted levels.</li> <li>The Board encourages partners to finance broader and additional HCV treatment needs, including those identified within Global Fund grant programs.</li> <li>The Board acknowledges the close working relationship and collaboration among the Global Fund, UNITAID and other partners on market-shaping activities, including the expansion of access to HCV treatments.</li> </ol>

The Board approves the Global Fund Human Resources Framework, as laid out in Annex 1 to Global Fund Human Resources Policy Framework (GF/EDP/08/16), which shall be brought into effect on 1 January 2009.

<p>The Board authorizes the issuance of, and therefore approves, the Global Fund's 2014 Statutory Financial Statements, which have been audited by Ernst &amp; Young SA, as set forth in Annex 2 to GF/B33/03 - Revision 1. </p>

<ol> <li>The Board reaffirms the Global Fund‟s strong and continuing commitment to the highest standards of transparency and accountability.<br /><br /></li> <li>The Board further reaffirms the Global Fund‟s commitment to a fully independent and transparent Office of the Inspector General as set forth in the OIG Charter and Terms of Reference.<br /><br /></li> <li>The Board looks forward to receiving the views of the High Level Independent Review Panel on Fiduciary Controls and Oversight Mechanisms on existing arrangements and its recommendations on ways to further improve the fiduciary controls and oversight within the Global Fund.</li> </ol>

<p>Notwithstanding the effect of Decision 1 (GF/B25/EDP20 applied post factum) above, paragraph 11 of the Global Fund's 'Policy on Eligibility Criteria, Counterpart Financing Requirements, and Prioritization of Proposals' (GF/B23/14), which allows NGOs from Upper Middle Income Countries not listed on the OECD's DAC list of ODA recipients to apply for HIV/AIDS funding, shall remain applicable to the Transitional Funding Mechanism.</p>

<ol> <li>The Board approves a reporting arrangement for the Ethics Officer as follows: <ol type="a"> <li>The Ethics Officer will report on its activities directly to the Board through the Committee responsible for ethics matters (the "Committee").</li> <li>The Ethics Officer will provide regular advice and support: <ol type="i"> <li>To the Executive Director on ethical matters pertaining to the Secretariat's activities, including issues related to grant recipients, CCMs, third-party providers (e.g., LFAs and suppliers) and staff. Based on the Ethics Officer's advice, the Executive Director will determine and implement appropriate remedial actions.</li> <li>To the Committee on all other ethical matters not included in paragraph 1(b)(i) above. Based on the Ethics Officer's advice, the Committee will determine appropriate remedial actions.</li> </ol> </li> <li>The Ethics Officer will be located within the Office of the Inspector General for administrative purposes only. </li> </ol> </li> </ol>

The Board approves the amendments to the Charter and Terms of Reference of the Office of the Inspector General and the Policy for Disclosure of Reports Issued by the Inspector General as set out in the Annexes 2 and 3 of the Report of the Finance and Audit Committee to the Board (GF/B20/6).

<ol> <li>The Board acknowledges that C19RM was established to support (i) COVID-19 control and containment interventions, (ii) COVID-19 risk-related mitigation measures for programs to fight HTM, and (iii) expanded reinforcement of key aspects of health systems, and recognizes that C19RM requests and awards through the end of 2021 largely focused on the acute response to the COVID-19 pandemic;</li> <li>The Board acknowledges that the pandemic is evolving, and that recipient priorities are correspondingly shifting towards longer-term investments in health systems’ infrastructure and capacities for pandemic preparedness and response;</li> <li>To facilitate careful planning of such investments, including alignment with potential funding requests for the Seventh Replenishment grant cycle, the Board approves that C19RM funds may be awarded through 30 June 2023, with opportunity for subsequent C19RM portfolio optimization awards;</li> <li>To enable maximization of impact from investments in resilient and sustainable systems for health, the Board approves that any C19RM funds may be implemented through 31 December 2025 and will finance interventions across the Sixth and Seventh Replenishment periods – acknowledging that the Secretariat will continue to ensure rapid deployment of funds and quality implementation notwithstanding this deadline;</li> <li>The Board approves that C19RM funding requests will continue to be developed through appropriate, multi-sectoral consultation and fully inclusive decision-making, which must engage communities and civil society, and which must ensure coordination with the national COVID-19 response coordinating body or provide other evidence of alignment with the national approach to COVID-19 response in the absence of such a coordinating body;</li> <li>The Board approves that the Secretariat may use up to 4.5% of C19RM funds, representing an increase from the prior ceiling of 3%, to cover additional management and operating costs related to extension of C19RM; and</li> <li>The Board agrees that all other parameters of C19RM under GF/B46/EDP06 remain unchanged.</li> </ol>

<p>The Board:</p> <ol> <li>Approves additional funding for the next implementation period for the grant listed in Table 1 in the amount indicated for such grant, based on the understanding that the amount approved is the upper ceiling rather than the final funding amount for that period and that on-going implementation arrangements for such grant shall be pursued by the Secretariat consistent with the principles of the recommendation set forth in the related Memo submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that the funding for the renewal of such grant shall be committed in annual tranches (GF/B25/DP16, paragraph 7 of Annex 1)</li> <li>Reaffirms that the maximum funding amount available for the next implementation period of such grant shall be the sum of the amount set out in Table 1 below for such grant and the amount of any funds approved for the prior implementation period which have not been utilized during that period, either as undisbursed funds or cash balances held by recipients under the grant</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 6,026,955 for the following grant: MYS-H-MAC</p>

<p>1. The Board: <br /> a. Notes its approval of the Terms of Reference of the Ethics Officer (the "Terms of Reference") (GF/B33/EDP14); <br /> b. Notes the requirement set forth in the Terms of Reference whereby the Audit and Ethics Committee ("AEC") and the Executive Director are to jointly select the Ethics Officer, for appointment by the Board on a no-objection basis; <br /> c. Notes the AEC's delegation of authority to Claude Rubinowicz and Wendy Harrison to jointly select, with the Executive Director, the Ethics Officer for recommendation to the Board (GF/AEC12/EDP02); <br /> d. Recognizes the work of the AEC, the Executive Director and the Secretariat to select a suitable candidate for this position; and <br /> e. Accepts the joint recommendation of the AEC and the Executive Director, as set forth in document GF/B34/ER07.</p> <p>2. Accordingly, the Board: <br /> a. Approves the appointment of Nick Jackson to the position of Global Fund Ethics Officer for a three-year term which can be renewed no more than once; and <br /> b. Authorizes the Secretariat to enter into a contract of employment with Nick Jackson for an annual salary subject to the Amended and Restated Global Fund Human Resources Policy Framework, and requests the Secretariat to proceed with that process pursuant to standard Human Resources procedures. <br /><br /></p>

<p>The Board agrees that the COVID-19 pandemic poses a global public health emergency and that failure to control the pandemic threatens to derail the Global Fund’s mission to fight HIV/AIDS, tuberculosis, and malaria and strengthen systems for health. The Board acknowledges that without immediate action, health facilities, communities and geographies served by Global Fund programs will be severely impacted. As a major actor in global health, the Global Fund is uniquely positioned to deliver rapid support to countries developing responses to control the COVID-19 pandemic. In light of the urgency of the situation, and the need to take swift and decisive action with partners to control the impact of COVID-19 on the Global Fund mission and country health systems, the Board:</p> <ol> <li>Approves the creation of a temporary COVID-19 response mechanism (C19RM) to provide additional support for country responses to the pandemic and to ensure the continuity of the fight against HIV, tuberculosis, and malaria. C19RM will: <ol type="a"> <li>Support the rapid deployment of funds to support implementer countries’ COVID-19 responses, using expedited decision-making approaches determined by the Secretariat and coordinated with partners;</li> <li>Finance interventions consistent with World Health Organization (WHO) guidance on COVID-19 and national Strategic Preparedness and Response Plans, including: <ol type="i"> <li>COVID-19 control and containment interventions, including personal protective equipment, diagnostics, treatment, communications and other public measures as specified in WHO guidance;</li> <li>COVID-19-related risk mitigation measures for programs to fight HIV/AIDS, tuberculosis, and malaria; and</li> <li>Expanded reinforcement of key aspects of health systems, such as laboratory networks, supply chains, and community-led response systems, to address advocacy, services, accountability, and human-rights based approaches;</li> </ol> </li> <li>Finance interventions across the 5th and 6th replenishment periods;</li> <li>Be administered within the established internal control framework of the Global Fund; and</li> <li>Be additional to amounts approved by the Global Fund for programming towards COVID-19 interventions under existing grants.</li> </ol> </li> <li>Approves initial funding for C19RM of up to USD 500 million, comprised of: <ol type="a"> <li>USD 180 million from the USD 300 million of available funds approved by the Audit and Finance Committee on 16 March 2020 under GF/AFC12/DP01; and</li> <li>Up to USD 320 million of additional funds approved as available by the AFC under section E.6 of the Amended and Restated Comprehensive Funding Policy.</li> </ol> </li> <li>Agrees that C19RM funds may be used to procure COVID-19 products approved under the WHO Emergency Use and Listing procedures or under other emergency procedures set up by any Stringent Regulatory Authorities as defined under the Quality Assurance Policy for Pharmaceutical Products and Quality Assurance Policy for Diagnostic Products.</li> <li>Agrees that C19RM is a Board-approved initiative for which the Global Fund may mobilize additional resources from private and public donors, in accordance with existing policy.</li> <li>Agrees that the Secretariat may approve requests for C19RM funds for an initial six-month period through 30 September 2020, and that C19RM funds may be used through 30 June 2021. These dates may be extended by the Board, based on updated information on needs as the pandemic evolves.</li> <li>Requests the Secretariat to further operationalize the investment and management modalities for C19RM, including working with partners to deliver critical technical assistance, ensuring the appropriate involvement of Country Coordinating Mechanisms and alignment with the Global Fund’s underlying principles of gender equity and human rights, and providing the flexibility to take rapid action, including at global and regional level, in close collaboration with WHO and other critical partners, and provide regular reporting to the Board on the operationalization of C19RM, including on any investments made with C19RM funds.</li> </ol>

<ol><li>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard.<br/><br/>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.<br/><br/></li><li>The Board approves a 3-month extension to the deadline for the satisfaction of the following condition in the Yemen Round 3 HIV Grant Score Card[1]:<br/><br/>Within 12 months of Board approval of continued funding, the Principal Recipient shall provide evidence to the Global Fund that it has met at least 80% of the targets for that period contained in the proposal for each of the following indicators:<br/><br/>Number of PLWHA receiving antiretroviral combination therapy; <br/>Number of people receiving VCT; <br/>Number of high risk vulnerable persons reached with IEC activities; <br/>Number of staff trained in behavioral surveillance; and Number of service deliverers trained in IEC, BCC community outreach, VCT, STD, ART, care and support. Should these targets not be met by September 2008, all further funding of this proposal shall cease.<br/><br/>The revised deadline to meet the condition is set at 31 December 2008.<br/><br/><br/>SCHEDULE A<br/><br/>Kosovo, TB – Round 4<br/>Grant Number(s): KOS-405-G01-T<br/>CCM Requested Amount (Total Phase 2 in US$): 1,830,050<br/>Approved Funding Amount (Incremental in US$): 1,830,050<br/>Recommendation Category: Go<br/><br/>Macedonia, TB – Round 5<br/>Grant Number(s): MKD-506-G02-T<br/>CCM Requested Amount (Total Phase 2 in US$): 1,628,608<br/>Approved Funding Amount (Incremental in US$): 1,628,608<br/>Recommendation Category: Go<br/><br/>Malawi, Malaria – Round 2<br/>Grant Number(s): MLW-202-G02-M<br/>CCM Requested Amount (Total Phase 2 in US$): 19,674,096(1)<br/>Approved Funding Amount (Incremental in US$): 18,816,000<br/>Recommendation Category: Conditional Go<br/><br/>Tajikistan, Malaria – Round 5<br/>Grant Number(s): TAJ-506-G04-M<br/>CCM Requested Amount (Total Phase 2 in US$): 2,611,509<br/>Approved Funding Amount (Incremental in US$): 2,611,509<br/>Recommendation Category: Go</li></ol>

<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)^[1].</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 149,519,079 for the following grants: BOL-809-G08-M ; DMR-809-G05-M ; DMR-809-G06-M ; ERT-809-G06-H ; KEN-708-G09-H ; MDG-809-G11-H ; MDG-809-G12-H ; MUS-809-G01-H ; MUS-809-G02-H ; MWP-507-G05-M ; SWZ-809-G07-T ; TAJ-809-G07-H ; TAJ-809-G08-M ; TAJ-809-G09-T</p>

<p>Based on the recommendation of the Ethics and Governance Committee, the Board:</p> <ol> <li>Amends Article 7.1 of the Global Fund Bylaws by deleting the text which states “One Swiss citizen with his or her domicile in Switzerland authorized to act on behalf of the Global Fund to the extent required by Swiss law; and”, and replacing it with the following text: “One representative of the public donors which are not part of a voting donor constituency but have each pledged a contribution of at least $10 million in the current replenishment cycle; and”;</li> <li>Requests that the Secretariat invite the public donors included in the group which are not part of a voting donor constituency but have each pledged a contribution of at least $10 million in the current replenishment cycle to join this new non-voting Board constituency and develop a process for selecting its Board representation in accordance with the Bylaws and the Operating Procedures of the Board and Committees of the Global Fund; and</li> <li>Requests the Donor Voting Group report at the 39th meeting of the Global Fund Board on its revised process for public donor seat allocation, which will ensure that new public donors, who commit to the principles in the Framework Document of the Global Fund and contribute/pledge more than a defined threshold amount for two consecutive replenishment periods, will be integrated into a voting public donor constituency.</li> </ol>

The Board:<br/>Approves extension of the relevant implementation period for each grant listed in Table 2 of Section IV to GF/B34/ER12.

<p>The Board declines approval of additional funding for the Phase 2 period for the Round 6 Sri Lanka TB grant (SRL-607-G08-T).</p><p>See attached table.</p>

Mr Kieran Daly from the Private Foundations constituency is designated as Rapporteur for the 34th Board Meeting.

<p>The Board approves additional funding for two years for the Continuity of Services for the proposal listed in Schedule B and described in Annex 1, with the clear understanding that the amount approved is an upper ceiling rather than a final funding amount, and based on the understanding that the Secretariat shall pursue implementation arrangements for such proposal consistent with the recommendation set forth in Annex 1.</p> <p>See attached tabledetailing total recommended funding amount of 413,096 US$ for the following grant: HTI-304-G04-T</p>

The Board extends the Phase 2 Ending Date of the Kosovo HIV Grant KOS-708-G02-H from 30 September 2013 to 30 June 2014. The Board also changes the Phase 1 Starting Date of the Kosovo TB Grant KOS-911-G03-T from 1 January 2011 to 1 October 2011 and extends the Phase 1 Ending Date from 31 December 2012 to 30 September 2013, and subject to approval of Phase 2 of this Grant, authorizes the extension of the Phase 2 Ending Date from 31 December 2015 to 30 September 2016.

<ul><li>The report of the Sixth Board Meeting is approved. </li></ul>

<ol> <li>The Board recognizes that an effective system of fiduciary control that spans from proposal development through grant implementation is essential to the Global Fund. <br /><br /></li> <li>As such, the Board requests the Secretariat to take the following actions as specified in Part 5.2.i-iv of the Report of the Comprehensive Reform Working Group (CRWG Report) GF/B23/13, and report on its progress and implementation of these actions at the Twenty-Fourth Board Meeting:<br /><br />i. Develop an accountability framework for fiduciary control and risk management;<br /><br />ii. Strengthen the application and enforcement of minimum Principal Recipient requirements;<br /><br />iii. Develop a fully transparent information system and an effective communications strategy; and<br /><br />iv. Develop a calibrated and differentiated response mechanism.<br /><br /></li> <li>Pursuant to Part 5.2.v of the CRWG Report, the Board requests that the Finance and Audit Committee (FAC) review and refine the position and scope of audit and investigation functions, and report on its progress at the Twenty-Fourth Board Meeting.</li> </ol>

#

<p>The Board recognizes the importance of addressing gender issues, with a particular focus on the vulnerabilities of women and girls and sexual minorities, in the fight against the three diseases, more substantially into the Global Fund's policies and operations. </p><p>The Board authorizes the Secretariat as a matter of priority to immediately appoint senior level "Champions for Gender Equality", with appropriate support, who will:</p><p>a. Work with technical partners and relevant constituencies to develop a gender strategy.</p><p>b. As an immediate priority, provide guidance to the Portfolio Committee on revisions to the Guidelines for Proposals for Round 8 to encourage applicants to submit proposals that address gender issues, with a particular reference to the vulnerability of women and girls and sexual minorities.</p><p>The Board requests the Policy and Strategy Committee to review the Gender Strategy and present it to the Board for approval at the Seventeenth Board meeting.</p>

The Board acknowledges that, in developing a roadmap for future collaboration with UNITAID, the Policy and Strategy Committee, working together with the Secretariat and the Finance and Audit Committee, may consider the possibility of UNITAID providing direct funding to third party procurement mechanisms to support Global Fund grants. The Board notes that the roadmap, including the contribution structure and funds-flow mechanism, will be presented to the Board for its approval.

The report of the Eleventh Board Meeting (GF/B12/2) is approved, as amended at the Twelfth Board Meeting.

<p>The Board:</p> <ol> <li>Notes its decision in GF/B46/EDP06, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$45 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020);</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER14; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

<p>It was noted that the draft Global Fund/World Bank agreement had not yet been thoroughly reviewed by the World Bank, and further negotiations would be required. A short, simple agreement for phase one should be quickly drafted and agreed between the World Bank, Secretariat Legal Counsel, and a working group of the Board.</p><p>It was decided that the Chair and Vice Chair establish interim arrangements so that support from WHO would continue.</p><p>It was suggested, and eventually decided that the title of the Working Group on Monitoring and Evaluation be changed to Monitoring, Evaluation, and results-based disbursement.</p><p>Mr. Ritter informed the Board that discussions on establishing a quasi-intergovernmental organization had been initiated with the Swiss Government. The Secretariat is currently waiting for WHO to provide a detailed description of services and costs.</p>

<ol> <li>The Board: <ol type="a"> <li>Welcomes the invitation of the government of the Former Yugoslav Republic of Macedonia to host the Global Fund’s 39th Board Meeting on 9-10 May 2018; and</li> <li>Acknowledges the recommendation set forth in GF/B38/ER07.                              </li> </ol> </li> </ol> <ol start="2"> <li>Accordingly, the Board agrees to convene the 39th Board Meeting in Skopje, Former Yugoslav Republic of Macedonia.</li> </ol>

<ul><li>Recommend approval of the 2003 Secretariat Work Plan and Budget as present in Board Document GF/B4/11.</li></ul><ul><li><b>(Deferred to GF/B4/11 report decisions)</b> Direct the MEFA Committee to review the performance of the Secretariat on the 2003 Work Plan and Budget and report their findings at the June and October meetings of the Board in 2003.</li></ul><ul><li>Direct the MEFA Committee to review the trustee agreement and performance and direct the Secretariat to negotiate new terms and fees for the trustee basedon emerging Global Fund needs.</li></ul>

<p>The Board:</p> <ol> <li>Notes its decision in GF/B44/EDP18, which requires the Secretariat to recommend to the Board, for its approval, any COVID-19 Response Mechanism (“C19RM”) awards exceeding US$35 million, as measured in aggregate by country (not including any funding awarded for COVID-19 commodities through fast-track investments or C19RM funding awarded in 2020), as well as increases to C19RM awards previously approved by the Board that either exceed USD 10 million or include interventions not previously approved by the Board;</li> <li>Approves the funding recommended for each country, as listed in Table 1 of GF/B46/ER03; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper ceiling of funding available for each country among its constituent grants in accordance with the previously approved principles under GF/B44/EDP18.</li> </ol>

The Board endorses the "Draft Paper on a Process to Develop a Policy on Donations of Products and Services" (GF/B14/9, Annex 7) and requests the Chair of the Finance and Audit Committee (FAC), in consultation with the Policy and Strategy Committee (PSC), to constitute the Joint Steering Group on Product and Service Donations as per the parameters outlined in Annex 7 of GF/B14/9. The Board requests the FAC to report back on progress at the Fifteenth Board meeting.

<p>1. The Board acknowledges and commends the call by the UN Secretary General and the Roll Back Malaria (RBM) Partnership to help countries achieve the G8, the World Health Assembly and RBM targets to achieve universal coverage of an essential malaria control intervention package by December 31, 2010. In particular, the Board recognizes the epidemiological rationale set forth by the WHO for a massive scale-up of effective preventive measures to reach these targets. As the largest external financier of malaria programs worldwide, the Board is committed to ensuring that the Global Fund is acting as a key partner, along with others, in this extraordinary public health effort to meet the demand from countries to scale-up their malaria programs.</p><p>2. Given the urgency of the need to devote additional resources and to increase implementation capacities at country level to achieve universal coverage, the Board urges countries to submit ambitious Round 8, Round 9, and Rolling Continuation Channel proposals aimed at scaling up comprehensive malaria control programs (particularly the distribution of long-lasting insecticide treated nets (LLINs) and ACTs) and are linked to broader health systems strengthening.</p><p>3. The Board also urges countries to take advantage of the flexibility offered in Global Fund financing and, if appropriate, to consider revising budgets for existing and new grants and for Phase 2 requests to frontload resources and accelerate implementation and scale-up of LLIN distribution, ACTs and other malaria control interventions.</p><p>4. The Board, recognizing the increased demand from applicants for high quality technical assistance, urges the RBM Partnership to finance and operationalize the Malaria Implementation Support Team to ensure maximum effectiveness of Global Fund resources to achieve universal coverage. </p>

<p>The Board extends the deadline for the signing of grant documentation for the proposals listed in Annex A for three months to 10 February 2011.</p><p>The Board also extends the Phase 2 Period of the AMFm host grant in Uganda (UGD-405-G5-M) until 10 February 2011 and authorizes the host grant activities specified for that grant in Annex A to be implemented.</p>

<p>The Board:</p> <ol> <li>Approves the reinvestment of funds from the TB-HIV grant BFA-C-IPC and the RSSH grant BFA-S-PADS to the malaria grant BFA-M-PADS, as listed in Table 1 of Section IV to GF/B36/ER01 (“Table 1”);</li> <li>Affirms the reinvestment of funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of the grant BFA-M-PADS, (b) decreases the upper-ceiling amount that may be available for the relevant implementation period(s) of the TB/HIV grant BFA-C-IPC and RSSH grant BFA-S-PADS, (c) is subject to the availability of funding, and (d) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <p>Approves additional funding for the Phase 2 period of the Rwanda SSF HIV grant (RWN-H-MOH) in the amount listed in Table 4, subject to relevant clarifications and conditions stipulated by the TRP. The amount approved represents the upper ceiling rather than the final funding amount for the Phase 2 period and on-going implementation arrangements for the grant shall be pursued by the Secretariat consistent with the principles of the recommendations set forth in the related Grant Score Card submitted to the Board and in accordance with Global Fund policies. Approval is also subject to the availability of funding and to the provision that continued funding for the grant shall be committed in annual tranches (GF/B25/DP16, para 7 of Annex 1).</p> <p>See attached tabledetailing total recommended funding amount of USD 150,684,607 for the following grant: RWN-H-MOH</p>

<p><b>Decision Point 1: </b> </p><p>The Board adopts the Resource Mobilization Framework developed by the Finance and Audit Committee, attached as Annex 1 of the Report of the Finance and Audit Committee (GF/B13/9), and requests the Finance and Audit Committee to monitor the implementation of the framework, and its role in guiding the replenishment process, and report regularly to the Board.</p><p><b>Decision Point 2:</b> </p><p>The Board requests the Finance and Audit Committee to keep under review the strategy development process led by the Policy and Strategy Committee as it relates to Resource Mobilization and to develop a longer term resource mobilization policy in the light of the approved strategy.</p>

<p>Daniel Graymore from the United Kingdom constituency is designated as Rapporteur for the 40^th Board Meeting.</p>

<p>The Board notes the initial work undertaken by the Finance and Audit Committee (FAC) to develop a policy for disclosure of reports issued by the Inspector General. The Board notes that the FAC has established a sub-group, composed of the World Bank delegate, the United States delegate and the Inspector General <i>ad interim,</i> supported by the Chief Financial Officer and the Legal Counsel, to continue development of the OIG disclosure policy, in consultation with Deloitte. The Board requests that the FAC, after consultation with the Policy and Strategy Committee, to present its recommendations for the OIG disclosure policy to the Board for approval at the Sixteenth Board Meeting.</p><p>The Board decides that, prior to Board approval of such policy, the Chair, the Vice Chair and the Chair of the FAC, after consulting the Inspector General and the Legal Counsel, shall have the authority to determine public disclosure of OIG reports after they have been made available. </p>

<ol> <li>The Board approves the Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as revised and set forth in Annex 1 to GF/B37/22- Revision 1 (the “Terms of Reference”), which shall enter into force upon the conclusion of the 37th Board Meeting in May 2017.</li> <li>The Terms of Reference shall supersede any and all prior versions of terms of reference of the Board Chair and Vice-Chair previously approved by the Board.</li> </ol>

The Board requests the Portfolio Committee (PC) to oversee the Secretariat's study of the quality assurance status of pharmaceutical products other than anti-retroviral, anti-malaria and anti-tuberculosis medicines. The Secretariat shall present the findings of the first phase of the study to the PC at its 12^th Meeting in September 2009. Based on these findings, the PC may permit the Secretariat to undertake the later stages of the study to explore the possibility of establishing a quality assurance policy for these products. The Board requests the PC to update the Board on the progress of the study at the Board's first meeting in 2010.

<p><span>The Board:</span></p> <ol> <li><span>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B41/ER13 (“Table 1”);</span></li> <li><span>Acknowledges each country’s disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</span></li> <li><span>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</span></li> <li><span>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</span></li> </ol>

The Board delegates its authority to the Finance and Audit Committee to deal with all matters related to the Global Fund Provident Fund.

<p>1. Based on the recommendation of the Audit and Finance Committee, the Board approves<br />the following:<br /><br />a. Corporate Work Plan and Budget Narrative 2017, as set forth in GF/B36/05B; and<br /><br />b. 2017 Operating Expenses Budget in the amount of USD 300.0 million, as set forth<br />in GF/B36/05A, which includes USD 17.1 million for the Office of the Inspector<br />General's 2017 operating expenses.</p>

<p>The Board:</p><ol><li>Declines approval of additional funding for the next implementation period for the Round 10 Jordan TB grant (JOR-011-G04-T).</li></ol><p>Table 1: Secretariat’s Recommendation for Discontinuation of Funding for a Renewal </p><p><i>See attached table.</i></p>

<p>Based on the recommendation of the Strategy Committee, the Board approves the amended and restated Global Fund Quality Assurance Policy for Diagnostic Products, as set forth in Annex 1 to GF/B37/06.</p>

<p>The Board:</p> <p>Approves, in accordance with its decision to launch the transition to the New Funding Model (GF/B28/DP5), incremental funding in the amount listed for the interim-applicant grant in Table 2 (the “Recommended Incremental Funding under the New Funding Model”), which will be in addition to the relevant grant’s total budget amounts that the Board has already approved for the implementation period. The Recommended Incremental Funding under the New Funding Model increases the upper-ceiling amount available for commitment rather than representing the final funding amount for the relevant implementation period, and is subject to the availability of funding and to the provision that the approved funding for the relevant grants shall be committed in annual tranches.</p> <p>See attached table detailing total recommended funding amount of EUR 731,918 for the following grant: MOL-H-PCIMU for Moldova.</p>

<p>Based on the recommendation of the Audit and Finance Committee (AFC), and the recommendation of the Secretariat to supplement the AFC’s recommendation, the Board approves the following:</p> <ol type="i"> <li>the 2023 Work Plan and Budget Narrative, as set forth in GF/B48/02A – Revision 1; and</li> <li>the 2023 Operating Expenses Budget in the amount of US$ 340 million (comprising (i) PART A Secretariat Operating Expenses of US$ 272 million, which includes US$ 16.5 million for the Office of the Inspector General’s 2023 Operating Expenses; and (ii) PART B In-Country and Independent Bodies of US$ 68 million), as set forth in GF/B48/02A – Revision 1.</li> </ol>

<p>1. The Board notes the progress made to date, and authorizes the Secretariat, under the oversight of the Finance and Audit Committee, to proceed with the negotiation and costing of the remaining alternative administrative arrangements as described in detail in the Report of the Finance and Audit Committee to the Fourteenth Board meeting (GF/B14/9).</p><p>2. The Board authorizes the Secretariat to pursue the most beneficial arrangement for providing pension services to the staff. The Board recognizes the need to provide support to these negotiations. </p><p>3. The Board requests the FAC to present the final fully costed implementation plan for decision of the Board at the Sixteenth Board Meeting.</p>

<p>1.  The Board approves all the Round 10 proposals recommended for funding by the Technical Review Panel (TRP) as "Category 1", "Category 2" and "Category 2B", subject to the below provisions. </p><p>2.  The Board approves for funding for an initial two years all those Round 10 proposals recommended for funding by the TRP as "Category 1", "Category 2" and "Category 2B" as listed in Annex 1 of GF/B22/13, subject to paragraphs 3, 4 and 5 below. This includes all Round 10 proposals focusing on Most-at-Risk Populations for HIV/AIDS, which have been submitted under the dedicated reserve referred to in its decision entitled "Prioritization for funding amongst Round 10 TRP-recommended Proposals" GF/B21/DP18 and recommended for funding by the TRP. </p><p>3.  The applicants whose proposals are recommended for funding as 'Category 1' (as indicated in Annex 1 of GF/B22/13) shall conclude the TRP clarifications process, as indicated by the written approval of the Chair and/or Vice Chair of the TRP, not later than eight weeks after the applicant's receipt of notification in writing from the Secretariat of the Board's decision.</p><p>4.  The applicants whose proposals are recommended for funding as 'Category 2', including the subset of proposals identified as 'Category 2B' (as indicated in Annex 1 of GF/B22/13), shall:</p><p>a.  provide an initial detailed written response to the requested TRP clarifications and adjustments by not later than six weeks after the applicant's receipt of notification in writing by the Secretariat of this Board decision; and</p><p>b.  conclude the TRP clarifications process, as indicated by the written approval of the Chair and Vice Chair of the TRP, not later than three months from the Secretariat's receipt of the applicant's initial detailed response to the issues raised for clarification and/or adjustment. </p><p>5.  As required under the Income Level and Cost Sharing Policy, the lifetime grant amount of approved Round 10 proposals that will be implemented in Upper-Middle Income Countries ("UMI Proposals") shall be subject to a collective maximum limit of 10 percent of the lifetime grant amount of all Round 10 approved proposals. The Board notes that this limit will be applied at the time of approving additional commitments for approved Round 10 UMI Proposals. </p><p>6.  The Board declines to approve for funding those proposals recommended by the TRP as 'Category 3', as indicated in Annex 1 of GF/B22/13. These applicants are encouraged to re-submit a proposal in a future funding round after major revision of the proposal. </p><p>7.  The Board declines to approve for funding those proposals recommended by the TRP as 'Category 4', as indicated in Annex 1 of GF/B22/13. </p><p>8.  The Board notes the TRP's request to have additional financial analysis support as part of the clarifications process and requests the Secretariat to make the necessary arrangements.</p><p>9.  Prior to the signing of a grant, the Secretariat will provide confirmation that, as far as can be determined based on data available to the Secretariat, the grant budget is in accord with value for money considerations including unit costs.</p>

<p>The Board approves for funding for an initial two years those Round 8 proposals recommended for funding by the Technical Review Panel (TRP) and identified as ‘Category 2B’ proposals with composite index 6 and as listed in the following table, subject to Decision Point GF/B18/DP13 and paragraph 5 of Decision Point GF/B18/DP14. </p>

<p>Recognizing the continued role of the Technical Evaluation Reference Group (TERG) in the follow-up to the Five Year Evaluation (5YE), as part of the TERG mandate to provide independent advice, assessment and oversight for the Global Fund's work on monitoring and evaluation (M&amp;E), the Board:</p> <p>1. welcomes the findings and recommendations included in the Study Area (SA) 3 Report and in the Synthesis Report of the 5YE, as summarized in the TERG Report (GF/B19/10);</p> <p>2. endorses the TERG's call for action for the Global Fund to work with partners to strengthen country monitoring and evaluation, and information systems for performance and impact, to build analytical capacity in countries and to support development of country-owned impact evaluation platforms;</p> <p>3. requests the Secretariat to articulate a process and timeline for responding to and implementing the recommendations set out in SA3 and the Synthesis Report by 15 June 2009, and to report to the Board at its Twentieth Meeting, through the Policy and Strategy Committee (PSC), on the Secretariat's progress in responding to recommendations contained in the SA1, SA2, SA3 and Synthesis Reports, as well as the TERG recommendations in relation to these reports;</p> <p>4. requests the Chair of the Board, in consultation with Committee Chairs, to set up a small ad-hoc committee by 30 June 2009 with the specific task of assisting the Board, through the PSC, to (i) follow-up on, and formulate the Board's responses to the 5YE recommendations, and (ii) further define the role of the TERG in relation to independent evaluations, the resources required and Board oversight of the process.</p> <p>This decision supersedes the Board Decision (GF/B18/DP21).</p>

<p><b>Decision Point 1:</b> </p><p>The Board decides to refer the Honduras Round 1 HIV proposal back to the CCM for further processing as a Revised Request for Continued Funding.</p><p><b>Decision Point 2:</b> </p><p>The Board decides to refer the Senegal Round 1 HIV proposal back to the CCM for further processing as a Revised Request for Continued Funding.</p>

<ol> <li>Bearing in mind its fiduciary responsibilities:<br /><br /> <ol> <li>The Board welcomes and accepts the offer of the World Health Organization (WHO) to assign, with immediate effect, its Director, Office of Internal Oversight Services (lOS) to lead temporarily the Global Fund's Office of the Inspector General (OIG) for a period of four to six months. This arrangement will be reviewed at the Fifteenth Board meeting in April 2007.<br /><br /></li> <li>The Board approves the engagement by the Director, lOS of an external contractor to provide substantive support in accordance with the scope of work outlined in Part 3 of the Joint Report of the Chairs of the Finance and Audit Committee and the Performance Assessment Committee, presented at the Special Board Meeting held on 8-9 February 2007 (GF/SBM1/5), which may be modified by the Chair and Vice Chair based on input from the Director, lOS. <br /><br /></li> <li>The Board is satisfied that these actions will result in the immediate reestablishment of an effective OIG function to fulfill the Global Fund's immediate assurance requirements. <br /><br /></li> </ol> </li> <li>The Board requests the Finance and Audit Committee to submit, at the Fifteenth Board meeting in April 2007, recommendations with respect to clarifying the role, remit and priorities of the OIG, documenting an overall assurance framework for the Global Fund, reviewing and clarifying the reporting lines, relationships and options for resourcing of the OIG and defining an Action Plan, including terms of reference, selection criteria and provision for candidate review by experts in internal audit and other relevant areas, for the recruitment of the next Inspector General.<br /><br /></li> <li>The recruitment process shall be launched upon approval at the Fifteenth Board meeting in April 2007, and shall result in the appointment of a new Inspector General not later than 31 July 2007.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B46/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>The Board:</p> <p>1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER19 (“Table 1”);</p> <p>2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</p> <p>3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</p> <p>4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP. </p>

The Board approves the 2005 Financial Statements of the Global Fund which have been audited by Ernst &amp; Young, attached as Annex 7 to the Report of the Finance and Audit Committee (GF/B13/9).

<p>The Board decides that the following criteria apply to the Appeal Panel which reviews appeals of funding decisions with respect to the Rounds-based and Rolling Continuation Channels:</p><p>a. the Appeal Panel shall be comprised of five experts, including three nominated by the Stop TB Partnership, Roll Back Malaria Partnership and UNAIDS, in close collaboration with WHO tuberculosis, HIV/AIDS and malaria departments (collectively, the "Independent Members") and two who are TRP members;</p><p>b. the Independent Members may serve on the Appeal Panel for two consecutive years; and</p><p>c. commencing from Round 8, employees of the United Nations and its specialized agencies are ineligible to serve as members of the Appeal Panel.</p>

The Board approves the amendments to the document entitled "Global Fund Policy on Secretariat Procurement of Goods and Services" (approved at the Fifth Board Meeting and presented as Annex 4 to GF/B5/8) as presented in Annex 6 to the Report of the Finance and Audit Committee (GF/B14/9).

The Board notes with concern the questions raised by the Ethics Committee on existing Secretariat secondment practice, and requests that the Ethics Committee undertake a review the Secretariat policy on secondments and associated conflict of interest issues and report back to the Board at the Fourteenth Board meeting.

<p>The Agenda is adopted with the following amendments: Fiduciary Arrangements will be presented before Monitoring and Evaluation Strategy on Day 1; Day 2 will begin at 8:00 a.m.; delete tracking study from the agenda.</p>

<p>The Board will recognize and accept that all constituencies have interests and that these may lead to potential, actual and perceived conflicts of interest. Article 14 of the By-Laws makes provision for a policy on this matter to be established. To ensure fairness in the Board’s decision-making and to protect the Fund’s interests, the Board adopts the Policy on Ethics and Conflict of Interest, which applies to all Board members and other interested persons (including, but not limited to, alternates, members of any Committee, expert panel, Technical Review Panel, and employees of the Secretariat including the Executive Director). This policy is based on clear definitions of potential areas of conflict, a duty to disclose, and a mechanism for managing conflicts as they arise.</p><p>The Policy on Ethics and Conflict of Interest is adopted subject to refinement as appropriate based on legal review, and applies to all activities from here on including consideration of Round 2 proposals. This policy currently applies to both personal and institutional conflicts. Subsequent review should focus attention on institutional conflicts, and the differentiation between personal and institutional conflicts of interest.</p>

<ol> <li>The Board approves the appointment of:<br /> <ol type="i"> <li>Edward Ouko as Chair of the Audit and Finance Committee:</li> <li>Sylvie Chantereau as Vice-Chair of the Audit and Finance Committee:</li> <li>Paul Schaper as Chair of the Ethics and Governance Committee</li> <li>Julia Martin as Chair of the Strategy Committee</li> <li>Carolyn Gomes as Vice-Chair of the Strategy Committee</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Revanta Dharmarajah, Developed Country NGOs</li> <li>Andriy Klepikov, Developing Country NGOs</li> <li>Sara Osman, Eastern Mediterranean Region</li> <li>Birgitte Hagelund, European Commission, Belgium, Italy, Portugal and Spain</li> <li>Hiroshi Matsumura, Japan</li> <li>Andreas Karlberg Pettersen, Point Seven</li> <li>Greg Ferrante, Private Foundations</li> <li>Erika Satterwhite, Private Sector</li> <li>Rai Mahimapat Ray, South East Asia</li> <li>Michael Ruffner, the United States of America</li> <li>Daniel Domelevo, West and Central Africa</li> <li>Jiayan Huang, Western Pacific Region</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as non-voting members of the Audit and Finance Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Aisha Al Kuwari, Additional Public Donors</li> <li>Alexandru Chitic Patapievici, the World Bank</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve in their personal capacity as voting members of the Ethics and Governance Committee:<br /> <ol type="i"> <li>Erika Castellanos, Communities</li> <li>Edellin Calixte Randriamiandrisoa, Eastern and Southern Africa</li> <li>Miŝo Pejkovic, Eastern Europe and Central Asia</li> <li>Mohamed Chakroun, Eastern Mediterranean Region</li> <li>Sarah Burwood, France</li> <li>Annette Chammas, Germany</li> <li>Roisin Fegan, the United Kingdom</li> <li>Anthony (Jin) Park, the United States of America</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as voting members of the Strategy Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Timothy Poletti, Canada, Switzerland and Australia</li> <li>Javier Hourcade Bellocq, Communities</li> <li>Gerald Gwinji, Eastern and Southern Africa</li> <li>Tonka Varleva, Eastern Europe and Central Asia</li> <li>Stéphanie Seydoux, France</li> <li>Birgit Pickel, Germany</li> <li>Hampus Holmer, Point Seven</li> <li>Sherwin Charles, Private Sector</li> <li>Sarah Boulton, the United Kingdom</li> <li>Massimo Ghidinelli, Latin America and the Caribbean</li> <li>Djalo Boukou Oumar Mele, West and Central Africa</li> <li>Jim Tulloch, Western Pacific Region</li> </ol> </li> <li>The Board approves the appointment of the following individuals to serve as non-voting members of the Strategy Committee, representing the Board constituency listed by their name:<br /> <ol type="i"> <li>Melanie Renshaw, Partners</li> <li>Victor Bampoe, UNAIDS</li> <li>Mubashar Sheikh, World Health Organization</li> </ol> </li> <li>The Board notes that the Chairs of the Technical Review Panel and the Technical Evaluation Reference Group (to be succeeded by the Independent Evaluation Panel pursuant to Board decision GF/B46/DP06) also serve as non-voting members of the Strategy Committee.</li> <li>The Board further notes that each of the individuals named in this decision will commence their term on 13 May 2022 and will serve for two years or until appointment of their successor.</li> </ol>

<p>Based on the recommendation of the Audit and Finance Committee, the Board approves the:</p> <ol> <li>2022 Work Plan and Budget Narrative, as set forth in GF/B46/02; and</li> <li>2022 Operating Expenses Budget in the amount of US$ 322.2million, as set forth in GF/B46/02 (the “2022 OPEX Budget”), which includes (i) US$ 65.5 million for in-country and external assurance activities, as described in GF/B46/02, and (ii) US$ 14.9 million for the Office of the Inspector General’s 2022 operating expenses.</li> </ol>

The agenda for the Sixteenth Board Meeting (GF/B16/1 Revision 2) is approved.

The Board acknowledges that the condition upon which the Board approved continued funding to Gabon Round 5 Malaria grant (GAB-509-G04-M) to the Ministry of Health and Public Hygiene of Gabon required the Principal Recipient to achieve a satisfactory level of performance within sixteen months of signature of the Phase 2 Grant Agreement. Recognizing that the condition has not been fulfilled, the Board decides to discontinue funding for the remaining period of the grant and requests the Secretariat to close out the grant in accordance with its delegated authority for Grant Closure Activities (GF/B17/DP6).

<p>1. The Board approves the following amendments to the fourth paragraph of Article 7.6 of the Bylaws: </p><p>Notwithstanding the foregoing, the Board may decide to take action on a no-objection basis. On such basis, and subject to procedures set by the Board, a motion shall be deemed approved unless four Board members of one of the voting groups described above objects to the motion, except that a motion not to make a renew funding for a proposal beyond the initial funding commitment shall be deemed approved unless four Board members of each of the voting groups described above object to the motion. </p><p>2. The Board approves the following amendments to Article 12 of the Board Operating Procedures:</p><p>"<b>Article 12. No-Objection Process for Approving Funding </b></p><p>Notwithstanding Sections 10 and 11, decisions by the Board to provide funding for approved proposals beyond the initial funding commitment or proposals requesting continued funding for grants that are reaching the end of their funding terms may be made on a no-objection basis under the following process.</p><p>As directed by the Board, the Secretariat shall issue a request for decision on each funding commitment for which a Board decision is required, and shall notify the Board accordingly. Unless four Board members of one of one of the voting groups described in Section 10 object to the requested decision within a time period specified by the Board following the date of notification the requested decision shall be deemed approved by the Board, except that a requested decision not to make a renew funding of a proposal beyond the initial funding commitment shall be deemed approved by the Board unless four Board members of each of the voting groups described in Section 10 object to the recommendation within a time period specified by the Board following the date of notification."</p>

<ul type="disc"><li>The agenda for the Seventh Board Meeting is approved with the following amendments:</li></ul><div type="disc" style="margin-left: 2em;"><ul type="circle"><li>Prioritization in Resource Constrained Environments is moved to Friday 19 March</li></ul></div><div type="disc" style="margin-left: 2em;"><ul type="circle"><li>A closed Executive Session will held at the end of the first day (18^thMarch) as well as the beginning of the second day (19^thMarch)</li></ul></div><div type="disc" style="margin-left: 2em;"><ul type="circle"><li>The approval of the Annual Report has been removed from the agenda. Approval will occur via email in the beginning of April 2004.</li></ul></div>

<ol> <li>The Board approves the appointment of Ms Shirley Carruthers, representing the Canada, Switzerland and Australia Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> <li>The Board approves the appointment of Mr Chimi Dorji, representing the South East Asia Constituency, as a voting member of the Audit and Finance Committee for a term that will expire in May 2022, or until the appointment of his successor.</li> <li>The Board approves the appointment of Ms Nathalie Olijslager, representing the Point Seven Constituency, as a voting member of the Ethics and Governance Committee for a term that will expire in May 2022, or until the appointment of her successor.</li> </ol>

The Board acknowledges that additional time is required for the Phase 1 implementation period for the Tanzania Round 7 Malaria grant (TNZ-708-G10-M) in order to allow the grant to be consolidated with the Round 9 grant into a Single Stream of Funding and to ensure that AMFm activities are not interrupted during this time. The Board therefore approves the extension of the Phase 1 period for the Round 7 malaria grant (TNZ-708-G10-M) by an additional 3 months until 31 March 2011 without committing additional funding for the Phase 1 period.

<p>The Board:</p> <ul> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Attachment 1 to GF/B32/ER01.</li> </ul>

<p>The Board adopts the requirements and recommendations as proposed in Annex 3a, and treats all requirements in this document as recommendations, in order to improve the functioning of Country Coordinating Mechanisms as public-private partnerships of all relevant stakeholders.</p><p>With regards to HIV/AIDS, coordination efforts should be done within the overall framework of the "Three Ones".</p><p>The Board decided to table Option 1 of Recommendation 9.</p><p>The Board decided to replace Recommendation 13 with the following:</p><ul><li>The Board takes note of the recommendation contained in the reports of GPC, MEFA and TRP concerning the need to strengthen technical assistance and capacity development. Considering the urgency and cross-cutting nature, the Board recommends the formation of a special Ad Hoc Working Group to assess needs and make policy recommendations to facilitate the provision of technical assistance and capacity development for and through Country Coordinating Mechanisms, Principal Recipients, Sub-Recipients, inclusive of all phases of the Fund's grant cycle. The Ad Hoc Working Group will present recommendations for approval at the Ninth Board Meeting.</li></ul><p>The Board decided to replace Recommendation 15a with the following:</p><ul><li>The Board further directs the Secretariat, in consultation with the TERG, to develop a pilot set of auditable standards for benchmarking the performance of CCMs and report back through the GPC by the Ninth Board Meeting.</li></ul>

The Board delegates to the Portfolio Committee the authority to approve the guidelines and proposal forms for each future funding opportunity under both the Rounds-Based Channel and the Rolling Continuation Channel. 

<p>1. The Board is asked to approve for funding proposals recommended by the Technical Review Panel and according to the categories listed below, with the clear understanding that budgets requested are upper ceilings rather than final budgets and the Secretariat will report to the Board the results of the negotiations with the Principal Recipient on the final budget for acknowledgement.</p><ul><li><b>Category 1</b>: Recommended proposals with no or minor modifications, which should easily be answered within 6 weeks and given the final approval by the TRP Chair and Co-Chair.</li><li><b>Category 2</b>: Recommended proposals provided clarifications are met within a limited timeframe (6 weeks for the applicant to respond, at most 6 months to obtain the final TRP approval should further clarifications be requested). The primary reviewer, secondary reviewer as well as TRP Chair and /or Co-Chair need to give final approval.</li><li><b>Category 3</b>: Not recommended in its present form but strongly encourage to re-submit.</li><li><b>Category 4</b>: Not recommended for funding.</li></ul><p>2. The Board is asked to acknowledge the lessons learnt of the Secretariat and the TRP during this process and allow adequate measures to be taken to improve Round 3. </p>

The Board:<br/>1. Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B33/ER18 (collectively, "Table 1");<br/>2. Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Tables 1a and 1b, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;<br/>3. Approves the additional funding for the Zimbabwe HIV Program and its resultant total program budget, as listed in Table 1c of Section IV to GF/B33/ER18;<br/>4. Approves the reinvestment of within-allocation efficiencies for the Bangladesh malaria and Cote d'Ivoire malaria grants and their resultant total program budget, as listed in Table 2 of Section IV to GF/B33/ER18;<br/>5. Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and<br/>6. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.<br/>This decision does not have material budgetary implications for the 2015 Operating Expenses Budget.

<ul type="disc"><li>Ms. Lucia Fiori from the Italian Constituency is designated as Rapporteur for the Ninth Board Meeting.</li></ul>

1. The Board acknowledges the 2017 - 2022 Strategic Key Performance Indicator Framework (the "Strategic KPI Framework"), as presented in Annex 1 to GF/B35/ER05, and the additional methodological work required to set performance targets.<br/>2. Accordingly, the Board approves the Strategic KPI Framework and directs the Secretariat to present the Board with the Strategic KPI Framework's performance targets for approval at the final Board meeting in 2016.

<p><b>Decision Point 1:</b> </p><p>The Board approves the composition of the Executive Director Nomination Committee to be composed of Carol Jacobs, Lieve Fransen, Carsten Staur, Carol Presern, Jimmy Kolker, Peter Van Rooijen, Urbain Olangena Awono and Ren Minghui.</p><p><b>Decision Point 2:</b> </p><p>The Board decides that the Executive Director Nomination Committee shall operate under the following terms of reference:</p><p>1. The Nomination Committee shall assist the Board with the selection of the next Executive Director of the Global Fund under an Action Plan approved by the Board. To that end, it shall:</p><p>- select an executive search firm, based on a competitive process;</p><p>- guide recruitment based on the criteria for selection of the Executive Director that were approved by the Board; and</p><p>- oversee the search process.</p><p>2. The Nomination Committee shall present a list of 5 candidates to the Board, giving reasons for their assessments which should include the extent to which each candidate fulfils the relevant selection criteria and the candidate's ability to perform the duties of the Executive Director as outlined in the Terms of Reference. </p><p>3. The Nomination Committee shall prepare a decision making process for the Board on the selection of candidate at the Fourteenth Board meeting.</p><p>4. Membership in the Committee shall not count towards the two-committee limit set forth in Section 23 of the Board Operating Procedures.</p>

#

<p>The Board approves additional funding for the Phase 2 period for the proposals listed in Schedule A in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue ongoing implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Scorecard. Approval is also subject to paragraph 3.c. of the revised Comprehensive Funding Policy <span>(GF/B20/DP9).</span>⁷</p> <p>The Board reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</p> <p>See attached tabledetailing total recommended funding amount⁸ of US$ 56,930,178 for the following grants: CIV-607-G07-T ; ETH-607-G06-T ; EGY-608-G03-H ; GNB-607-G04-M ; MKD-708-G03-H ; SRL-607-G09-H ; SRL-607-G07-T ; ZIM-509-G09-M</p>

<p>The Board recognizes that the Global Fund should be guided by a strategy that reflects the principles in the Global Fund's Framework Document. The work on developing the next strategy should be based on the six broad objectives discussed at the Global Fund Board Retreat on 10 - 11 December 2010 and outlined in the Chair's summary of the Board Retreat (GF/B22/19) and the final report of the Board Retreat.</p><p>The Board decides that the next strategy will cover the period up to the end of 2016, with a mid-point review in 2014. </p><p>The strategy will be a concise, high level document setting out the broad strategic direction of the Global Fund (the "Strategy Document"), with further details captured in an accompanying implementation plan (the "Implementation Plan"). The strategy will take into account the action plan of the reform working group.</p><p>The Policy and Strategy Committee (PSC) will steer the strategy development work and make recommendations to the Board. The Secretariat will be actively involved in the development of and deliberations on the strategy, and will also ensure that any necessary content development work is carried out. </p><p>The Board requests the PSC to develop a complete draft of the Strategy Document including objectives, targets, and strategic initiatives for discussion at the Board meeting in May 2011. The Secretariat shall then develop the Implementation Plan for the strategy. The PSC shall seek appropriate input on the strategy at the Fourth Partnership Forum (in consultation with the Partnership Forum Steering Committee, which shall advise on the nature of such input). The final Strategy Document and its Implementation Plan shall be approved at the Board meeting at the end of 2011.</p>

H.E. Dr Leslie Ramsammy from the Latin America and Caribbean constituency is designated as Rapporteur for the Nineteenth Board Meeting.

Mr. Alvaro Bermejo from the Developed Country NGO constituency is designated as rapporteur for the Twenty-Fifth Board Meeting.

<ul><li>Current numbers of Board delegates from recipient countries,NGO's and Communities Living With the Diseases offered funding by the Secretariat for travel should be maintained.</li></ul><ul><li>Class of air travel guided by the current Secretariat travel policy and consistent with the WHO policy on class of air travel should be continued with emphasis placed on using the most economical available fares within those policies.</li></ul>

<p>The Global Fund's constituency based governance model is core to the organization's identity as a public private partnership. The Board reiterates its support for this model and stresses that its effective functioning requires active and informed engagement by all constituencies. </p><p>To further facilitate the engagement of the Board constituencies of the implementing voting group in the Global Fund's governance processes, the Board decides to make available, on an annual basis, funds to these constituencies for communication, meeting, travel and staff costs incurred for intra-constituency functions, as specified in the Board Constituency Funding Policy (GF/B20/4 Annex 3).</p><p>The Board decides that each implementing constituency application in accordance with paragraph 8 of GF/B20/4 Annex 3 should be limited to US$ 80,000 for 2010. Exceptions to this ceiling may be permitted by the Secretariat, in consultation with the Chair of the Policy and Strategy Committee, and within the overall funding ceiling approved by the Board.</p><p>The Board delegates oversight of the Board Constituency Funding Policy to the Policy and Strategy Committee and requests the Secretariat to provide that committee with periodic reports on its impact on constituency participation, particularly in view of possibilities for joint action with UNAIDS and other relevant partners in this area. The first such report to the PSC should be at its first meeting in 2011. </p>

<p>The Board:</p> <ol> <li>Approves the incremental funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of Attachment 1 to GF/B31/ER26 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with the Global Find policies;</li> <li>Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country disease component’s constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol> <p>Table 1: Secretariat’s Funding Recommendation on Additional Funding from the 2014 Allocation. (see attached: Moldova, HIV/AIDS, MDA-H-PAS, MDA-H-PCIMU).</p>

The Board approves the appointment of the Latin America and Caribbean Constituency as a member of the Ethics Committee until the adjournment of the Twenty-Third Board Meeting.

<p>The Board acknowledges its previous decision establishing the Global Fund COVID-19 Response Mechanism (C19RM) and agrees that the COVID-19 pandemic continues to have a devastating impact on global health systems, jeopardizing the fight against HIV, tuberculosis, and malaria and progress towards 2030 goals for the three diseases. Recognizing the acute needs at country-level, and the threat of diversion of resources towards COVID-19, the Board agrees that additional funding to support country responses to COVID-19 is necessary to safeguard the USD 14 billion raised through the 6th replenishment for HIV, tuberculosis, and malaria (HTM) programs. The Board further acknowledges that certain public donors wish to make significant additional pledges to the Global Fund to provide further support for country responses to COVID-19 and that this decision does not preclude further discussion and Board decisions within the Strategy development process on the future role and scope of Global Fund support for pandemic preparedness and response.</p> <p>The Board agrees that C19RM should leverage existing Global Fund processes, controls, and frameworks, while acknowledging that modifications may be necessary to ensure the level of speed and agility necessary for an emergency response. The Board further agrees on the need for greater transparency on the operationalization and implementation of C19RM, to facilitate and ensure an appropriate degree of oversight from, and accountability to, the Board.</p> <p>The Board therefore approves the following:</p> <p>1. Timelines:</p> <ol type="a"> <li>C19RM is a temporary, timebound mechanism established to address the current global emergency related to the COVID-19 pandemic;</li> <li>The Secretariat will, through 31 December 2021, continue to mobilize additional funds from public donors and, pursuant to existing policies, private donors, which will be used to support C19RM;</li> <li>C19RM funds may be awarded through 31 March 2022;</li> <li>C19RM will continue to finance interventions across the 5th and 6th replenishment periods; and</li> <li>While C19RM funding is expected to be used rapidly for emergency needs, the final deadline for use of C19RM funds will be 31 December 2023, to reduce the additional cost and burden associated with establishing and monitoring an independent deadline within core grants.</li> </ol> <p>2. Use of funding:</p> <ol type="a"> <li>C19RM funding will finance interventions consistent with applicable World Health Organization (WHO) guidance, including on COVID-19;</li> <li>C19RM funding must be aligned with national Strategic Preparedness and Response Plans;</li> <li>C19RM funding may be used for the following types of interventions: <ol type="a"> <li>COVID-19 control and containment interventions, including personal protective equipment, diagnostics, treatment, communications and other public measures as specified in WHO guidance;</li> <li>COVID-19-related risk mitigation measures for programs to fight HTM (including, but not limited to, support for COVID-19 interventions needed to safely implement campaigns, community and health facility level HTM programs, and additional delivery and procurement costs for HTM programs where related to addressing COVID-19 disruptions); and</li> <li>iii. Expanded reinforcement of key aspects of health systems, such as laboratory networks, supply chains, and community-led response systems, to address advocacy, services, accountability, and human rights based approaches;</li> </ol> </li> <li>C19RM funds may be used to procure COVID-19 products approved under the WHO Emergency Use and Listing procedures or under other emergency procedures set up by any Stringent Regulatory Authorities as defined under the Quality Assurance Policy for Pharmaceutical Products and Quality Assurance Policy for Diagnostic Products; and</li> <li>The Secretariat will develop detailed technical guidance on eligible C19RM interventions for countries, in consultation with relevant partners, as described in paragraphs 27.a and 44 of GF/B44/ER12 – Revision 2.</li> </ol> <p>3. Allocations:</p> <ol type="a"> <li>C19RM funding awards will use countries’ 2020-2022 allocations as a starting basis; and</li> <li>C19RM funding awards will be qualitatively adjusted to better reflect countries’ COVID-19 needs using the following factors: (i) COVID-19 burden; (ii) level of disruption to systems of health, including HTM services; (iii) availability of other sources of funding; and (iv) utilization of funds already awarded.</li> </ol> <p>4. Funding requests:</p> <ol type="a"> <li>C19RM funding requests must be endorsed by Country Coordinating Mechanisms;</li> <li>C19RM funding requests must be developed through appropriate, multisectoral consultation, and fully-inclusive decision-making, which must engage communities and civil society, and ensure coordination with the national COVID-19 response coordinator;</li> <li>C19RM funding request development must include consideration of appropriate community, rights, and gender-related interventions, in alignment with the Global Fund’s underlying principles of gender equity and human rights, and funding requests must articulate national HTM program adaptation needs and how these needs will be covered (e.g. through C19RM funding, grant funding, or other sources); and</li> <li>The Board calls on partners to support countries at the country, regional and global levels to develop robust, technically-sound C19RM funding requests.</li> </ol> <p>5. C19RM Funding Request Review and Approval:</p> <ol type="a"> <li>GAC: <ol type="i"> <li>C19RM funding requests will be shared with partners on the Grant Approvals Committee (GAC) for review and input;</li> <li>C19RM funding requests will also be shared with a technical advisory group composed of relevant ACT-Accelerator partners with technical COVID-19 expertise (CTAG) for review and input;</li> <li>iii. The Secretariat will consider input from GAC partners and CTAG in determining C19RM funding awards or recommendations; and</li> <li>The Secretariat will convene regular GAC review of C19RM to discuss awards made, emerging thematic issues relating to C19RM and Global Fund programs, and concerns and observations from partners. CTAG partners will be invited to participate in these reviews.</li> </ol> </li> <li>TRP: <ol type="i"> <li>The TRP will be requested to input into upfront technical guidance relating to HTM adaptations/risk mitigation as referenced in paragraph 2.e above; and</li> <li>The TRP will also be requested to conduct an expedited review of HTM program adaptation/risk mitigation elements of C19RM funding requests that entail material changes to existing Global Fund programs.</li> </ol> </li> <li>Fast-track investments: The Secretariat may award countries up to USD 900 million of C19RM funding on an accelerated basis to support urgent needs for COVID-19 commodities (including personal protective equipment, diagnostics, and therapeutics) and costs relating to the effective deployment of such commodities.</li> <li>Board approval: <ol type="i"> <li>The Board must approve any C19RM awards exceeding USD 35 million, as measured in aggregate by country and not including any funding awarded pursuant to paragraph 5.c above or previously awarded C19RM funding;</li> <li>Commodity orders relating to paragraph 5.d.i above may be placed pending Board approval; and</li> <li>iii. For C19RM awards approved by the Board, the Secretariat will have delegated authority to increase such awards by up to USD 10 million, in order to avoid the need for repeated Board approvals for increases to the same grants. This authority will be limited to increases that scale up interventions previously approved by the Board.</li> </ol> </li> </ol> <p>6. Reporting, Monitoring and Evaluation:</p> <ol type="a"> <li>The Board emphasizes the need for comprehensive reporting, monitoring and evaluation of C19RM investments, while acknowledging the challenges of measuring results within an emergency response to a rapidly evolving pandemic. The Secretariat and TERG will further develop an evaluation approach for C19RM, as described in paragraphs 50 - 56 of GF/B44/ER12 – Revision 2. This approach will be presented to the Strategy Committee at its 16th meeting (July 2021) for review and input;</li> <li>The Board emphasizes the need for enhanced transparency on C19RM. The Secretariat will provide monthly detailed reporting to the Board on C19RM operationalization, as described in paragraph 21 of GF/B44/ER12 - Revision 2. This reporting will also be available on the Global Fund’s external website to increase transparency of investments and support coordination of external support for COVID-19; and</li> <li>The Secretariat will continue to provide updates through regular Board and Committee engagements.</li> </ol> <p>7. Centrally Managed Investments</p> <ol type="a"> <li>Up to 2.5% of C19RM funding may be used for centrally managed investments to address needs that are not well addressed through awards to individual countries, as described in paragraph 57 of GF/B44/ER12 – Revision 2; and</li> <li>The Secretariat will develop any centrally managed investments under this provision in coordination with GAC and CTAG, and will report all such investments to the Board and its relevant Committees.</li> </ol> <p>8. Management and Operating costs</p> <ol type="a"> <li>Up to 3% of C19RM funds may be used by the Secretariat to cover additional management and operating costs relating to C19RM. These costs may include (i) additional Secretariat resources and expertise, (ii) additional assurance costs, (iii) additional costs relating to enhanced reporting and monitoring and evaluation of C19RM investments, and (iv) additional costs to support CCMs;</li> <li>Management and operating costs under this provision are timebound, reflecting the temporary nature of C19RM, and will not form part of the Secretariat’s annual budget for operating expenditures;</li> <li>The Audit and Finance Committee will review the Secretariat’s plan for costs under this provision; and</li> <li>The Secretariat will provide regular reporting on any costs under this provision to the Audit and Finance Committee and the Board.</li> </ol> <p>9. Additional changes:</p> <ol type="a"> <li>The Board will monitor C19RM on an ongoing basis to determine whether any changes are required as the pandemic continues to evolve; and</li> <li>The Secretariat will return to the Board, through its Committees, as relevant, for additional consideration and approval of any further modifications to C19RM.</li> </ol> <p>10. Limited exceptions to Quality Assurance Policies:</p> <ol type="a"> <li>The Secretariat may continue to grant limited exceptions to the Quality Assurance Policies to waive the requirement for pre-shipment sampling and testing (as originally approved under paragraph 3 of GF/B42/EDP10) through 31 March 2022.</li> </ol>

<p>Based on the recommendation of the Strategy Committee (the “SC”), as presented in GF/B41/03 - Revision 1, the Board:</p> <ol> <li>Acknowledges that the total amount of sources of funds for allocation for the 2020-2022 allocation period will be decided by the Board in November 2019, based on the recommendation of the Audit and Finance Committee following announced replenishment results from the 6th Replenishment;</li> <li>Approves that the total amount of funding for catalytic investments in the 2020-2022 allocation period, as described in the Allocation Methodology approved under GF/B41/DP03, will be determined by the total amount of sources of funds for allocation for the 2020-2022 allocation period;</li> <li>Approves catalytic investments for the 2020 – 2022 allocation period as set forth in the scenarios described below: <ol type="i"> <li>USD 900 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are greater than or equal to USD 13.1 billion, USD 900 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 1 of Annex 1 of GF/B41/03 - Revision 1 (“Annex 1”);</li> <li>USD 800 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 13.1 billion and greater than or equal to USD 12.1 billion, USD 800 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 2 of Annex 1;</li> <li>USD 600 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 12.1 billion and greater than or equal to USD 11.1 billion, USD 600 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 3 of Annex 1;</li> <li>USD 400 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 11.1 billion and greater than or equal to USD 10.6 billion, USD 400 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 4 of Annex 1; and</li> <li>USD 200 million scenario: If sources of funds for allocation for the 2020 – 2022 allocation period are below USD 10.6 billion and greater than or equal to USD 10.1 billion, USD 200 million will be made available for catalytic investments, in accordance with the priorities and associated costs set forth in Table 5 of Annex 1.</li> </ol> </li> <li>Requests the Secretariat to return to the SC with a new recommendation on catalytic investments if sources of funds for allocation for the 2020 – 2022 allocation period are below USD 10.1 billion, for SC recommendation to the Board;</li> <li>Agrees that in the event that sources of funds for allocation for the 2020-2022 allocation period are above the midpoint of the funding range specified for a scenario above, the Secretariat may recommend the Board to approve an additional total amount up to USD 100 million for catalytic investments, to be invested in the priority areas for the scenario immediately preceding the applicable scenario in the list above;</li> <li>Requests the Secretariat to (i) implement a rigorous approval process for all catalytic investments, including strategic initiatives, by a review body with clear and transparent management of conflicts of interest to maintain the integrity of decision making, whether financial or programmatic; (ii) execute a credible, robust technical review process on the activities, mechanisms, and the requested amounts; and (iii) report regularly to the SC on all catalytic investments; and</li> <li>Notes the Secretariat will (i) have flexibility to operationalize catalytic investments; (ii) update the SC and Board on such operationalization; (iii) have flexibility to reallocate associated costs among the approved priorities under any applicable scenario, within 10% of the approved amount of associated costs for a specific priority; and (iv) present any reallocations of associated costs exceeding 10% for a specific priority for the SC’s approval.</li> </ol>

<p>The Board:</p> <ol> <li>Approves the funding recommended for each country disease component, and its constituent grants, as listed in Table 1 of GF/B44/ER01 (“Table 1”);</li> <li>Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li> <li>Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and</li> <li>Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li> </ol>

<p>Decision Point GF/B37/EDP04: Approval of Contingency Voting Procedures</p> <ol> <li>The Board recalls: <ol type="a"> <li>its approval at the 36th Board Meeting of the voting procedure for the selection of the Executive Director, as set forth as part of the Summary of Voting Process in Annex 2 to GF/B36/07 (the “Summary of Voting Process”); and</li> <li>the contingency procedures in the event of ties/deadlock, described in section 3 of the Summary of Voting Process, to be proposed for Board approval in advance of any voting.</li> </ol> </li> <li>As contemplated in the Summary of Voting Process, the Board approves the following contingency procedures: <ol type="a"> <li>In the event of a tie during weighted voting cycles: <ol type="i"> <li>the more-preferred candidate will be allowed to proceed (i.e., the candidate with the higher number of first and second place points will move forward);</li> <li>if the tie persists after applying paragraph 2.a.i of this decision point, the Board shall repeat the voting cycle; and</li> <li>except in the cycle with the final two candidates, if the tie continues to persist, both candidates will be removed from consideration.</li> </ol> </li> <li>In the event of deadlock in the final affirmative vote (i.e., if the final candidate is not selected with an affirmative two-thirds majority vote of each of the donor and implementer groups), the voting thresholds for the selection of the final candidate will be gradually lowered as follows, so that the final candidate will be appointed to the position of Executive Director with the approval of a: <ol type="i"> <li>Qualified Two-Thirds Majority vote: Two-Thirds Majority of the full Board and Simple Majority (i.e., over one-half) in each of the donor and implementer groups;</li> <li>Simple Two-Thirds Majority vote: Two-Thirds Majority by the full Board, without regard to groups, if the final candidate is not selected through the Qualified Two-Thirds Majority vote described in (i) above; or</li> <li>Simple Majority vote: Over 50% of the vote by the full Board, without regard to groups, if the final candidate is not selected through the Simple Two-Thirds Majority vote described in (ii) above.</li> </ol> </li> </ol> </li> </ol>

<ol> <li>The Board notes the Terms of Reference of the Chair and Vice-Chair of the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria, as originally approved through GF/B19/DP10, and as last amended through GF/B32/DP05 (the “Board Leadership Terms of Reference”).</li> <li>In connection with the upcoming launch of the call for nominations for the next Chair and Vice-Chair of the Board, the Board decides to amend and restate Section IV of the Board Leadership Terms of Reference and include the following new Section V in the Board Leadership Terms of Reference: <br /> <ol start="4" type="i"> <li>TIME COMMITMENT <ol> <li>Depending on how the Chair and the Vice-Chair divide the responsibilities between them, the Board Chair should be prepared and able to dedicate an average of 40-50% of an individual’s working time to Global Fund matters, while the Vice Chair should anticipate an average of 25-40% to the same. This commitment may not be uniformly distributed throughout the calendar year. For example, Board, Committee and Coordinating Group meetings, as well as periods before and after such meetings, may require the Board Chair and Vice-Chair to commit full capacity to Global Fund matters for several consecutive days.</li> <li>The time commitment for the Board Chair and Vice-Chair is highly dependent on the Replenishment and Strategy cycles of the Global Fund. In years where there will be either a Replenishment or the development of the Strategy for the upcoming period, it is anticipated that the time commitment of the Board Chair and Vice-Chair would be higher. The Board Chair and Vice-Chair should also be prepared and able to commit additional time in exceptional circumstances.</li> <li>The Board Chair and Vice-Chair shall communicate regularly with Committee Chairs and Vice-Chairs, Board Members, the Secretariat, partners and other stakeholders between Board Meetings. Additionally, the Board Chair and Vice-Chair should be prepared and willing to travel as representatives of the Global Fund, in some cases to locations with security, economic and infrastructural challenges.</li> </ol> </li> <li>HONORARIUM <ol> <li>An honorarium may be provided to the Board Chair and/or Vice-Chair for service in accordance with an honorarium framework as may be approved, or as separately approved on an individual basis, by the Board.”</li> </ol> </li> </ol> </li> <li>The Board decides an annual honorarium in the amount of US$ 40,000 and US$ 30,000 will be available for the next Board Chair and Vice-Chair, respectively.</li> </ol>

The agenda for the Nineteenth Board Meeting (GF/B19/1, Revision 3) is approved.

<ol> <li>The Board acknowledges the current political context and challenging implementation environment in Iraq due to ongoing conflicts. and</li> <li>Accordingly, the Board approves the following policy exceptions for processing IRQ-T-UNDP related transition funding application: <ol type="a"> <li>Maintaining the counterpart financing threshold at the level of 40%;</li> <li>Waiver of the “willingness to pay” requirement; and</li> <li>Waiver of the CCM eligibility requirements to access transition funding.</li> </ol> </li> </ol>

<p>The Board:</p> <ul> <li>Approves extension of the relevant implementation period for each grant listed in Table 2 of Attachment 1 to GF/B32/ER07 - Revision 1.</li> </ul> <p>.Annex Table 2: Papua New Guinea (PNG-012-G09-H)</p>

<p>The Board endorses the recommendation of the Policy and Strategy Committee, as part of the strategic issue of "Market Dynamics," that the Global Fund assume a deliberate and strategic role in improving impact of grants through influencing market dynamics.</p><p>The Board notes the draft objective and guiding principles for developing the Global Fund's market dynamics strategy set out in the Report of the Policy and Strategy Committee (GF/B14/7).</p><p>The Board requests that the Policy and Strategy Committee further explore the issue and present any additional matters, including any potential modifications to the objective and guiding principles for the Global Fund's market dynamics strategy, for Board consideration at the Fifteenth Board meeting.</p>

<ol start="1" type="1"><li><b>(Deferred) </b> Agree that Board commitments should be fully covered by pledges, with agreement by donors that pledges for a given calendar year are callable on demand following commitments made in that or subsequent years.</li></ol><ol start="2" type="1"><li><b>(Deferred) </b> Agree that signed Grant Agreements should be fully covered by cash assets received in the Trustee Account, implying that payment of any unpaid pledges made for a current or previous calendar year must rapidly follow commitments.</li></ol><ol start="3" type="1"><li><b>(Not approved) </b> Endorse the financial targets and instruct the Executive Director and the proposed Board Resource Mobilization standing committee to pursue a corresponding resource mobilization strategy.</li></ol><ul><li><b>In 2003, a total of USD 2.5 billion is the minimum needed </b> to make commitments to high-quality proposals anticipated in Rounds Two and Three. This requires USD 1.6 billion of new pledges and payments in addition to payment of outstanding pledges for 2002 (equal to 90 million) and current pledges for 2003 (equal to 305 million).</li></ul><ul><li><b>In 2004, approximately USD 3.8 billion is needed </b> to make new commitments to high-quality proposals anticipated in Rounds Four and Five. New pledges of USD 3.5 billion are required in addition to payment of current pledges earmarked for 2004 (equal to 305 million).</li></ul>

<p>The agenda for the First Special Board Meeting (GF/SB1/1) is approved.</p>

<p>The Board:</p><ol><li><i></i> Approves the incremental funding recommended for each country (or, as the case may be, regional) disease component, and its constituent grants, as listed in Tables 1a and 1b of Section IV to GF/B34/ER02 (collectively, "Table 1");</li><li><i></i> Acknowledges each country (or, as the case may be, regional) disease component's constituent grants will be implemented by the proposed Principal Recipients listed in Table 1, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;</li><li><i></i> Approves the reinvestment of within-allocation efficiencies for the Zanzibar TB/HIV grant and its resultant total program budget, as listed in Table 2 of Section IV to GF/B34/ER02;</li><li><i></i> Affirms the incremental funding approved under this decision (a) increases the upper-ceiling amount that may be available for the relevant implementation period of each country (or, as the case may be, regional) disease component's constituent grants, (b) is subject to the availability of funding, and (c) shall be committed in annual tranches; and</li><li><i></i> Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the "TRP") validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.</li></ol>

<p>The Board refers to its decision at its Twenty-First Meeting, which requested the Finance and Audit Committee (FAC) to conduct a review of the Global Fund Comprehensive Funding Policy (CFP) (GF/B21/DP13). It also notes the issues raised in the report of the FAC Working Group on the Review of the Comprehensive Funding Policy (GF/FAC15/08) and its associated annexes.</p> <p>The Board notes the importance of increasing the level of assurance and predictability of donor funding to the Global Fund, promoting inter-donor equity and ensuring that donor funding is used as effectively as possible for the benefit of people in need. In this context, the Board notes the need for formalization of donor commitments made through the replenishment process.</p> <p>The Board decides that in order to increase the level of assurance and predictability of donor commitments following the announcement of pledges, while taking into consideration the budgetary systems of individual donors, the Secretariat should seek to conclude multi-year contribution agreements between individual donors and the Global Fund. The Board agrees that such multi-year contribution agreements should, as appropriate, be developed on the basis of the principles outlined in GF/FAC15/08 Annex 3.</p> <p>The Board notes that the conclusion of multi-year contribution agreements does not require amendment to the CFP. However, the FAC and the Working Group will pursue the review of the CFP to ensure donor funding is used as effectively as possible for the benefit of people in need, while maintaining appropriate levels of financial assurance. The FAC will present any recommended changes thereto, beyond those set out below, to the Board for decision at its Twenty-Second Meeting.</p> <p>The Board notes Annex 5 to GF/FAC15/08, entitled "The CFP and Promissory Notes from Private Donors", and decides to replace paragraph 4 of the CFP as follows:</p> <p>The Global Fund shall consider as assets for the purposes of entering into grant agreements the following: cash; promissory notes or similar obligations issued by the government of a sovereign state (or its designated depository); and, subject to approval by the Finance and Audit Committee, promissory notes or similar obligations issued by private donors. For these purposes, promissory notes and similar obligations shall be non-negotiable, non-interest bearing and payable at par value to the account of the Global Fund in the designated depository on demand or in accordance with an encashment schedule agreed on between the contributor and the Secretariat.</p>

<p><b>Decision Point 1:</b> </p><p><b>The Board amends Article 8 of the Bylaws as follows:</b> </p><p>Article 8. Secretariat</p><p>8.1 Composition</p><p>The Secretariat is responsible for managing the day-to-day operations of the Foundation.</p><p>The Secretariat is headed by an Executive Director, who is selected by the Foundation Board <u>based on merit, in a non-political, open and competitive manner. The Executive Director</u> <strike>and</strike> acts as the chief executive officer of the Foundation <u>and serves for a term of four years, renewable for not more than one additional term of three years</u>.</p><p>The Executive Director is responsible to the Foundation Board for the day-today management of the Foundation, and for specific duties and responsibilities assigned to him <u>or her</u> by the Foundation Board.</p><p>Secretariat staff are selected by the Executive Director, under policies and procedures approved by the Foundation Board. </p><p><b>Decision Point 2: </b> </p><p><b>The Board amends Section 17 of the Board Operating Procedures as follows:</b> </p><p>17. Executive Director</p><p>The Executive Director shall attend all Board Meetings, and shall be responsible for the preparation and distribution of all materials required for the meeting, and for such other duties and responsibilities as may be assigned by the Board or the Chair. The Executive Director shall be appointed by the Board <u>for a term of four years, renewable for not more than one additional term of three years</u> <strike>two year renewable term</strike>.</p>

<p>The Board recognizes that Decision Point GF/B19/DP19 entitled “Flexibilities to Set Grant Start Dates” delegates to the Secretariat the authority to set the Start Date for grant agreements up to 18 months after Board approval of a proposal to allow for alignment and harmonization.</p> <p>The Board extends that delegated authority by further authorising the Secretariat to delay a Start Date to allow for exceptional circumstances. The following events are indicative of the standard required to justify „exceptional circumstances‟: natural disasters, sudden outbreaks of disease, sudden or unforeseen outbreaks of civil or political unrest that would severely hinder programmatic start up activities.</p> <p>This decision does not have material budgetary implications for the 2011 Operating Expenses Budget.</p>

<ol> <li>Based on the recommendations of the Audit and Finance Committee, the Board approves the Amended and Restated Global Fund Policy for Restricted Financial Contributions, as revised and set forth in Annex 1 to GF/B37/04 (the “Amended and Restated Policy”).</li> <li>The Amended and Restated Policy shall supersede the prior version of the Policy as approved by the Board in November 2014 under decision point GF/B32/DP13.</li> </ol>

The Board approves the selection criteria for the recruitment of the Executive Director in Annex 3 to the Report of the Executive Director Transition (GF/B13/14) as revised at the Thirteenth Board meeting.

<p>The PMPC recommends that PSM Advisory Panel consider necessary policies for the Global Fund related to the procurement of diagnostics and other products related to the provision of medications. Refer to GF/B4/7) for further details.</p><p><b>(No options are approved by a 2/3 majority vote) </b> The PMPC requests that the Board adopt one of the three policies on domestic production as discussed GF/B4/7).</p><ul><li><b>Option 1:</b> Zero Price Premium</li><li><ul><li>Donors: Yes: 7 No: 2</li><li>Recipients: Yes: 2 No: 6 Abstain: 1 </li></ul></li><li><b>Option 2:</b> 15% Price Premium over the lowest price imported generics </li><li><ul><li>Donors: Yes: 1 No: 7 Abstain: 1  </li><li>Recipient: Yes: 0 No: 8 Abstain: 1</li></ul></li><li><b>Option 3:</b> 15% Price Premium over lowest imported product </li><li><ul><li>Donors: Yes: 2 No: 6 Abstain: 1</li><li>Recipients: Yes: 6 No: 2 Abstain: 1</li></ul></li></ul> <p>The PMPC recommends that the Board amend the policy adopted on exemption on duties, tariffs and taxes to allow but not to encourage that Fund resources be used to pay possible product duties, tariffs and taxes. The amended policy should read as follows: "The Fund strongly encourages the relevant national authorities in recipient countries to exempt from duties and taxes all products financed by Global Fund grants and procured by NGOs or any other Principal Recipient or sub-recipient."</p><p>The Board is invited to acknowledge PMPC's decisions 4.a - 4.l on pages 6-10.</p><ul><li>4a: The PMPC has agreed to the creation of a PSM Advisory Panel, according to the Terms of Reference in Part 1 Annex II, to provide technical advice to the PMPC as required</li><li>4b: The PMPC has agreed to consider the subject of product quality monitoring processes, on the basis of both WHO input and advice by the PSM Advisory Panel, and make appropriate recommendations to the Fifth Board Meeting.</li><li>4c: The PMPC has agreed to consider how the Global Fund should ensure the assessment of NDRA recognized laboratories for product quality monitoring, drawing on the advice of the PSM Advisory Panel, and make appropriate recommendations to the Fifth Board Meeting.</li><li>4d: The PMPC has agreed to consider potential PSM-related conflicts of interest based on advice of the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4e: The PMPC has agreed to consider issues related to global bidding mechanisms based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4f: The PMPC has agreed to approve the importance of capacity building for procurement and supply management as proposed by the PSM Task Force and request the Secretariat to ensure that information on the subject be made available to potential grantees and Principal Recipients.</li><li>4g: The PMPC has agreed on the Terms of Reference for a Pricing Reporting Mechanism design study, as attached in Part 1 Annex III, and has directed the Secretariat to commission this study and implement the resulting system for collecting and reporting prices paid for pharmaceutical products by Global Fund recipients by September 2003.</li><li>4h: The PMPC has agreed to refer the issueof the direct payment of suppliers to the Secretariat,with further analysis by the Advisory Panel as necessary.</li><li>4i: The PMPC has agreed to refer the issueof product prices used for budgeting proposals to the Secretariatfor operationalization, with further analysis by the Advisory Panel as necessary.</li><li>4j: The PMPC has agreed to consider issues related to in-kind contributions, if they are considered eligible by the Board of the Global Fund for resource mobilization, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4k: The PMPC has agreed to consider the previous recommendation made to the Third Board Meeting on the issue of international and national law, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li><li>4l: The PMPC has agreed to consider the previous recommendation made to the Third Board Meeting on the issue of supply chain management, based on advice from the PSM Advisory Panel and make appropriate recommendations to the Fifth Board Meeting.</li></ul>

<p>The Board refers to its earlier decisions regarding the Affordable Medicine Facility - malaria ("AMFm") and clarifies its intent that the Global Fund will only expand from Phase 1 (the pilot phase) of AMFm to a global scale-up on the basis of evidence gathered during the pilot phase that the initiative is likely to achieve its four stated objectives: (i) increased ACT affordability, (ii) increased ACT availability, (iii) increased ACT use, including among vulnerable groups, and (iv) "crowding out" oral artemisinin monotherapies, chloroquine and sulfadoxine-pyrimethamine by gaining market share. The Board further clarifies that it will consider evidence that the AMFm will achieve these four objectives more cost-effectively than other financing models that aim to achieve similar objectives solely or principally through the expansion of public sector services (i.e., public health facilities and community health workers only).</p> <p>The Board requests the AMFm Ad Hoc Committee to review the findings of the independent evaluation of AMFm Phase 1 against the four objectives and to make a recommendation to the Board at its first meeting in 2012 on whether to expand, accelerate, modify, terminate or suspend the AMFm business line in countries participating in the pilot. The Board notes that, in addition, it may decide to extend the pilot phase beyond its first meeting in 2012, if necessary. Any such extension would be subject to available funding and the Board reiterates that AMFm Phase 1 is currently funded as a 24-month program and countries should plan accordingly.</p> <p>The Board decides that, in addition to the AMFm 'identifier', all AMFm co-paid ACTs should bear a logo that is universal for all countries participating in AMFm. During implementation of AMFm Phase 1, based on lessons learned and discussions with participating countries and with due regard to the independent evaluation, other donors should be encouraged and permitted to use the logo on ACTs procured directly by such donors, provided that such ACTs meet the Global Fund's quality assurance policy. The Board requests RBM to work with participating countries, donors and all partners to coordinate the progress towards a universal logo for all quality-assured ACTs.</p> <p>The Board approves the revised AMFm Phase 1 Policy attached as Annex 1 to the Report of the AMFm Ad Hoc Committee to the Board (GF/B20/7).</p>

<p>The Board:</p> <ol> <li>Approves additional funding for the Phase 2 period for the proposals listed in Table 1 in the amounts indicated for each proposal, with the clear understanding that the amounts approved are upper ceilings rather than final funding amounts, and based on an understanding that the Secretariat shall pursue on-going implementation arrangements for each proposal consistent with the recommendations set forth in its Grant Score Card. Approval is also subject to paragraph 3.c. of the Comprehensive Funding Policy (GF/B20/DP9)^[1].</li> <li>Reaffirms that the maximum funding amount for Phase 2 of each proposal shall be the sum of the amount approved by this decision and the amount of any funds approved for Phase 1 which have not been disbursed by the Global Fund at the end of the Phase 1 period.</li> </ol> <p>See attached tabledetailing total recommended funding amount of US$ 50,244,443 for the following grants: ARM-809-G03-T ; BUR-809-G08-M ; BUR-809-G09-M ; SLV-708-G05-H ; SLV-708-G06-H ; SLV-202-G01-H-00 ; SLV-202-G03-H-00 ; PKS-809-G09-T ; PKS-809-G10-T ; PRY-809-G04-H</p>

<ol> <li>The Board acknowledges that a health crisis may emerge in an ineligible non-high income country that could have an adverse impact on the global response against HIV/AIDS, tuberculosis, and/or malaria, and that the health crisis may be of such a magnitude that the Global Fund should consider providing support; and</li> <li>Based on the recommendation of the St